Samsung 2022 Annual Report

The 12th Accounting Period
From January 1, 2022

To December 31, 2022
※ Disclaimer
This document was disclosed voluntarily for foreign investors. The original Korean version of the
disclosure can be found on KIND(http://kind.krx.co.kr), DART(http://dart.fss.or.kr). If and when there
is any discrepancy between the English and Korean versions, the Korean text shall prevail.
Therefore, it is essential for the investors to consult the Korean text before making investment
decisions.
To. Financial Services Commission

Korea Exchange March 9, 2023
Type of Corporation Subject to Submit Stock-listed Corporation
Reason for Exemption Not applicable
Name of Company Samsung Biologics Co., Ltd.
CEO Rim John Chongbo
Place of Principal Office 300, Songdo Bio-daero, Yeonsu-gu, Incheon, Korea

(Songdo-dong, Samsung Biologics Co., Ltd.)
(Tel.) 82-032-455-3114
(Homepage) http://www.samsungbiologics.com
Principal Officer (Title) Director of Business Support Center

(Name) Kim Dongjoong
(Tel.) 82-032-455-3114
I. Company Overview
1. Company Overview
A. Consolidated subsidiaries overview(summary)
Number of consolidated subsidiaries Number of

Classification major
Beginning End subsidiaries
Increase Decrease
of period of period
Listed - - - - -
Unlisted 1 13 1 13 1
Total 1 13 1 13 1
※ For details, refer to XII. Table of Information – 1. Consolidated subsidiaries overview
B. Change of consolidated subsidiaries
Subsidiary Reason
Transfer from joint venture to subsidiary
13
Newly consolidated by acquiring additional shares
- -
SVIC 36 New
Technology Investment Liquidated
No longer consolidated Association
- -
C. Legal and commercial name

The Company’s name is ‘SAMSUNG BIOLOGICS CO., LTD.’
D. Establishment date
Samsung Biologics Co., Ltd. was established on April 22, 2011.
E. Address, telephone number, and homepage

Address of head office : 300, Songdo Bio-daero, Yeonsu-gu, Incheon, South Korea
(Songdo-dong, Samsung Biologics Co., Ltd.)
Telephone number : 82-032-455-3114
Homepage : www.samsungbiologics.com
F. Status of SME
Samsung Biologics Co., Ltd. (hereinafter, Samsung Biologics or the Company) does not fall within small
and medium enterprises (SMEs) in accordance with Article 2 of the Framework Act of Small and Medium
Enterprises and Article 3 of the Enforcement Decree of the Framework Act on Small and Medium
Enterprises as of the date when the report is submitted.
Small Enterprises Not Applicable
Venture company Not Applicable
Medium Enterprises Not Applicable
G. Main business
The Company consists of two business segments: CDMO (Contract Development and Manufacturing
Organization) business; and biopharmaceutical development and commercialization business. The
CDMO division provides contract production and cell line process development services for
biopharmaceuticals, and the biopharmaceutical division engages in biopharmaceutical development
and commercialization. In the current period, revenue generated from CDMO product, services,
biopharmaceutical product development and commercialization product account for 72.0%, 5.9% and
22.1% of the total revenue respectively. By region, the Company has generated the total revenue from
the following regions: Europe – 59.5%, United States – 28.5%, Korea – 5.2%, and Others – 6.8%.
Refer to「II. Business Overview」for more details about the business.
H. Credit rating
Credit Rating Agency

Date Securities Ratings Note
(Rating Range)
6-1,6-2 Private Korea Investors Service
2020.02.07 - Non-periodic rating
non-guaranteed bond (AAA~D)
7-1,7-2 Public Korea Investors Service
2021.07.26 A+ Initial rating
2021.08.05 A+ Initial rating
2022.04.28 AA- Periodic rating
2022.05.09 AA- Periodic rating
※ The credit rating for 6-1.6-2 private bonds is not provided under the non-disclosure agreement.
[Credit rating system]

- Korea Investors Service : Corporate Bond Ratings
Corporate bond rating scale is composed of 10 broad rating categories from AAA to D that indicate
different levels of likelihood of interest and principal payment as illustrated in the table below. Securities
rated between AAA to BBB indicate adequate (or stronger) capacity to meet financial commitments.
Securities rated between BB and C are judged to have speculative elements and are subject to
substantial credit risk.
Rating Definition
AAA An ‘AAA’ rating indicates the highest likelihood of interest and principal payment.
An ‘AA’ rating indicates very high likelihood of interest and principal payment. The likelihood may,
A
nevertheless, be slightly lower than is the case for the highest rating category (AAA).
An ‘A’ rating indicates high likelihood of interest and principal payment. The likelihood may,
B nevertheless, be more susceptible to changes in circumstances and in economic conditions than
is the case for higher rating category (AA).
A ‘BBB’ rating indicates moderate likelihood of interest and principal payment, but changes in
BBB circumstances and in economic conditions are more likely to impair this likelihood than is the case
for higher rating category (A).
A ‘BB’ rating indicates some uncertainty over the likelihood of interest and principal payment and
BB
speculative elements.
A ‘B’ rating indicates substantial uncertainty over the likelihood of interest and principal payment
B
and is considered more speculative than higher rating category (BB).
A ‘CCC’ rating indicates high risk of default and questionable likelihood of interest and principal
CCC
payment.
A ‘CC’ rating indicates very high risk of default and extremely low likelihood of interest and principal
CC
payment.
A ‘C’ rating indicates extremely high risk of default and lack of likelihood of interest and principal
C
payment.
D A ‘D’ rating indicates default.

※ '+' or '-' modifier can be attached to ratings through AA to B to differentiate ratings within broader rating categories.
- Korea Ratings : Rating of Bonds
Rating Definition
AAA Capacity for timely payment is extremely strong.
AA Capacity for timely payment is very strong, but somewhat less than 'AAA'
A Capacity for timely payment is strong, but somewhat susceptible to external changes in the future.
Capacity for timely payment is adequate, but more likely to be weakened by future market
BBB
changes.
BB Capacity for timely payment faces no immediate problems, but speculative in its future stability.
B Capacity for timely payment is poor and speculative.
CCC Contain the possibility of default.
CC Contain more possibility of default.
C Highly likely default.
D In default at the present time.

※ The ratings from 'AA' to 'B' may be modified by the addition of a plus(+) or minus(-) sign to show relative standing within the
major rating categories.
※ For preliminary rating, "P" is added in front of the relevant rating symbol.
※ For undisclosed grades, add "U" in front of the grade symbol.
I. Whether the Company is listed (or registered or designated) and matters related to special
listed companies
Listing Date listed Subject to regulations for
Special listed company
(or registered or designated) (or registered or designated) special exception companies
Stock market (KOSPI) 2016.11.10 Not applicable Not applicable
2. Company History
A. Company location changes
Changes in the place of principal office since the establishment of the Company are as follows :
Date Address Remarks
2011.04.22 104B, Pilot Plant, 7-50, Songdo-dong, Yeonsu-gu, Incheon, South Korea Establishment
3003, Songdo Technopark IT Center M, 172-1, Songdo-dong, Yeonsu-gu,

2012.01.26 -
Incheon, South Korea
2012.06.26 201-2, Songdo-dong, Yeonsu-gu, Incheon, South Korea -
Changed to
125, Cheomdan-daero, Yeonsu-gu, Incheon, South Korea road name-
2014.01.07
(Songdo-dong, Samsung Biologics Co., Ltd.) based
address
Changed to
300, Songdo Bio-daero, Yeonsu-gu, Incheon, South Korea road name-
2016.07.04
(Songdo-dong, Samsung Biologics Co., Ltd.) based
address
B. Important changes in management executives
(1) Change of Chief Executive Officer

- On December 16, 2020, John Rim was appointed as the Chief Executive Officer
※ On December 16, 2020, Executive director John Rim was appointed as the new Chief Executive
Officer and Kim Taehan resigned from his position of Chief Executive Officer during the 10th board of
director’s meeting.
(2) Change in key management
As of December 31, 2022, the Company's Board of Directors (BOD) consists of three Executive
directors (Kim Taehan, John Rim, and Kim Dongjoong) and four Independent directors (Heo
Geunnyoung, Eunice Kim, Lee Changwoo, and Bahk Jaewan).
Type of Appointment
Date shareholder Expiry or Dismissal
meeting Initial Extension
Executive director
Kim Dongjoong
Annual
Independent director Independent director Independent director
2019.03.22 General
Heo Geunnyeong Jeong Seokwoo Yoon Byungchul
Meeting
Independent director
Kwon Soonjo
Executive director
Annual John Rim Executive director
2020.03.20 General -
Independent director Kim Taehan
Meeting
Eunice Kim
Independent director Executive director Independent director
Annual Lee Changwoo Kim Dongjoong Jeong Seokwoo
2022.03.29 General
Meeting Independent director Independent director Independent director
Bahk Jaewan Heo Geunnyeong Kwon Soonjo
※ On January 18, 2023, independent director Bahk Jaewan resigned.

※ On February 15, 2023, the company announced the "Announcement of Convocation of General Shareholders Meeting" on the
electronic disclosure system. As previously announced, the company plans to propose an agenda for the appointment of
directors at the 12th shareholders' meeting (March 17, 2023), and the current status of candidates for appointment is on Ⅷ.
Executives and Employees. For the results of the shareholders' meeting, please refer to the "shareholders' meeting results"
scheduled to be disclosed on the electronic disclosure system on March 17, 2023.
C. Changes in the largest shareholder
Date Before After Remarks
Samsung Everland (Old) Cheil Industries The change of the largest

2014.07.04
Samsung Electronics Samsung Electronics shareholder’s name
Following the merger between

(Old) Cheil Industries and
(Old) Cheil Industries (Old) Samsung C&T Corporation,
2015.09.02 Samsung C&T Corporation
Samsung Electronics the company name of
(Old) Cheil Industries was changed to
Samsung C&T Corporation.
D. Company name changes

- Not applicable
E. Details and results in case the Company went through or currently goes through
compositions, reorganization proceedings, and other equivalents
- Not applicable
F. Mergers and Acquisitions
(1) Transfer of Samsung Bioepis Shares

Biogen Therapeutics Inc. has a call option that allows it to purchase up to 50%-1 shares of Samsung
Bioepis under an agreement between shareholders on December 6, 2011.
The transfer of assets is related to the report on major issues on June 29, 2018 (decision to transfer
shares and equity securities of other corporations). On November 7, 2018, the transfer of shares and
payment were completed, and the transaction was closed.
Category Dates
Contract Between Shareholders 2011.12.06
Evaluation of external evaluation agencies 2018.06.22 ~ 2018.06.29
Key item report submission date 2018.06.29
Transfer of shares and payment date 2018.11.07
(2) Transfer of Samsung Bioepis Shares

The Company entered into a stock sales contract on January 28, 2022 to acquire an additional stake in
Samsung Bioepis held by Biogen Therapeutics Inc., and acquired 10,341,852 shares on April 20, 2022
to secure 100% of the stake and gained the control of Samsung Bioepis.
For details on the acquisition of shares, please refer to the Report on Major Matters (Decision to acquire
stocks and investment securities of other corporations) first published on January 28, 2022.
Category Dates
G. Important changes in the Company’s business

- Not applicable
H. Other important matters related to the management activities
[Samsung Biologics]
Date Details
2011.04.22 Established Samsung Biologics Co., Ltd.
2011.04.28 Signed a lease agreement for the plant site in Songdo
2011.05.06 Started the construction of Songdo Plant 1
2012.02.28 Established Samsung Bioepis Co., Ltd.
2013.07.18 Signed a contract with BMS regarding DS manufacturing
2013.10.18 Signed a contract with Roche regarding DS manufacturing
Signed a contract with BMS regarding DS manufacturing enhancement and
2014.04.16
DP manufacturing
2014.06.23 Established a joint venture, Archigen Biotech Ltd.
Changed the largest shareholder’s company name
2014.07.04
(Samsung Everland Inc. → Cheil Industries Inc.)
Date Details
Changed the largest shareholders (Before: Samsung Electronics Co., Ltd. 46.79%, Cheil
Industries Inc. 46.79%, Samsung C&T Corporation 4.25%
2015.09.02
→ After: Samsung C&T Corporation 51.04%, Samsung Electronics Co., Ltd. 46.79%)
2015.11.30 Obtained an approval of Songdo Plant 1’s manufacturing license from FDA
(no observation)
2016.04.01 Signed a contract with Samsung Bioepis regarding biosimilar manufacturing

2016.05.03 Signed a contract with a US pharmaceutical company regarding DP manufacturing
2016.07.29 Obtained an approval of Songdo Plant 1’s manufacturing license from EMA
2016.11.10 Became listed on the KOSPI
2016.11.16 Signed a contract with Cilag regarding DS manufacturing
2017.01.24 Signed a contract with a Swiss pharmaceutical company regarding DS manufacturing
2017.07.04 Signed a contract with Sun Pharma regarding DS manufacturing
2017.07.20 Signed a contract with a Europe pharmaceutical company regarding DS manufacturing
2017.09.06 Signed LOI with Ichnos Science regarding DS manufacturing
2017.09.22 Obtained an approval of Songdo Plant 2’s manufacturing license from FDA
2017.11.08 Signed a contract with a US pharmaceutical company regarding DS manufacturing
2017.12.21 Obtained an approval of Songdo Plant 2’s manufacturing license from EMA
2017.12.21 Signed a contract with UCB regarding DS manufacturing
2018.02.01 Signed an additional contract with a Asia pharmaceutical company regarding DS manufacturing
2018.02.21 Signed a contract with an US pharmaceutical company regarding DS manufacturing
2018.04.30 Signed an additional contract with a Europe pharmaceutical company regarding DS manufacturing
2018.06.01 Signed a contract Ichnos Sciences S.A. regarding DS manufacturing
2018.06.29 Biogen’s execution of call option and Stock transfer decision
2018.08.14 Signed a contract with an Asia pharmaceutical company regarding DS manufacturing
2018.09.11 Signed a contract with Immunomedics, Inc. regarding DS manufacturing
2018.11.07 Transferred 9,226,068 Samsung Bioepis’ shares to Biogen Therapeutics Inc.
2019.04.01 Signed a contract with Cytodyn Inc. regarding DS manufacturing
2019.05.17 Signed a contract with UCB regarding DS manufacturing
2019.11.05 Signed an additional contract with Ichnos Sciences S.A. regarding DS manufacturing
2019.12.03 Signed a contract with an US pharmaceutical company regarding DS manufacturing
2019.12.24 Signed a contract with a Swiss pharmaceutical company regarding DS manufacturing
2020.01.29 Established Samsung Biologics America, Inc.
2020.04.23 Signed an additional contract with Immunomedics regarding DS manufacturing
2020.07.27 Signed a contract with Eli Lilly and Company regarding DS manufacturing
2020.08.05 Signed a contract with GlaxoSmithKline Trading Limited regarding DS manufacturing
2020.08.05 Launched the proprietary cell line technology, S-CHOice
2020.09.21 Signed a contract with AstraZeneca UK Ltd. regarding DS/DP manufacturing
2020.10.29 Established CDO R&D center in San Francisco, U.S.
2021.01.15 Signed a contract with Roche regarding DS manufacturing
Date Details
2021.05.21 Signed a contract with Moderna regarding DP manufacturing
2021.06.11 Issued the first Sustainability R eport
2021.09.13 Participated in a FSS-led climate risk management model
2021.09.22 Launched the CDO-accelerating platform, S-Cellerate
2021.09.28 Signed an additional contract with Roche regarding DS manufacturing
2021.09.29 Signed LOI with MSD regarding DS manufacturing
Supplied its first batch of domestically produced Moderna COVID-19 mRNA for domestic
2021.10.28
use
Awarded ‘A’ rating in Comprehensive ESG Assessment for the first time as a
2021.11.01
biopharmaceutical company
2021.11.03 Signed a Land Purchase Agreement for Plant 5 in Songdo District 5
2021.11.13 Joined Dow Jones Sustainability Index (DJSI) for the first time as a Life Science company
Signed a contract with GreenLight Biosciences regarding DS manufacturing of mRNA
2021.11.25
vaccine candidate substances
2021.12.07 Obtained the international standard for a Quality Management System (ISO 9001)
Obtained a marketing authorization from the Ministry of Food and Drug Safety of Korea for
2021.12.14
Moderna’s COVID-19 vaccine
2022.01.28 Agreed to acquire Biogen’s stake in Samsung Bioepis
2022.03.28 Signed an additional contract with Eli Lily Kinsale Limited regarding DS manufacturing
2022.03.29 Agreed to a Land Purchase Agreement for Second Bio Campus in Songdo Disctrict 11
2022.03.29 Invested in Samsung Life Science Fund, U.S. Cell and Gene Therapy Developer
2022.04.20 Acquired 100% of Samsung Bioepis shares
2022.04.28 Additional stock listing from paid-in capital increase
2022.06.07 Signed a contract with Novartis regarding DS manufacturing
2022.07.11 Published ESG Report
2022.07.18 Purchased the Land for Second Bio Campus in Songdo Disctrict 11
2022.08.02 Successful test production of mRNA drug substance
2022.08.17 Samsung Life Science Fund, Invested in US nanoparticle drug delivery platform company
Introduced new development platforms S-DUAL™, a high-yield bispecific antibody
2022.10.06
platform, and DEVELOPICK™, a rapid developability assessment platform.
2022.11.24 Joined RE100 with a target of reaching net zero across all operations by 2050
2022.11.24 Received 'Grade A' rating on ESG evaluation for two consecutive years
2022.12.11 Named to the Dow Jones Sustainability World Index two years in a row
2022.12.14 ESG partnership with partners
Published its first report aligned to the recommendations of the Task Force on Climate-
2022.12.30
Related Financial Disclosures (TCFD)
[Samsung Bioepis]
Date Details
2012.02.28 Established Samsung Bioepis Co., Ltd.
2013.02.18 Signed the marketing partnership contract with Merck
2013.12.13 Signed the marketing partnership contract with Biogen
2015.09.07 Sales approval of ETOLOCE(Enbrel Biosimilar) in Korea
2015.12.04 Sales approval of REMALOCE (Remicade Biosimilar) in Korea
2016.01.14 Sales approval of BENEPALI(Enbrel Biosimilar) in Europe
Date Details
2016.05.26 Sales approval of FLIXABI(Remicade Biosimilar) in Europe
2017.04.21 Sales approval of Renflexis(Remicade Biosimilar) in US
2017.08.24 Sales approval of IMRALDI(Humira Biosimilar) in Europe
2017.09.20 Sales approval of ADALLOCE(Humira Biosimilar) in Korea
2017.11.08 Sales approval of SAMFENET(Herceptin Biosimilar) in Korea
2017.11.15 Sales approval of ONTRUZANT(Herceptin Biosimilar) in Europe
2019.01.18 Sales approval of ONTRUZANT(Herceptin Biosimilar) in USA
2019.04.25 Approval of ETICOVO(Enbrel Biosimilar) in USA
2019.07.23 Sales approval of HADLIMA(Humira Biosimilar) in USA
2019.11.05 Signed additional marketing partnership contract with Biogen
2019.12.19 Acquired the WHO PQ certification of ONTRUZANT(Herceptin Biosimilar)
2020.11.03 Awarded the global generic and biosimilar award(Leading company of the year)
2020.11.19 Awarded the excellent product design award(Brand design Ministerial Award)
2021.01.25 Moved into new building in Songdo
2021.03.11 Sales approval of ONBEVZITM(Avastin Biosimilar) in Korea
2021.04.22 Awarded the iF design award in communication and packaging part
2021.08.18 Sales approval of BYOOVIZ(Lucentiz Biosimilar) in Europe
2021.09.17 Sales approval of BYOOVIZ(Lucentiz Biosimilar) in USA
2021.12.21 Issued the first Sustainability Report
2022.05.13 Sales approval of AMELIVU(Lucentiz Biosimilar) in Korea
2022.08.15 Sales approval of high concentration formulation of HADLIMA(Humira Biosimilar) in US,
Obtained the international standard for Environment and Energy Management System (ISO
2022.09.13
14001, ISO 50001)
2022.11.02 Received 'Global Generics & Biosimilars Award' (Company of the Year, Asia-Pacific)
3. Changes in Paid-in Capital
Status of capital increase (decrease)

(Unit: KRW, share)
Type of Classifica
12th 11th 10th 9th 8th
share tion
Number
of Issued 71,174,000 66,165,000 66,165,000 66,165,000 66,165,000
shares
Ordinary
Par value
share 2,500 2,500 2,500 2,500 2,500
per share
Total
177,935,000,000 165,412,500,000 165,412,500,000 165,412,500,000 165,412,500,000
equity
Number
of Issued - - - - -
shares
Preferred
Par value
share - - - - -
per share
Total
- - - - -
equity
Number
of Issued - - - - -
shares
Others Par value
- - - - -
per share
Total
- - - - -
equity
Total
Total 177,935,000,000 165,412,500,000 165,412,500,000 165,412,500,000 165,412,500,000
equity
※ On January 28, 2022, the Board of Directors of the Company resolved to increase its capital for the acquisition of construction
in-progress and securities of other entity. The Company issued additional 5,009,000 shares of common stock totaling
71,174,000 shares of common stock issued by the end of 2022.
4. Stock Information
A. Total number of shares

(As of December 31, 2022) (Unit: share)
Type of stocks
Classification Note
Common Preferred Total
Ⅰ. Authorized shares 500,000,000 - 500,000,000 -
Ⅱ. Issued shares (cumulative) 71,174,000 - 71,174,000 -
Ⅲ. Decrease in number of shares (cumulative) - - - -
1. Capital reduction - - - -
2. Cancellation - - - -
3. Redemption - - - -
4. Other - - - -
Ⅳ. Issued shares (Ⅱ-Ⅲ) 71,174,000 - 71,174,000 -
Ⅴ. Treasury shares - - - -
Ⅵ. Outstanding shares (Ⅳ-Ⅴ) 71,174,000 - 71,174,000 -
B. Treasury Shares
- Not applicable
C. Types of Registered Stock

- Not applicable
5. Articles of Incorporation
Amendment record
Date of change Meeting name Description Reason

Article 8 (Classes of Shares and Share Certificates)
Section 7 – Deleted
- Amendment/Deletion of relevant
Article 8-2 (Electronic registration on Rights to be
articles following the enactment
Indicated on Shares and Certificate of Preemptive
of the Act on Electronic
Right to new stocks)
Registration of Stocks, Bonds,
Section 3 – Introduced
etc.
Article 9 (Transfer agent) Section 3 – Amended
Article 10 (Shareholders’ Obligation to report on
- Reflection of flexible operation
address, name and signet or signature) – Deleted
8th Annual scheme and exception regulation
2019.03.22 Article 17-2 (Electronic registration on Rights to be
General Meeting of BOD following the leave of
Indicated on Bonds and Certificate of Preemptive
CEO/Member of Audit committee
Right to new stocks) – Introduced
Article 18 (Applicable Provisions regarding Issuance
- Reflection of changes in rights to
of Bonds) – Post-amendment Review of Section
appoint an external auditor
Article 33 (Duties of Directors) Section 3 – Amended
following the amendment of the
Article 42 (Composition of Audit Committee)
Act on External Audit of Stock
Section 7 – Introduced
Companies
Article 43 (Duties, etc. of Audit Committee)
Section 6 – Amended
※ The latest date of change in the Company’s articles of incorporation is March 22, 2019.
No change was made at the Company’s 12th Annual General Meeting, held on March 17, 2023.
II. Business Overview
1. Business Overview
The Company is organized into two segments consisting of CDMO and biopharmaceutical development
and commercialization businesses. The CDMO business provides clients with the service of
manufacturing biopharmaceuticals and development of cell line, and the biopharmaceutical
development and commercialization business focuses on development and commercialization of
biopharmaceuticals. The Company acquired an additional 10,341,852 shares of Samsung Bioepis Co.,
Ltd to secure a 100% stake in the company. As a result, biopharmaceutical development and
commercialization of Samsung Bioepis Co., Ltd. was added as a separate business segment.
The Company achieved consolidated sales of 3.0013 trillion won in 2022, sales of CDMO goods, etc.
were 2.1613 trillion won, service sales were 176.2 billion won, and biopharmaceutical development and
commercialization segment product sales were 663.8 billion won. 2021 annual sales was 1.568 trillion
won, and sales of biopharmaceuticals were 1.442 trillion won in product sales and 126 billion won in
service revenue from CDMO business segment.
(1) CDMO
Samsung Biologics offers a wide range of services focusing on the development and commercialization
of biosimilar and CMO service of manufacturing biopharmaceuticals and development of cell line,
manufacturing process, characterization, and analysis method for pipelines ranging from cell line
development to early stage clinical phase.
The Company operates commercial manufacturing capacity of 420,000L (Plant 1 – 30,000L, Plant 2 –
150,000L, Plant 3 – 180,000L, Plant4 – 60,000L) and clinical manufacturing capacity of 4,000L in
Incheon Free Economy Zone (Songdo region). This is the largest manufacturing capacity in the global
CMO industry. The Company established an overseas subsidiary, Samsung Biologics America, Inc. in
the United States to secure stable sales growth and overseas expansion. In addition, the Company
achieved a fruitful performance in both CDO and Drug Product(DP) businesses, remarked by its DP
production of Moderna mRNA vaccine.
In 2022, the global biopharmaceutical market is valued at USD 389 billion, which accounts for 30.5%
of the entire pharmaceutical market. The biopharmaceutical market is expected to increase with an
average growth rate of 11.9% by 2026. The rapid growth is expected to boost the expansion of the
overall pharmaceutical market. In addition, the recent trend shows the greater reliance on CMO
companies by global pharmaceutical companies (Evaluate Pharma, May 2022). The CDMO industry is
expected to increase from USD 19.1 billion in 2022 to USD 27 billion in 2026 with an average growth
rate of 12.2%, based on the following factors (BCG, May 2022).
The Company is a contract manufacturer specializing in mammalian cell-based antibody drugs, which
is a major component of the biopharmaceutical market. The market is oligopolistic, dominated by a few
players with large-scale manufacturing facilities. As of 2022, there are three companies with a global
production capacity of over 300,000L production: Korea-based Samsung Biologics, Switzerland-based
Lonza, and Germany-based Boehringer Ingelheim. The Company runs 424,000L production facilities
as of now, including Plant4 partial operation as of Oct 2022, and plans to concrete its leading position
as it completes the construction of Plant 4 with 180,000L capacity by 2023.
The Company is currently widening the scope of business to CDO services, mRNA, and cell/gene
therapy manufacturing to transform into a global biopharmaceutical company. The CDO business
provides cell line and process development and characterization services for small and medium-size
biotechs, which do not have their own development facilities. The Company launched a high-performing
cell line ‘S-CHOice’, which delivers high productivity and viability, and ‘S-Cellerate’, which is a platform
that innovatively shortens the development period through a standardized process for each
development stage. Furthermore, the Company opened its first global CDO R&D center in the renowned
San Francisco Biopharma Cluster in October 2020 and currently plans to widen the scope of the market
to Boston, Europe, and China. The Company has implemented mRNA production capacity within its
existing manufacturing plant, which is cGMP ready in April 2022. Additionally, the Company is under
review for various options including construction and M&A, considering overall technology trends,
marketability and profitability related to cell and gene therapy.
(2) Biopharmaceutical development and commercialization
Samsung Bioepis conducts business focusing on the development and commercialization of

biopharmaceuticals, and is promoting R&D in various disease areas such as autoimmune diseases,
tumor diseases, ophthalmic diseases, and blood diseases. Since the establishment of the company in
2012, six biosimilars (Remicade, Herceptin, Enbrel, Humira, Avastin, and Lucentis similar) have been
released to date, and are actively sold throughout the world, including the United States, Europe,
Canada, Australia, and Brazil. As such, the Company has succeeded in the approval and
commercialization of biosimilar products ranging from autoimmune diseases and oncological diseases
to ophthalmic diseases. In addition, the Company is developing biosimilars for Soliris for blood diseases,
Eylea for eye disease, Prolia for endocrine disease, and Stelara for immune disease. Soliris similar is
preparing to apply for approval in major countries after completing phase 3 clinical trials, and Eylea,
Prolia, and Stelara's similar products are currently undergoing phase 3 clinical trials. Based on the
experience in development and commercialization of biosimilars, the Company expects to expand its
future business and continue to innovate.
[Financial Status Summary by Business Division]
The revenue in 2022 was 3.0013 trillion won with an operating profit of 983.6 billion won.
(Unit: KRW Mil)
2022 2021 2020

Business Unit Type
Amount Share Amount Share Amount Share
1. Revenue 2,337,523 77.9% 1,568,007 100.0% 1,164,777 100.0%
2. Operating
CDMO 915,589 93.1% 537,309 100.0% 292,787 100.0%
Profit/Loss
3.Asset 8,821,696 53.2% 7,970,011 100.0% 6,424,201 100.0%
1. Revenue 663,772 22.1% - - - -
Biopharmaceutical
development and 2. Operating
68,038 6.9% - - - -
commercialization Profit/Loss(*2)
(*1)
3.Asset 7,760,354 46.8% - - - -
1. Revenue 3,001,295 100.0% 1,568,007 100.0% 1,164,777 100.0%
2. Operating
Total 983,627 100.0% 537,309 100.0% 292,787 100.0%
Profit/Loss
3.Asset 16,582,050 100.0% 7,970,011 100.0% 6,424,201 100.0%
※ Consolidated basis in accordance with K-IFRS
(*1) The Company acquired an additional 10,341,852 shares of Samsung Bioepis Co., Ltd to secure a 100% stake in the company.
As a result, biopharmaceutical development and commercialization of Samsung Bioepis Co., Ltd. was added as separate sales
segment.
(*2) The impact of amortization on the fair value of identifiable assets due to business combinations is reflected in the development
and commercialization of biopharmaceuticals.
2. Key Products and Service
A. Major products
(Unit: KRW Bil)
2022 2021 2020

Business Unit Type Item
Goods Biologics 2,161.3 72.0% 1,442.0 92.0% 1,102.6 94.7%
CDMO
Services Others 176.2 5.9% 126.0 8.0% 62.2 5.3%
Biopharmaceutical
development and
commercialization Goods Biosimilar 663.8 22.1% - - - -
(*1)
Total 3,001.3 100.0% 1,568.0 100.0% 1,164.8 100.0%

※ Consolidated basis in accordance with K-IFRS.
As a result, biopharmaceutical development and commercialization of Samsung Bioepis Co., Ltd. was added as a separate
business segment.
B. Price fluctuation of major products

(1) CDMO
The selling price of the product to be produced by the Company is adjusted according to the ratio of
reflecting the CPI (Consumer Price Index) announced every year to the initial sales price determined
under the contract with the customer, or it may be adjusted according to the terms of the contract, such
as increasing by the fixed ratio stated in the contract

The direct sales channel adjusts the sales price according to the market conditions, while in the case
of indirect sales through a distributor, the product price is calculated by considering the country's market
price of the product, various deductions, and the partner's margin according to the contract with the
distributor.
3. Raw Materials
A. Purchase of major raw materials

(Unit: KRW Bil)
Amount of Remarks
purchase (place of purchase)
- Global Life Sciences Solutions Singapore,
Raw
Resin, etc. 494.6 Life Technologies Corporation, Sigma-
materials
CDMO Aldrich Korea etc.
Auxiliary - Merck Limited, Satorious Korea Biotech,
Filter, etc. 277.2
materials Imarket Korea, etc.
Raw
Biopharmaceutical Resin, etc. 52.4 -
materials
development and
Spare
commercialization Syringe, etc. 33.2 -
parts
Total 857.4
※ The CDMO business generally receives a full refund of raw/auxiliary materials and handling fees in form of BOM (Bill of
Material) from customers.
※ In the biopharmaceutical development and commercialization sector, the procurement is made to order by the purchaser due
to the nature of the business, and in the case of major purchasers, the detailed information is omitted according to the
competitive situation and the contents of the mutual contract.
B. Raw materials price trends and major components
(1) CDMO
The major raw materials used in the pharmaceuticals are either confirmed by the customer for reasons
such as quality control or purchased through the vendor assigned by the customer. Pre- or post-
settlement (reimbursement) is made by the customer for the purchased raw materials and incidental
expenses. Due to these terms and conditions, the risks associated with the purchase of raw materials,
such as price fluctuations, are limited. Meanwhile, the Company signs a long-term contract with raw
material suppliers to obtain a stable supply of raw materials, and applies the inflation rate (approx.
1~2%) level of raise to a price increase. Therefore, risks relating to price fluctuation due to the limited
contract terms.
The main raw materials for biopharmaceuticals have relatively low price liquidity due to mid- to long-
term supply, and are less affected by economic trends. The global supply risks caused by COVID-19 in
2020-2021 that occurred in some items have been largely resolved since the 1H of 2022 and stable
supply condition has been maintained since the 4Q of 2022.
Logistics costs are showing a stable trend as the logistics index returns to pre-COVD-19 levels in the
4Q of 2022, but overall inflation is expected to increase raw material prices by 5-20% in 2023. As the
USD exchange rate has stabilized at the previous level and the EUR exchange rate continues to remain
stable, the Company is concentrating on securing safety stock and controlling total cost increase
through close cooperation with raw and subsidiary material suppliers.
C. Production capacity, production performance and operating rate
The Company calculates operating rate by separating actual working time from non-working time of key
production facilities, where the annual production capability is calculated by considering the Slowdown
and Product Changeover period per Drug Substance production plant.
(Unit: batch)
2022 2021 2020

Production capacity 515 455 392
Production performance 404 367 237
Operating rate 78.4% 80.7% 60.5%
D. Manufacturing facilities and investment
(1) Manufacturing facilities

(Unit: KRW Mil)
Acquisition
Other
Beginning due to End
Assets Acquisition Disposal Depreciation increase/ Remarks
of period business of period
reduction
combination
Land - 186 133,036 - - 7,843 141,065 Note 1

Building 719,023 28,189 165,426 - (26,341) 347,477 1,233,774 -
Fixtures 9,297 627 2,532 - (312) (548) 11,596 -
Machinery 876,566 38,393 15,106 (1,869) (136,043) 380,560 1,172,713 -
Vehicles 163 1 - - (75) 194 283 -
Others 18,655 5,076 4,556 (4) (10,243) 13,859 31,899 -
Assets under
583,360 986,826 6,380 (55) - (751,312) 825,199 -
construction
Total 2,207,064 1,059,298 327,036 (1,928) (173,014) (1,927) 3,416,529 -
Note 1) The Company is exempted from paying rental fees as the Company satisfied the requirements for rental fee exemption
in accordance with the Ordinance of Common Property Management of Incheon Metropolitan City by signing a lease
agreement with Incheon Metropolitan City.
※ Fair value is excluded as an objective estimation for major tangible assets is difficult.
※ The manufacturing facilities status is based on consolidated basis in accordance with K-IFRS.
(2) Investments
(Unit: KRW Bil)
Business Segment Classification Investment Period Target assets Investment Amount
New, extended, Manufacturing

CDMO 2022.01~2022.12 1,214.0
supplemented, etc. facilities, etc.
4. Sales
A. Sales performance
(1) Sales performance by product type

(Unit: KRW Bil)
2022 2021 2020

Goods Biologics 2,161.3 72.0% 1,442.0 92.0% 1,102.6 94.7%
CDMO
Services Others 176.2 5.9% 126.0 8.0% 62.2 5.3%
Biopharmaceutical
development and
commercialization Goods Biosimilar 663.8 22.1% - - - -
(*1)
Total 3,001.3 100.0% 1,568.0 100.0% 1,164.8 100.0%

As a result, biopharmaceutical development and commercialization of Samsung Bioepis Co., Ltd. was added as a separate
business segment.
(2) Sales performance by location

(Unit: KRW Bil)
2022 2021 2020

Location
Korea 154.7 5.2% 346.3 22.1% 296.6 25.5%
Europe 1,785.9 59.5% 753.8 48.1% 527.5 45.3%
US 854.0 28.5% 448.6 28.6% 289.5 24.8%
Others 206.7 6.8% 19.3 1.2% 51.2 4.4%
Total 3,001.3 100.0% 1,568.0 100.0% 1,164.8 100.0%
B. Sales channel
(1) CDMO
order (from the date when a customer’s request for proposal was received until the date when a contract
The most important thing for Samsung Biologics’s sales activities is to sign contracts with customers
since the CMO business in which the Company is engaged is a contract-based industry. It usually takes
6~12 months to win an is concluded), and is implemented as follows :
[Order-winning process]
Category Details
• Inspect the status of customers (organization, number of products,
Discover a
Contact the clinical test progress, capacity, etc.)
potential
customer • Contact a customer when participating in exhibitions and introduce
customer
CMO services
Request for Meeting of • Email, telephone, visit and meeting, etc.
the persons in charge • Take the minutes of a meeting
customer’s Check the volume • Sign a confidential agreement, provide corporate profile data (incl.
CMO(RFP) to order capacity), attract to visit the Songdo site
• Review related divisions of each field
• Financial risk: review differentiated batch prices
Review risks
• Legal risk: existing products ordered, noncompetitive review with
Samsung Biologics’ products
Submit a
• Suggest contract terms in which the customer’s conditions for
proposal
manufacturing process are reflected
Review terms and
• Consider conditions including contract period, time available to
conditions
manufacture, price, scope of services, minimum volume
guaranteed, capacity reserve, etc.
Select candidate
• A customer selects 2~3 candidate CMOs
CMOs
Select a CMO
Select a preferred
• A customer selects a preferred CMO through final evaluation
CMO
• Review related divisions of each field
• Financial risk: minimum volume guaranteed/reserve volume,
Review risks
service sales item, etc.
• Legal risk: liability scope, noncompetitive clauses, etc.
Consult on
Consult on basic • Negotiate on and adjust major conditions
contract terms
contract terms • Prepare MOU and LOI
Consult on
detailed contract • Consult on conditions for master service agreement
terms
Exchange a final
Win a contract • Develop a final contract
contract
Following these procedures, the Company recognizes sales at the point of quality release (QR) by the
customer for the products manufactured, and delivers the customer’s inventory stored in the Company’s
warehouse to a location designated by the customer (generally a customer’s carrier) in accordance with
the contract. Meanwhile, the Company does not have separate sales channels or agencies.
(2) Biopharmaceutical Development and Commercialization

Samsung Bioepis products can be divided into two sales channel.
① Company → Partner → Wholesale/Hospital
Established partnerships with global or national pharmaceutical companies, and sells products to
wholesalers/hospitals by country through partnership.
② Company → Wholesale/Hospital
Products are sold to wholesalers or hospitals in some European countries through direct bidding or
contract.
C. Sales method and conditions
(1) CDMO
The sales method and conditions for biopharmaceutical manufactured by the Company are separately
determined by a contract with the customer. According to the contract, annual minimum volume of
production is determined, and the volume requested for PO by the customer is manufactured and
delivered to the designated location. Sales recognition and billing are implemented at the time when
the customer’s quality approval is obtained for the products manufactured, and the payment is collected
within 30~60 days after billing.

Samsung Bioepis manages the entire process related to development and production and hands over
the manufactured products to its partners. The sales method differs depending on the contract terms
with each partner, and sales are recognized through distribution of profits from products sold through
the partner company.
D. Sales strategy
(1) CDMO
The Company provides company information such as cutting-edge manufacturing facilities,
technological competence, and excellent manpower through various methods including homepage,
advertisements, press releases, overseas exhibitions/conferences, company presentations, and virtual
due diligence and exhibition hall while striving to raise its profile worldwide as a bio-company of
Samsung Group. Based on these efforts, the Company has participated every year in the BioPhorum,
a conference of executives from global biopharmaceutical manufacturers, since joining in 2012.
The Company will make new contracts and expand existing contracts by constantly communicating
about the Company’s production capacity, facility expansion progress, and future plans and by
maintaining relationships with existing/potential customers. The Company also leads strategic sales
activities by actively participating in various inner circle meetings to identify demand for
biopharmaceutical production and competitors’ production plans.
In addition, we are expanding our customers from large pharmaceutical companies to small and
medium-sized biotech companies, and to increase orders, we continue to strengthen our marketing
capabilities and expand our global network. Besides, we are enhancing our potential customers'
confidence in our production and quality control capabilities through thorough track record management.

Samsung Bioepis sells 6 types (3 autoimmune diseases, 2 cancer treatments, 1 eye disease) of
biosimilar products in various parts of the world, including the US and Europe, through partnerships
with global pharmaceutical companies. Bioepis is also selling 5 types (3 autoimmune diseases, 2 cancer
treatments) of products domestically through partnerships. Recently, the first eye disease treatment
(Lucentis biosimilar) was released in the US, and one autoimmune disease treatment(Humira biosimilar)
and one cancer treatment(Avastin biosimilar) were first released. Samsung Bioepis plans to
continuously lay the foundation for future growth as a global biosimilar leader by expanding our portfolio
of various biosimilar products including autoimmune diseases, cancer treatment, eye disease treatment
and rare diseases.
E. Sales condition
Initial
Total
Business commercial Delivered Order
Item Deadline Case amount of
Segment production amount backlog
contracts
year
Amount
9,466 4,458 5,008
Minimum Take (USD Mil)
or Pay Production
~2031 39,036,000 19,312,000 19,724,000
Antibody (Liter)
CDMO 2015 *Subject to
drugs each contract Amount
Expected demand (USD Mil) 15,993 4,458 11,535
when the customers
develop the products Production 63,131,000 19,312,000 43,819,000
(Liter)
Note 1) Total contract amounts may also increase after the consultation depending on the increase in customers’ demands.
Note 2) Total contract amounts above exclude raw material revenue from raw materials and supplies that have been put into
production and service revenue from production process improvements and additional services such as quality analysis.
5. Financial Risk Management and Derivative Instruments
A. Financial Risk Management Policy
The Company’s risk management policies are established to identify and analyze the risks faced by the
Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk
management policies and systems are reviewed regularly to reflect changes in market conditions and
the Company’s activities. The Company, through its training and management standards and
procedures, aims to maintain a disciplined and constructive control environment in which all employees
understand their roles and obligations. The Board of Directors oversees how management monitors
compliance with the Company’s risk management policies and procedures and reviews the adequacy
of the risk management framework in relation to the risks faced by the Company.
B. Credit Risk
Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial
instrument fails to meet its contractual obligations and arises principally from the Company’s receivables
from customers. The carrying amount of financial assets represents the maximum credit exposure. The
maximum exposures to credit risk at the end of 2022 and 2021 are as follows:
(Unit: KRW Thousand)
Description End of 2022 End of 2021
Cash and cash equivalents(*) 890,819,571 47,410,384
Short-term financial instruments 2,168,901,000 450,000,000

Financial assets at fair value
98,505,712 850,039,877
through profit or loss
Long-term financial instruments 7,335,813 189,491
Accounts receivable and other receivables 694,956,897 354,616,237
Derivative assets 18,137,458 4,091,971
Guarantee deposits 62,743,713 46,812,354
Total 3,941,400,164 1,753,160,314

(*) The cash amount held by the Company is excluded.
C. Liquidity Risk
Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated
with its financial liabilities which are settled by delivering cash or other financial assets. The Company’s
approach to managing liquidity is to ensure, as much as possible, that it will always have sufficient
liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without
incurring unacceptable losses or risking damage to the Company’s reputation.
The ultimate responsibility for liquidity risk management remains with the Board of Directors, which
establishes fundamental policies to adequately manage short-term, medium- and long-term financing
and liquidity management regulations. To maintain adequate liquidity, the Company manages liquidity
risk by periodically forecasting and adjusting its capital balance.
Contractual maturity dates of financial liabilities as of the 2022 and 2021 are as follows. The amount
includes interest paid and excludes the impact of netting agreements. The Company does not anticipate
that the cash flow included in the maturity analysis could occur significantly earlier or at different
amounts.
(1) End of 2022

Contractual More than
Description Book Value In 1 year 1-2 years 2~3 years
Cash Flow 3 years
Accounts payable and
2,157,597,481 2,180,535,735 1,624,767,738 555,767,997 - -
other payables
Lease liabilities 410,142,588 411,115,210 142,383,881 134,707,660 128,536,398 5,487,271
Bonds 539,031,053 562,194,181 50,279,070 387,507,876 2,632,800 121,774,435
Short-term borrowings 582,783,298 605,740,603 605,740,603 - - -

Long-term borrowings 982,076,000 1,036,664,018 552,276,183 367,541,644 116,846,191 -
Total 4,671,630,420 4,796,249,747 2,975,447,475 1,445,525,177 248,015,389 127,261,706
(2) End of 2021

Contractual More than
Description Book Value In 1 year 1-2 years 2~3 years
Cash Flow 3 years
Accounts payable and
345,578,834 345,578,834 342,930,338 2,648,496 - -
other payables
Lease liabilities 18,208,298 19,043,888 7,699,851 5,212,986 5,329,081 801,970
Bonds 538,553,996 573,433,181 11,239,000 50,279,070 387,507,876 124,407,235
Short-term borrowings 50,000,000 50,812,192 50,812,192 - - -
Long-term borrowings 685,985,000 711,781,531 123,454,360 435,842,182 152,484,989 -
Total 1,638,326,128 1,700,649,626 536,135,741 493,982,734 545,321,946 125,209,205
D. Foreign Exchange Risk
The Company is exposed to currency risk on sales, purchases, and borrowings. The currencies in which
these transactions primarily are denominated are USD and so forth. The Company establishes a plan
to manage currency risk through currency forwards and so forth, if considered necessary.
(1) Exposure to currency risk
The Company’s level of exposure to foreign currency risk is as follows :
End of 2022 End of 2021

Description
USD EUR JPY GBP Others USD EUR JPY GBP
Assets:
Cashable
211,388,497 173,584 - 3,067,221 196,680 2,609 - - -
asset
Short-term
financial 468,901,000 - - - - - - - -
instruments
Trade
receivable and
668,368,288 2,517,962 - 971,501 495,285 320,350,462 100,535 - 608,143
other
receivables
Contract
47,141,315 - - - - 27,999,271 - - -
asset
Subtotal 1,395,799,100 2,691,546 - 4,038,722 691,965 348,352,342 100,535 - 608,143
Liability:
Borrowings
116,821,298 - - - - 11,855,000 - - -
(*)
Trade
payables and
1,576,202,706 23,509,157 2,500,456 682,508 599,154 4,839,226 2,362,327 2,001 142,919
other
payables
Subtotal 1,693,024,004 23,509,157 2,500,456 682,508 599,154 16,694,226 2,362,327 2,001 142,919
Total (297,224,904) (20,817,611) (2,500,456) 3,356,214 92,811 331,658,116 (2,261,792) (2,001) 465,224
(*) Swap-covered borrowings are excluded as they are not exposed to currency risk.
(2) Exchange rate

The exchange rate applied during 2022 and 2021 are as follows :
(Unit: KRW)
2022 2021
Description
Average End Average End
USD 1,291.95 1,267.30 1,144.42 1,185.50
EUR 1,357.38 1,351.20 1,352.79 1,342.34
JPY(100￥) 983.44 953.18 1,041.45 1,030.24
GBP 1,592.33 1,527.67 1,573.96 1,600.25
(3) Sensitivity analysis

The Company regularly estimates the foreign exchange risk for fluctuations in KRW exchange rates.
The impact of fluctuations in exchange rates on income before income taxes when KRW exchange
rates change by 10% to each foreign currency as of the end of 2022 and 2021 are as follows :

Category
Increase of 10% Decrease of 10% Increase of 10% Decrease of 10%
USD (29,722,490) 29,722,490 33,165,812 (33,165,812)

EUR (2,081,761) 2,081,761 (226,179) 226,179
JPY (250,046) 250,046 (200) 200
GBP 335,621 (335,621) 46,522 (46,522)
Others 9,281 (9,281) - -
Total (31,709,395) 31,709,395 32,985,955 (32,985,955)
E. Interest Rates Risk
The Company is exposed to interest rate risk because it raised funds with interest paid at a variable
rate. If the interest rate changes by 0.5% as the end of 2022 and 2021, the effect of the change in the
interest rate on the income before income tax is as follows :

Description
Increase of 0.5% Decrease of 0.5% Increase of 0.5% Decrease of 0.5%
Increase(decrease) in
net income before (4,130,486) 4,130,486 (1,454,110) 1,454,110
income tax expense
F. Capital Management
The Company’s capital management is for the purpose of maximizing the shareholders’ interest by
maintaining an optimal capital structure. To achieve optimal capital structure, the Company may improve
its financial structure by monitoring financial ratios, such as the debt-to-equity ratio.
Debt ratio as of the end of 2022 and 2021 are as follows :

Description End of 2022 End of 2021

Liabilities (A) 7,597,575,863 2,978,908,646
Capital (B) 8,984,474,395 4,991,102,141
Debt ratio (A/B) 84.56% 59.68%
G. Derivative Instruments and Put-back Options
[Samsung Biologics]
The Company has established contracts for financial derivatives for foreign currency borrowings for
the purpose of hedging exchange rate risk of foreign currency receivables/debts and interest rate, and
the details are listed below.
(1) Currency Interest Swap Contract
Currency Committed Interest rate(%)

Financial Contract Contract Maturity
Classification Category exchange
institution Amount Date Date
Sell Buy rate Received Paid
Currency
USD Libor(3M)
Trading interest Hana bank 2018.05.31 2023.05.31 USD KRW 1,080 3.70
30,000,000 + 1.70
swap
Currency
USD Libor(3M)
Trading interest Woori bank 2021.08.30 2024.08.30 USD KRW 1,164 2.15
30,000,000 + 1.20
swap
(2) Interest Swap Contract
Interest rate(%)
Classification Category
Received Paid
Interest KRW CD(91Days)

Trading Woori bank 2020.09.28 2023.10.02 2.25
swap 50,000,000,000 + 1.23
(3) Derivative liabilities related to the acquisition of investment securities by other corporations
(conditional consideration)
The Company entered in an agreement to acquire 10,341,852 shares of Samsung Bioepis Co., Ltd.
owned by Biogen Therapeutics Inc. on January 28, 2022. The Company will determine whether the
conditions for payment of contingent considerations are satisfied by year according to the sales
performance of the investee company through the seller, and then decide the size of the contingent
consideration during 2027. The nominal amount that the Company is likely to pay in the future in
accordance with the above arrangement is in the range of USD 0 - 50,000,000. At the acquisition date,
the fair value of the contingent consideration was estimated as 20,541,985 thousand won using the
option valuation model.
(4) Gain and Loss on Valuation

(Unit: KRW)
Accumulated Other
Classification Gain on Valuation Loss on Valuation
Comprehensive Income
Currency Interest swap 7,168,254,287 - -
Interest swap 501,845,017 - -
Contingent considerations in
- 2,192,006,326 -
the stock purchase
[Samsung Bioepis]
The Company has established contracts for financial derivatives for foreign currency borrowings for the
purpose of hedging exchange rate risk of foreign currency receivables/debts and interest rate, and the
details are listed below.

Currency
USD Libor(3M)
30,000,000 + 1.80
swap

- Not applicable
(3) Gain and Loss Valuation of Derivative Liabilities

(Unit: KRW)
Accumulated Other
Currency Interest swap 111,659,231 - -
Interest swap - - -
6. Major Contracts for Business Management
A. License-Out Contracts
- Not applicable
B. License-In Contracts
- Not applicable
C. Sales Contracts
[Samsung Biologics]
As of the date of preparation of the disclosure document, the current status of major sales contracts
signed by the Company are as follows.
(Unit: USD Mil)
Contract Contract Payment

Company name Details Amount Remarks
start date end date method
Biopharm Cilag GmbH International CMO 2016.11.15 - 373.0 Cash -

Biopharm Sun Pharma Global FZE CMO 2017.07.04 - 55.5 Cash -
Biopharm U.S. based pharma CMO 2017.07.20 - 14.9 Cash -
Biopharm UCB CMO 2017.12.21 - 41.7 Cash -
Biopharm TG Therapeutics, Inc. CMO 2018.02.21 2026.12.31 50.3 Cash -
Swiss based subsidiary of a global
Biopharm CMO 2018.04.30 2025.12.31 449.4 Cash -
pharma
Biopharm Ichnos Sciences CMO 2018.06.01 - 15.1 Cash -
Biopharm Asia based pharma CMO 2018.08.14 - 127.6 Cash -
Biopharm Gilead Sciences, Inc. CMO 2018.09.11 2025.12.31 266.5 Cash -
Biopharm Immunovant Sciences GmbH CMO 2018.12.18 2029.12.31 43.5 Cash -
Biopharm CytoDyn Inc. CMO 2019.04.01 2027.12.31 50.2 Cash -
Biopharm UCB CMO 2019.05.17 - 33.8 Cash -
Biopharm H. Lundbeck A/S CMO 2019.09.27 2031.12.31 27.9 Cash -
Biopharm U.S. based pharma CMO 2019.12.03 - 58.2 Cash -
GlaxoSmithKline Trading Services
Limited
Biopharm Eli Lilly and Company CMO 2020.07.27 2026.08.30 268.3 Cash -
Limited
Biopharm AstraZeneca UK Ltd., CMO 2020.09.21 2023.12.31 16.0 Cash -
Biopharm AstraZeneca AB CMO 2020.09.21 2028.12.31 377.5 Cash -
Biopharm Checkpoint Therapeutics, Inc., CMO 2020.10.06 2030.10.02 19.7 Cash -
Biopharm U.S. based pharma CMO 2020.11.03 2030.12.31 16.1 Cash -
Biopharm F.Hoffmann-La Roche Ltd CMO 2021.01.15 2024.12.31 202.3 Cash -
Biopharm F.Hoffmann-La Roche Ltd CMO 2021.01.15 2024.12.31 550.2 Cash -
Letter of
Biopharm AstraZeneca UK Ltd., CMO 2021.05.14 - 351.0 Cash
Intent
Letter of
Biopharm Europe based pharma CMO 2021.10.30 2023.03.31 76.7 Cash
Intent
Biopharm Eli Lilly Kinsale Limited CMO 2022.03.28 2029.12.31 92.0 Cash -
Letter of
Biopharm Europe based pharma CMO 2022.04.25 2023.03.31 124.1 Cash
Intent
Letter of
Biopharm Novartis Pharma AG CMO 2022.06.04 - 81.0 Cash
Intent
Biopharm MSD International Business GmbH CMO 2022.07.02 2028.12.31 263.6 Cash -

Limited
[Samsung Bioepis]
As of the date of preparation of the disclosure document, the current status of major sales contracts
signed by the Company are as follows.
Contracting Contract purpose, Contract Contract Payment

Product Amount Remarks
party condition, etc start date end date method
SB2 (Remicade biosimilar) Marketing, sales, and supply of

SB3 (Herceptin biosimilar) products are carried out with US,
SB5 (Humira biosimilar) Organon LLC exclusive sales rights for 2013.02.18 Note 1 Note 1 Cash Europe,
SB8 (Avastin biosimilar) contracted products within the etc
SB4 (Enbrel biosimilar) target area.
Marketing, sales, and supply of

SB2 (Remicade biosimilar) Biogen products are carried out with
Europe,
SB4 (Enbrel biosimilar) International exclusive sales rights for 2013.12.13 Note 1 Note 1 Cash
etc.
SB5 (Humira biosimilar) Holding Ltd contracted products within the
target area.
Marketing, sales, and supply of
products are carried out with US,
SB11 (Lucentis biosimilar) Biogen
exclusive sales rights for 2019.11.05 Note 1 Note 1 Cash Europe,
SB15 (Eylea biosimilar) MA Inc
contracted products within the etc
target area.
Note 1) Details are not provided as they are considered as trade secrets.
D. Other Contracts
[Samsung Biologics]
(1) Contract signed to construct plant #4

At the Board of Directors meeting on October 26, 2021, the Company and Samsung Engineering Co.,
Ltd. decided to sign the contract. The actual signing was on October 29, 2021. The down payment
was KRW 911 billion (VAT excluded).
(2) Purchase of site for Knowledge & Information Industrial Complex

On November 3, 2021, the Company signed a contract with the Incheon Free Economic Zone
Authority to purchase the site at 218-3 Songdo-dong. The purchase price was KRW 7.8 billion.
(3) Signed a contract to acquire full ownership of Samsung Bioepis

For the diversification of its portfolio and enhancement of business competitiveness as a
Biopharmaceutical company, the Company agreed to acquire 10,341,852 shares of Samsung Bioepis
Co., Ltd. owned by Biogen Therapeutics Inc. in accordance with the resolution of the Board of Directors
on January 28, 2022. The total transaction payment amount of USD 2,300,000,000 comprises of the
purchasing price and contingent consideration amounting to USD 2,250,000,000 and USD 50,000,000,
respectively. On April 20, 2022, the Group acquired 10,341,852 shares of Samsung Bioepis Co., Ltd.
and secured control of the investee by obtaining 100% of the shares.
(4) 2nd Bio Campus site purchase contract

On July 18, 2022, the company entered into a contract with the Incheon Free Economic Zone Authority
(IFEZ) for the purpose of purchasing the 2nd Bio Campus site, and the purchase price was KRW 426
billion. The company must fulfill all procedures, such as facility construction plans and consent to use,
within a certain period from the effective date of the sales contract, otherwise the sales contract may
be canceled.
E. R&D Activities
(1) R&D organization
[Samsung Biologics]
The Company has R&D organizations as follows: Manufacturing Science And Technology
Department, CDO Development Center, Bio R&D Center, Samsung Biologics America R&D team.
These organizations provide technical support for clients’ manufacturing production and R&D services
for cell line development.
[Job description]
Category Details
1) Research services for improving client manufacturing production

Technical support for 2) Technology transfer
manufacturing production - R&D project between a client for products which are to be produced in the Company’s site
- Technology transfer or development service of analysis method
1) Cell line development service (develop high-productivity cell lines)

2) Process development service (improve the productivity through process development)
Cell line and process
- R&D by combining process conditions and culture medium to improve a tire when culturing cells
research/ development
- R&D for the process to improve target protein refining yield
- R&D related to quality analysis
[Samsung Bioepis]
Samsung Bioepis R&D is carried out in the Advance Development Division (CD team, etc.) and
Development Division(PD team, MSAT team, QE team, etc.), and is in charge of cell line and process
research/development, clinical medicine-related activities, and production-related technical support.
[Job description]
Category Details
1) Cell line development service (develop high-productivity cell lines)

2) Process development service (improve the productivity through process development)
Cell line and process
- R&D by combining process conditions and culture medium to improve a tire when culturing cells
research/development
- R&D for the process to improve target protein refining yield
- R&D related to quality analysis
1) Clinical related activities
- Preparation of clinical planning and protocol, preparation of clinical trial result report
- Clinical operation such as selection/management of clinical outsourcing companies, project
Clinical medicine execution, etc.
related activities - Management of clinical trial result data statistics and clinical data
2) Medical related activities
- Proof of medical excellence through external academic presentations, etc.
- Drug safety management and action in case of adverse events
1) Research services for improving client manufacturing production

Technical support for 2) Technology transfer
manufacturing production - R&D project between a client for products which are to be produced in the Company’s site
- Technology transfer or development service of analysis method
(2) R&D Manpower Status
[Samsung Biologics]
As of the reporting date, the Company has 608 staff members assigned to research and development
activities, with 68 holding doctorate degrees and 248 holding master’s degrees. The details are as
follows :
(Unit: person)
Team Ph.D M.S. Other Total

Manufacturing Science And
22 122 219 363
Technology Department
CDO Development Center 14 100 68 182
Bio R&D Center 32 26 4 62
SBA R&D Team - - 1 1
Total 68 248 292 608
[Samsung Bioepis]
As of the reporting date, the Company has 512 staff members assigned to research and development
activities, with 95 holding doctorate degrees and 205 holding master’s degrees. The details are as
follows :
(Unit: person)
Team Ph.D M.S. Other Total

Advance Development Division 21 11 8 40
Manufacturing Division 74 194 204 472
Total 95 205 212 512
(3) Key R&D Personnel
[Samsung Biologics]
The details of the Company’s key R&D personnel are as follows:
Name Position Function Career R&D Performance
[Theses]
- Development of drug-inducible
CRISPR-Cas9 systems for large-scale
functional screening. (2019, BMC
Genomics)
- Small molecule and pooled CRISPR
- Vice president, Vesalius
screens investigating IL-17 signaling
Therapeutics Platform Innovation
identify BRD2 as a novel contributor to
- Adjunct professor at University of
keratinocyte inflammatory responses.
California, SanFrancisco
Executive Bio R&D (2019, ACS Chem. Biol.)
Chung - AbbVie Head of functional
Vice Center - VHL synthetic lethality signatures
Namjin Genomics
President Leader uncovered by genotype-specific
- Principal Scientist, Bristol-Myers
CRISPR-Cas9 screens. (2019,
- Senior Scientist, Merck
CRISPR J.)
- Doctor of Phamacology and
- CRISPR/Cas9-targeting of CD40 in
oncology at Duke University
hematopoietic stem cells limits immune
activation mediated by anti-CD40.
(2020, PLoS One)
- VISTA is an activating receptor in
human monocytes. (2021, J. Exp.
Med.)
[Theses]
- A phase II trial of the pan-HER inhibitor
poziotinib, in patients with HER2-positive
metastatic breast cancer who had
received at least two prior HER2-
directed regimens: results of the
NOV120101-203 trial (2018,
International Journal of Cancer)
- Head of CDO, Samsung Biologics
- Once-Weekly Efpeglenatide Dose-
- CDO Business Unit Leader,
Range Effects on Glycemic Control and
Samsung Biologics
Body Weight in Patients With Type 2
- CEO, Lumebio
Diabetes on Metformin or Drug Naive,
- Clinical Research & Development
Head of Referenced to Liraglutide (2019,
Vice President,
Kang Vice CDO Diabetes Care)
Hanmi Pharmaceutical Company
Jahoon President Development - Body weight management and safety
- Senior Clinical Project Manager,
Center with efpeglenatide in adults without
Novartis
diabetes: A phase II randomized study.
- Clinical Research Associate,
(2019, Diabetes Obes Metab.)
Chong Kun Dang
- Efficacy and safety of oncemonthly
- Doctor of Pharmacy, Sookmyung
efpeglenatide in patients with type 2
Women’s University
diabetes: Results of a phase 2
placebocontrolled, 16-week randomized
dose-finding study (2020, Diabetes
Obes Metab.)
- Pharmacokinetic and dose-finding
studies on efpeglenatide in patients with
type 2 diabetes. Diabetes (2020, Obes
Metab.)
[Theses]
- Bioreactor Operation for Transgenic
Nicotiana tabacum Cell Cultures and
Continuous Production of Recombinant
Human Granulocyte-Macrophage
- MSAT Business Unit Leader,
Colony-Stimulating Factor by Perfusion
Samsung Biologics
Culture (2004, Enzyme Microb. Technol.)
Lee Vice Head of - Global Management Leader,
- Effects of Pluronic F-68 on Cell Growth
Sangyoon President Msat Celltrion
of Digitalis lanata in Aqueous Two-Phase
- Doctor of Biotechnology,
Systems (2004, J. Microbiol. Biotechnol.)
Inha University
- Perfusion Cultivation of Transgenic
Nicotiana tabacum Suspensions in
Bioreactor for Recombinant Protein
Production (2006, J. Microbiol.
Biotechnol.)
[Theses]
- Phytosphingosine and C2-
- USP2 Part Leader, phytoceramide induce cell death and
CDO
Samsung Biologics inhibit carbachol- stimulated
Lee Vice R&D
- Yuhan Corporation phospholipase D activation in Chinese
Jaesun President Team
- Doctor of Biochemistry, hamster ovary cells expressing the
Leader
Chungbuk National University Caenorhabditis elegans muscarinic
acetylcholine receptor (2001, FEBS
letters)
[Samsung Bioepis]
The details of the Company’s key R&D personnel are as follows:
[Theses]
- Optimized clinical performance of
Research & growth hormone with an expanded
Executive Early - Bristol Myers Squibb genetic code. (2011, PNAS)
Cho
Vice Development - Celgene - BeF3- acts as a phosphate analog in
HoSung
President Division - Doctor of Chemistry, UC Berkeley proteins phosphorylated on aspartate:
Leader structure of a BeF3- complex with
phosphoserine phosphatase. (2001,
PNAS)
[Theses]
- Samsung Bioepis QE Team Leader - Clb-independent degradation of Met:
Executive Development - Samsung Electronics Advanced way to avoid agonism of bivalent Met
Kim
Vice Division Institute of Technology targeting antibody (2012, Oncogene)
Kyungah
President Leader - Doctor of Toxcology, The Johns - Mitogenic influence of R-Spondin 1
Hopkins University Protein on the Intestinal Epithelium
Neurotrophin (2005, Science)
[Theses]
- Factor Xia-specific IgG and a reversal
agent to probe intrinsic pathway function
in thrombosis and hemostasis (2016,
- Catalent Pharma
Kim Vice CD Team Science Translational Medicine)
- Pfizer
YunCheol President Leader - Inhibitors of My D88-dependent
- Doctor of Microbiology, UCLA
proinflamatory cytokine production
identified utilizing a novel RNA
interference screening approach (2010,
Plos One)
[Theses]
- Real-time monitoring of glycerol and
methanol to enhance antibody
production in industrial Pichia pastoris
- Molecular Templates
bioprocesses (2015, Biocherrical
Kim Vice PD Team - Merck
Engineering Journal)
Sehoon President Leader - Doctor of Chemical Engineering,
- Inhibition of prostate cancer osteoblastic
Texas A&M University
progression with VEGF121/rGel, a
single agent targeting osteoblasts,
osteoclasts, and tumor neovasculature
(2011, Clin Cancer Res)
F. R&D Expenses
(Unit: KRW Bil, %)

2022 2021 2020
Raw material expenses 51.2 16.4 19.3
Labor expenses 100.4 44.4 35.7
Type of Depreciation expenses 22.8 16.0 10.5
expenses Outsourcing expenses 80.7 - -
Others 13.1 15.1 13.1
Total R&D expenses 268.2 91.9 78.6
SG & A expenses 81.3 3.4 5.1
Manufacturing expenses 118.2 88.5 73.5
Accounting
classification Development expenses
68.7 - -
(Intangible Assets)
Total R&D expenses 268.2 91.9 78.6
R&D expenses/ Sales Ratio
8.9% 5.9% 6.7%
[Total R&D expenses / Sales*100]
Note 1) Consolidated basis in accordance with K-IFRS.
Note 2) The Company is not applicable to government subsidies.
G. R&D Performance
[Samsung Biologics]
(1) R&D Progress Status and Future Plans

The Company provides Contract Manufacturing Organization (CMO) and Contract Development
Organization (CDO) services to clients. The Company operates four R&D organizations; Technology
Support Center, New Business Center, Bio R&D Center, and SBA R&D Team. These organizations are
dedicated to providing technical support for manufacturing production and R&D services for cell line
and process development. In addition, the Company is currently expanding its presence in contract
R&D services for cell line development for further expansion. While widening the scope of the business
area, the Company is doing its utmost to become the global CDMO provider.
(2) R&D Completion Performance

The Company provides a wide range of technical services to clients, including Cell Line Development
and Method Development. The Company currently has no completed pipelines.
[Samsung Bioepis]
(1) R&D Progress Status and Future Plans

As of the date of preparation of disclosure document, the current status of new medicines(including
incrementally modified drug, generic drugs(biosimilar), etc.) under R&D is as follows:
Current status
Research
Type Product Application Approval Remarks
start date Phase(Country)
date
New Phase I
SB26 Acute pancreatitis 2017 - -
medicine complete(US)
Phase III
(Korea, EU, etc)
Paroxysmal nocturnal completed and Self-
SB12 2014 -
hemoglobinura application for development
EU marketing
authorization
Neovascular age-related
Phase III
macular degeneration,
complete Self-
Biosimilar SB15 Macular Edema Following 2015 -
(Korea, US, EU, development
Retinal Vein Occlusion,
etc)
Diabetic macular edema
Phase III Self-
SB16 Osteoporosis 2015 2020
(Korea, EU) development
Plaque psoriasis Phase I Self-
-
Psoriatic arthritis complete(EU) development
SB17 2015
Crohn's disease Phase III Self-
2021
Ulcerative colitis (Korea, EU) development
※ For detailed information, refer to 'Table-4, R&D Performance(Details)'
(2) R&D Completion Performance

As of the date of preparation of disclosure document, the current status of new medicines (including
generic drugs(biosimilar), etc.) that have been developed is as follows:
Research Current Remarks

Type Product Application
end date Sales status (Partner company)
Rheumatoid arthritis
Biosimilar SB2 psoriasis, psoriatic arthritis 2015 Korea, US, EU Biogen, Organon, Yuhan
Crohn's disease, ulcerative colitis
SB3 Breast cancer 2017 Korea, US, EU Organon, Boryung
SB4 2015 Korea, EU Biogen, Organon, Yuhan
psoriasis, psoriatic arthritis
SB5 psoriasis, psoriatic arthritis 2017 Korea, EU Biogen, Organon, Yuhan
Colon cancer, lung cancer,
SB8 2020 Korea, EU Biogen, Organon, Boryung
ovarian cancer
US,
SB11 Macular degeneration 2021 Biogen, Samil pharm
Korea(approved)
※ For detailed information, refer to 'Table-4, R&D Performance(Details)'
7. Other Information
A. Laws and Regulations Affecting Business Operation
Pharmaceutical manufacturer is under strict government regulation throughout all phases (pre-clinical
phase, clinical phase, IND approval, production and distribution, etc.) due to their nature of providing
products which bring significant impact on human lives.
Laws Details
- Regulate overall matters concerning medicine manufacturing business such as quality

control and manufacturer designation
Pharmaceutical Affairs
- Obtain a manufacturing license according to the Act
Act
- Impose administrative measures (revocation of license) or criminal punishments
(imprisonment or punishment of a fine)
Unfair Competition
and Prevention and
- Regulate the act of unjustifiably using or disclosing trade secrets of clients
Trade Secret
Protection Act
Act on the
Registration and - Regulate the registration, evaluation, and management of chemical substances that are
Evaluation, Etc. of not controlled as drug and quasi-drug by the Pharmaceutical Affairs Act
Chemical Substances, - Registration and evaluation requires cost and time to import the drug substances that fall
Toxic Chemicals under chemical substances subject to the Act
Control Act
Transboundary
Movement, Etc. of - Inspect the risks posed by living modified organisms
Living Modified - Regulate the import of living modified organisms and registration of the research facility
Organisms Act
- Regulate unfair trading practices and unfair collective practices across the entire business
area including winning an order for CDMO project, building manufacturing facilities, and
Fair Trade Act
purchasing materials
- Impose corrective measures, penalty, fine, etc. if related matters are violated
B. Business-related Important Intellectual Property Rights

[Samsung Biologics]
Through continuous research and development related to biopharmaceutical manufacturing, the
Company applied for a number of patents and registered one patent in 2022 since the first patent
application in 2020. These patents (applications) are for materials, processes, and equipment related
to biopharmaceutical manufacturing, which is the main business field, and are used or will be used in
the future to perform the Company's main/strategic services.
During the first half of 2020, Samsung Biologics launched its proprietary cell line development platform
S-CHOice. As of the end of 2021, The brand name S-CHOice has officially obtained its trademarks in
six countries (Korea, US, EU, UK, China, and Japan). In addition, S-Cellerate, a CDO platform brand
that compiles our accumulated know-how, expertise, and innovative technology across all areas of
consignment development service, was completed the registration of domestic trademarks in December
2021. The Company completed the trademark registration of the slogan Driven. For Life. in South Korea
and Madrid as of the end of 2021. In addition, trademarks were registered for the bispecific antibody
platform S-DUAL and the new drug candidate discovery platform DEVELOPICK service, which were
launched in the 2nd half of 2022. The Company strives to secure intellectual property/ trademark rights,
including related patent and trademark rights, through continuous research development related to
biopharmaceutical manufacturing.
[Samsung Bioepis]
As of the filing date of the disclosure document, Samsung Bioepis has over 200 registered trademarks
in Korea and overseas, including Samfenet, Remaloce, Etoloce, and Onbevezy, in relation to the
products launched by Samsung Bioepis. In addition, the Company secured a number of related patents
through the development of biopharmaceuticals, and are striving to secure various intellectual property
rights through continuous R&D.
C. Environmental Regulations
With an environmental policy placing environmental contaminant reduction and green values at the top
of its priorities, the Company commits itself to do all it can to prevent undesired environmental events
and make utmost efforts to lead the sustainable future.
To put this into practice, the Company strives to achieve compliance with environmental regulations and
reduce contaminant generation in addition to actively being engaged in chemical accident prevention
by implementing a life cycle management system for all chemicals handled in its business sites. In
addition, the Company follows regulatory requirements for contaminant emission standards, reports the
amount of greenhouse-gas emission and energy usage and transparently discloses relevant
information to its stakeholders in order to meet the government’s low-carbon growth policies and
responses to climate change.
(Business site management, compliance with environmental regulations and contaminant reduction)
The Company has installed and is operating various facilities for water pollution prevention, air pollution
prevention, waste storage, noise control, etc. to minimize emission of contaminants generated from
biomedicine manufacturing processes so that impact on the surrounding social environment can be
minimized. For business site environment management, regular self-inspections in addition to
management and supervision of relevant authorities have been carried out. As such, the Company’s
excellent environment control capability was acknowledged by being selected as the Best Company for
Environment Management by the City of Incheon three times, in 2015, 2018 and 2021.
The Company discloses transparent information on environmental emission performance and operational
status each year and is making efforts for regulatory compliance and contaminant reduction through
continued investment.
- The Company has built a continuous monitoring system for basic

TMS System
environmental facilities to monitor contaminant emission standards and is
Operation
making constant efforts to prevent environmental pollution accidents.
- The Company is striving to reduce waste through various activities

including garbage separation and recycling systems for the wastes
Waste Resource discharged from its business sites. While the Company keeps an eye on
Circulation the entire process from waste emission to final disposal, it also carries out
regular inspections/ evaluations on outsourced waste disposal companies
on annual basis.
Investment on - The Company is making continuous investment on basic environmental

Environmental facilities for the sake of preventing and improving environmental pollution
Improvement of its business sites and local community.
(Chemical Substance Management)

The Company has built an integrated chemical substance management system in order to comply with
the [Chemical Substances Control Act] and the [Act on Registration, Evaluation, etc. of Chemicals.]
The Company is working actively to prevent chemical accidents by having all chemical substances go
through pre-evaluation before warehousing and managed throughout the process up to disposal.
Regular training is performed for those handling chemical substances, and safety management
activities are thoroughly executed by conducting training sessions on protective equipment wearing,
emergency response drilling, etc.
Integrated Chemical
- The Company is making efforts to prevent chemical accidents across the
Substance
Company by managing the lifecycle (entire process) of chemical
Management
substances using the chemical substance management system.
System
Management of - In an effort to manage and improve chemical substance handling facilities,

Hazardous the Company has installed double piping, sensors, emergency shutdown
Chemical facilities, etc. to prevent accidents from these facilities and regular
Substance Handling inspections on these installations are performed annually by specialized
Facilities agencies.
- The Company is operating and managing the 24-hour operated emergency
All-time Monitoring
response center (CCR: Central Control Room) for real-time monitoring of
System
abnormal signs and immediate emergency response.
(Response to Climate Change)

In accordance with Article 8 of the Act on the Allocation and Trading of Greenhouse-Gas Emission
Permits, the Company has followed relevant regulatory standards since 2017. The Company also
reports to the government its greenhouse-gas emission and energy use after 3rd party verification and
transparently discloses the report to its stakeholders.
In addition, the Company is reinforcing its management on unexpected risks including climate change,
natural disasters, etc. through certification of the international standard for Business Continuity
Management System (ISO 22301).
Greenhouse-Gas - Each year, the Company manages and discloses greenhouse-gas

Emission Control emission monitoring plans and statements through 3rd party verification.
- The Company is making efforts to reduce emission of contaminants

Total Air Pollution including nitrogen oxides, dusts, etc. that can impact climate warming
Load Management through monitoring on air contaminant emission sources and operating
highly efficient reduction systems.
- The Company is making investments to introduce and improve highly

Energy Use efficient facilities for sustained energy/greenhouse-gas reduction activities
Reduction and is also taking the lead in making efforts to reduce greenhouse-gas
emission through regular energy diagnosis from external agencies.
Greenhouse-gas emission and energy consumption for the recent five years are as follows :
Annual Greenhouse Gas Emissions (ton) Annual Energy Consumption (TJ)

Year
Direct Indirect Total Gas Electricity Steam Total
2018 40,967 75,612 116,579 803 1,557 - 2,360
2019 40,166 79,625 119,791 788 1,639 - 2,427
2020 41,793 83,014 124,807 820 1,709 - 2,529
2021 44,032 86,835 130,867 863 1,815 - 2,678
2022 54,571 109,422 163,933 1,071 2,286 - 3,357
※ The subjects are our plant, shuttle bus, rental building, etc.
※ The data provided above is submitted to the “National Greenhouse Gas Management System.”
※ Emissions and energy consumption may change depending on the verification results of external verification agencies.
※ Refer to H. Green management in 4. Subsequent events under XI. Other Information for details.
D. Industry Overview
[Samsung Biologics]
(1) Nature of Industry

The biopharmaceutical Contract Manufacturing Organization (CMO) business provides drug
development and manufacturing services to global pharmaceutical companies on a contract basis to
allow them to focus on R&D activities and marketing.
The Company operates primarily in the antibody drug segment, which requires large investments in
commercial plants and at least a three-year period to complete the commercialization process including
plant design, construction, and validation. In addition, antibody drug requires a high degree of quality
control management which ensures Good Manufacturing Practices (GMP) throughout all processes
using mammalian cells including cell culture, purification, and filling.
Furthermore, pharmaceutical companies spend typically over two years to complete technology transfer,
test production, multinational regulatory GMP certificates and other necessary steps to produce
commercial drugs using CMOs. Therefore, each CMO contract is usually long-term between five to ten-
year period.
(2) Growth Potential

1) Continuous Development of Blockbuster Biopharmaceuticals
Blockbuster biopharmaceuticals released around the year 2000 (immunosuppressant drugs, anticancer
drugs, antidiabetic drugs, etc.) still show a high level of sales growth, and new promising antibody drugs
for hyperlipidemia, Alzheimer’s disease, and atopic dermatitis along with immune checkpoint inhibitors
continue to be released.
2) Expansion of Production Outsourcing by Global Biopharma companies
Pharmaceutical companies are expanding the areas of production outsourcing to specialized CMOs
where massive capital investments are required to minimize the uncertainty in marketing authorization
and sales forecasting of drugs. This market change gives a new opportunity to CMOs.
3) Increasing Demand for End-to-end CDMO Service to Biopharma Companies
Global CDMO companies are aiming for a one-stop shop model that can provide end-to-end services
to reduce pharmaceutical companies' development to production, clinical development to
commercialization needs, and complexity of a single project.
4) Increasing Demand for Dual Sourcing to Secure Supply

Recently, regulatory authorities across the world have strongly recommended pharmaceutical
companies to secure a source for stable drug production. The U.S. Food and Drug Administration (FDA)
requested pharmaceutical companies to establish a contingency plan, believing that supply stability
cannot be guaranteed in case the drug is manufactured in a single site. Accordingly, pharmaceutical
companies are making use of CMOs to run multiple manufacturers for a single drug.
In 2022, the global biopharmaceutical market is valued at USD 359 billion, which accounts for 29.7%
of the entire pharmaceutical market. The market is expected to increase with an average growth rate of
10.6% in 2026, boosting the growth of the overall pharmaceutical industry.
Biopharmaceutical Market Size
Source: EvaluatePharma, May 2022
The global bio-CDMO market is valued at USD 14.3 billion in 2022 and is forecasted to reach USD 20.3
billion by 2026 at an average growth rate of 10.1% for the next five years.
Bio CDMO Market Size

Source: Evaluate Pharma and Frost&Sullivan (Jul 2021)
(3) Economic Fluctuation
- Not applicable
[Samsung Bioepis]
(1) Nature of Industry

A biosimilar is a drug that is replicated from an existing biologic. In the field of synthetic drugs, such
drugs are called generic drugs, whereas in the field of biopharmaceuticals, they are called biosimilar.
Unlike the structure and production process of synthetic drugs, biopharmaceutical is impossible to
duplicate with 100% identical structure and efficacy as it starts from a living organism and only possible
to develop and produce a drug with similarity over a certain standard. The global biosimilar industry has
become a favorable market environment for biosimilar development, reflecting the continued expiration
of patents for original drugs, increased market demand for cheaper biosimilars compared to original
drugs, and changes in government policies. Domestic biosimilar companies are becoming more
prominent in the global biosimilar market, and according to the Ministry of Food and Drug Safety,
domestic biosimilar exports increased more than 7 times over 7 years from $204.77 million in 2014 to
$1.60965 billion in 2020.
(2) Growth Potential

As the patent protection period of major original biopharmaceuticals expires in the future, the size of
the biosimilar, which is equally effective as original biologics and competitive in terms of price, market
is expected to continue to expand. In particular, it is predicted that the growth of the biosimilar industry
will continue as more than 15 biopharmaceutical patents expire by 2032. According to EvaluatePharma,
a market research firm, the biosimilar market is expected to grow at an average annual growth rate of
7% from $11.1 billion in 2021 to $18.1 billion in 2028.
(3) Economic Fluctuation

1) Life cycle
Compared to other industries, the life cycle of the pharmaceutical industry has long and stable
characteristics due to the monopoly rights of pharmaceuticals recognized by law in most countries.
2) Economic fluctuations and accountability

Similar to the characteristics of the biopharmaceutical industry, which treats cancer, autoimmune
diseases, and chronic diseases, the biosimilar industry is not prone to economic fluctuations or seasonal
issues.
3) Alternative market status

Pharmaceuticals can only be sold after getting approved through the approval process of the strict
standards set by the Country. In particular, it is difficult to form an alternative market compared to other
industries because specialty drugs are institutionally protected so that they can only be purchased with
a doctor's prescription.
E. Competition Status
[Samsung Biologics]
The Company has emerged as a global bio CMO based on production facilities by securing a total
capacity of 424,000 liters including 360,000L (Plant 1 – 30,000L, Plant 2 – 150,000L, Plant 3 – 180,000L)
of commercial production facilities, 4,000L of clinical production facilities, and 60,000L of Plant 4 partial
operation in Incheon Free Economic Zone (Songdo District). As of 2022, competitors with similar
capacity of more than 300,000 liters include Switzerland-based Lonza and Germany -based Boehringer
Ingelheim. In addition, China-based Wuxi Biologics and US-based Fujifilm Diosynth are aggressively
expanding capacity both domestically and internationally.
[Samsung Bioepis]
The Company's main competitors include Pfizer and Amgen (US), Sandoz (Switzerland) and Celltrion
(Korea). The Company competes with other biosimilars in major countries such as US and Europe
against 3 types from Pfizer (Remicade, Herceptin, Avastin), 4 types from Amgen (Humira, Herceptin,
Avastin, Remicade), 3 types from Sandoz (Remicade, Enbrel, Humira), and 3 types from Celltrion
(Humira, Remicade, Herceptin).
F. Competitiveness
[Samsung Biologics]
In CMO industry, it is essential to integrate 1) good quality management to secure adequate

environment for manufacturing biopharmaceuticals, 2) quick operational systems to serve clients in
timely manner, and 3) reliable sales activities for winning contracts.
The Company complies with global GMP standards in each stage of operations, and the clients have
rights to carry out audits and inspections of all manufacturing processes. In addition, the Company
ensures full documentation of each step and result throughout manufacturing process.
The Company’s global contract sales division is in charge of new business operation and sales activities,
and supports the activities for winning new contracts utilizing local manpower in main strongholds in the
Eastern and Western states of the United States including San Francisco, Boston, and New Jersey.
The sales division regularly holds meetings with global pharmaceutical companies and provides them
with information on the Company’s CMO services and manufacturing facilities at the meetings. The
division also continuously sends sales and marketing representatives to overseas bio-conferences to
identify latest technology trends in the market and contact potential customers as part of strategy to
maintain a strategic relationship with customers. In addition, the company has established non-face-to-
face platforms such as virtual exhibition halls and live virtual tour and inspection systems to minimize
the impact of COVID-19 prolonged period, and is strengthening non-face-to-face activities such as video
conferencing with customers and Webinars.
[Samsung Bioepis]
Since the establishment, the Company released 6 types of biosimilar (Remicade, Herceptin, Enbrel,
Humira, Avastin, and Lucentis similars). In this process, the Company shortened the development
period compared to other companies by developing a process that satisfies the quality requirements of
the permitting agency and conducted clinical trials efficiently. In addition, as a result of securing cost
competitiveness by developing process technology with high productivity, the Company launched
products that secured profitability despite a drop in market prices. The company will continue to develop
technologies to improve process optimization and operation efficiency to release products with
competitive advantages in the future.
G. New Business and Market Prospect
[Samsung Biologics]
The Company is currently widening the scope of business to CDO services, mRNA and cell/gene
therapy to transform into global biopharmaceutical company. The CDO business provides cell line and
process development and characterization services for small and medium-size Biotechs, which do not
have own development facilities. The Company successfully launched high-performing cell line ‘S-
CHOice’, which delivers high productivity and viability, and ‘S-Cellerate’, which is a platform that
innovatively shortens the development period through a standardized process for each development
stage. In September 2022, Biologics unveiled 'S-DUAL', a next-generation bispecific antibody platform
with improved safety and binding ability with a structure similar to human antibodies, and
'DEVELOPICK', a technology for screening new drug candidates. Biologics will continue to develop our
own new technology in CDO field.
Furthermore, the Company opened a global CDO R&D center in the renowned San Francisco
Biopharma Cluster in October 2020 and currently plans to widen the scope of the market to Boston,
and Europe. The Company has implemented mRNA production capacity within its existing
manufacturing plant, which is cGMP ready in April 2022. Additionally, the Company is under review for
various options including construction and M&A, considering overall technology trends, marketability
and profitability related to cell and gene therapy. Additionally, the Company signed a contract to
purchase the Land for Second Bio Campus to build additional plant in Songdo, Korea in July 2022.
III. Financial Affairs
1. Financial Statements
Refer to Audited Financial Statements published on the Company’s Website.
2. Consolidated Financial Statements

3. Notes to Consolidated Financial Statements

4. Separate Financial Statements

5. Notes to Separate Financial Statements

6. Dividends
A. Articles of Incorporation Regarding Dividends
In accordance with the Articles of Incorporation, the Company can pay out dividends of profits in cash
or shares, with the approval granted by the Board of Directors. For shareholders’ value enhancement,
dividends will be determined, considering the Company’s investment plan, financial status, and
dividends sustainability. We plan to review whether to pay cash dividends within 10% of free cash flow
(FCF) for the year after 2025.
The Company’s articles of incorporation regarding dividends are provided in the Articles 48 and 49.
Article Content
1. Dividends may be paid in either cash or stock.

Article 48 (Dividends) 2. Dividends under Paragraph 1 shall be paid to shareholders or pledgees registered in the
current Register of Shareholders as of the end of each fiscal year.
1. The Company may distribute interim dividends to current shareholders as of the date
determined by a resolution of the BOD under Article 462-3 of the Commercial Code.
2. Interim dividends under Paragraph 1 shall be distributed by a resolution of the BOD.
3. Interim dividends shall be limited to the amount calculated by deducting each of the
following sums from the net asset value in the balance sheet for the immediately
preceding fiscal year:
(1) Amount of the capital of the immediately preceding fiscal year;
(2) Sum of capital reserves and legal reserves accumulated up to the immediately
preceding fiscal year;
(3) Unrealized gains stipulated in the Enforcement Decree of the Commercial Code;
Article 49 (4) Amount determined by the ordinary general meeting of shareholders of the
(Interim Dividends) immediately preceding fiscal year for distribution of dividends;
(5) Discretionary reserves accumulated for specific purpose under applicable provisions of
these Articles of Incorporation or by a resolution of the general meeting of
shareholders until the immediately preceding fiscal period
(6) Profit reserve to be accumulated during the settlement period according to interim
dividends
4. In connection with interim dividends on shares issued by rights issues, bonus issues,
stock dividends, conversion of convertible bonds or exercise of bonds with warrants after
the commencement of applicable fiscal year and prior to the record date in Paragraph 1,
new shares shall be deemed to have been issued at the end of the fiscal year
immediately preceding the fiscal year when such shares were actually issued.
B. Key Dividend Index
Classification Type of Shares 2022 2021 2020
Par value per share (KRW) 2,500 2,500 2,500
Consolidated net profit (KRW mil) 798,056 393,589 240,975
Separate net profit (KRW mil) 686,793 423,177 250,969
Consolidated EPS (KRW) 11,442 5,949 3,642
Total cash dividend (KRW mil) - - -
Total stock dividend (KRW mil) - - -
Consolidated dividend payout ratio (%) - - -

Classification Type of Shares 2022 2021 2020
Common - - -
Cash dividend yield (%)
Preferred - - -
Common - - -
Share dividend yield (%)
Preferred - - -
Common - - -
Cash dividend per share
(KRW)
Preferred - - -
Common - - -
Stock dividend per share
(share)
Preferred - - -
C. Dividend History
Number of Consecutive Dividend Payout Average Dividend Payout
Quarterly(Interim) Dividend Annual Dividend 3-year 5-year
- - - -
※ The Company has no dividend payout history in the past five years.
7. Matters About Financial Through the Issuance of Securities
7-1. Financing Through the Issuance of Securities
[Issuance of Equity Securities]
Status of Capital Increase (reduction)

(As of December 31, 2022) (Unit: KRW, Share)
Date of stock Details of issued(reduced) shares

issuance Type of issuance (reduction) Face value Amount issued
(reduction) Class Volume Remarks
per share (reduced) per share
2011.04.22 - Common 1,500,000 5,000 50,000 Establishment
Capital increase with consideration

2011.09.07 Common 1,500,000 5,000 50,000 Increase rates of 100%
by allocation to shareholders





2013.02.19 Common 866,007 5,000 46,189 Increase rates of 8%

2013.08.20 Common 748,520 5,000 43,345 Increase rates of 7%


Date of stock Details of issued(reduced) shares
issuance Type of issuance (reduction) Face value Amount issued
(reduction) Class Volume Remarks
per share (reduced) per share


2016.09.12 Stock split Common 27,568,721 2,500 - -


※ On January 28, 2022, the Board of Directors of the Company resolved to increase its capital for the acquisition of construction-in-progress and securities
of other entity. The Company issued additional 5,009,000 shares of common stock totaling 71,174,000 shares of common stock issued by the end of 1H.
[Issuance of Debt Securities]

A. List of Issued Debt Securities
(As of December 31, 2022) (Unit: KRW Mil, %)
Issuing Type of Issuance Date of Total nominal Rating

Interest rate Maturity date Payment status Underwriter
company securities method Issuance amount (rating institution)
- - - - - - - - - -
- - - - - - - - - -
Issuing Type of Issuance Date of Total nominal Rating
Interest rate Maturity date Payment status Underwriter
company securities method Issuance amount (rating institution)
Total - - - - - - - - -
B. Commercial Paper Balance
(As of December 31, 2022) (Unit: KRW Mil)
Under Above 10 days Above 30 days Above 90 days Above 180 days Above 1 year Above 2 years
Issuing company Above 3 years Total
10 days /under 30 days /under 90 days /under 180 days /under 1 year /under 2 years /under 3 years
Public - - - - - - - - -
Balance Private - - - - - - - - -
Total - - - - - - - - -
C. Short Term Bond Unredeemed Balance
Under Above 10 days Above 30 days Above 90 days Above 180 days
Issuing company Total Issue limit Balance limit
10 days /under 30 days /under 90 days /under 180 days /under 1 year
Public - - - - - - - -
Balance Private - - - - - - - -
Total - - - - - - - -
D. Corporate Bond Unredeemed Balance
Under Above 1 year Above 2 years Above 3 years Above 4 years Above 5 years
1 year /under 2 years /under 3 years /under 4 years /under 5 years /under 10 years
Public - 380,000 - 120,000 - - - 500,000
Unredeemed
Private 40,000 - - - - - - 40,000
Balance
Total 40,000 380,000 - 120,000 - - - 540,000
E. Hybrid Bond Outstanding Balance
Under Above 1 year Above 5 years Above 10 years Above 15 years Above 20 years
1 year /under 5 years /under 10 years /under 15 years /under 20 years /under 30 years
Public - - - - - - - -
Unredeemed
Private - - - - - - - -
Balance
Total - - - - - - - -
F. Contingent Convertible Bond Outstanding Balance
Above 1 year Above 2 years Above 3 years Above 4 years Above 5 years Above 10 years Above 20 years Above
Issuing company Under 1year Total
/under 2 years /under 3 years /under 4 years /under 5 years /under 10 year / under 20 years / under 30 years 30 years
Public - - - - - - - -
Balance Private - - - - - - - -
Total - - - - - - - -
G. Details and Compliance of the Bond Management Contract
(As of December 31, 2022) (Unit: KRW Mil, %)
Settlement date of bond Debenture management

Name of security Date of issuance Maturity date Issued amount
management contract company
Samsung Biologics
2021.09.03 2024.09.03 380,000 2021.08.24 Korea Securities Depository
7-1 Unguaranteed Bond
Samsung Biologics
2021.09.03 2026.09.03 120,000 2021.08.24 Korea Securities Depository
7-2 Unguaranteed Bond
(As of December 31, 2022)
Contract details Consolidated debt ratio remains under 300%

Financial ratios
Implementation status Fulfilled (85%)
Contract details Total collateral value remains under 200% of consolidated equity
Constraint on collateral
Implementation status Fulfilled (0%)
Constraint on disposal of assets Contract details Total restricted value remains under 80% of consolidated assets
(excl. financial assets and inventories)
Implementation status Fulfilled (No disposal of assets exceeding KRW 6.1 trillion)
Contract details The entity remains as a member firm of Samsung Group

Constraint on governance
Implementation status Fulfilled
Submission of implementation report Implementation status Fulfilled(2022.09.13)

* The date of implementation status is when the most recent financial statements were prepared.
The constraint on governance is as of the reporting date.
7-2. Use of Funds Financed Through the Issuance of Securities
A. Use of Publicly Raised Funds

Plan Actual
Classification Name of bond Date of issuance Reason for difference
Purpose Amount raised Purpose Amount used
7-1 Public Investment in Investment in
Corporate bond 2021.09.03 380,000 380,000 -
non-guaranteed bond manufacturing plant manufacturing plant
7-2 Public Investment in Investment in
Corporate bond 2021.09.03 120,000 120,000 -
non-guaranteed bond manufacturing plant manufacturing plant
Execution in
accordance with facility
Paid-in capital - 2022.04.15 Facility Investment 1,998,351 Facility Investment 949,789
investment and
purchase payment plan
Funds to acquire shares Funds to acquire shares of
Paid-in capital - 2022.04.15 1,202.400 1,202.400 -
of Samsung Bioepis Samsung Bioepis
B. Use of Privately Raised Funds

Plan Actual
Classification Name of bond Date of issuance Reason for difference
Purpose Amount raised Purpose Amount used
- - - - - - - -
C. Unused Funds Management Report

Type of financial instrument Name of financial instrument Amount Contract period Investment term
Savings account MMDA 298,562 2022.12 ~ 2023.01 1 month
Savings account Fixed deposits 450,000 2022.10 ~ 2023.01 3 months
Savings account Fixed deposits 300,000 2022.11 ~ 2023.02 3 months
Total 1,048,562 -
8. Other Financial Information
A. Restatement of Financial Statements and Other Matters to Note
(1) Emphasis of matter and key audit matters in auditor’s report
The Company entered into a stock sales contract on January 28, 2022 to acquire an additional stake in
Samsung Bioepis held by Biogen Therapeutics Inc., and acquired 10,341,852 shares on April 20, 2022
to secure 100% of the stake and gained the control of Samsung Bioepis.
For details on the acquisition of shares, please refer to the Report on Major Matters (Decision to acquire
stocks and investment securities of other corporations) first published on January 28, 2022.
Category Dates
(2) Matters to be aware of when using other financial statements
□ Emphasis and Key Audit Matters in the Audit Report

Period Emphasis of matter Key audit matter
- Administrative lawsuit against

- Appropriateness of CMO revenue recognition
measures imposed by Securities
2022 - Appropriateness of acquisition price allocation in
& Futures Commission and
Prosecution charge
business combination
- Administrative lawsuit against - Impairment test of investment in associates and joint

measures imposed by Securities - Appropriateness of CMO revenue recognition
2021
& Futures Commission and - Existence of Construction in Progress and Occurrence of
Prosecution charge Acquisition transaction
- Administrative lawsuit against

measures imposed by Securities
- Impairment test of investment in associates and joint
& Futures Commission and
2020 ventures
Prosecution charge
- Appropriateness of CMO revenue recognition
- Initial adoption of K-IFRS in
separate financial statements
□ Ruling of the securities and Futures Commission in relation to the accounting for investment
in Samsung Bioepis Co., Ltd., the related administrative lawsuit and the indictment
Refer to Note 25 in Notes to Consolidated Financial Statements, published on the Company’s website
for detailed information about the litigation.
B. Allowance for Bad Debt
(1) Allowance for bad debt by account for the past 3 years
(Unit: KRW Mil, %)
Receivables amount Allowance amount Allowance (%)
Trade receivables 663,821 26,565 4.00%
Other receivables 84,900 56 0.07%

2022
Accruals 21,374 - 0.00%
Total 770,095 26,621 3.46%
Trade receivables 351,884 4,845 1.38%
Other receivables 17,985 12 0.07%

2021
Accruals 5,747 - 0.00%
Total 375,616 4,857 1.29%
Trade receivables 238,764 - 0.00%
Other receivables 4,020 - 0.00%

2020
Accruals 3,820 - 0.00%
Total 246,604 - 0.00%

(2) Allowance for bad debt by year

(Unit: KRW Mil)
2022 2021 2020
Beginning Balance 4,857 - -
Bad debt expense 21,764 4,857 -
Write off - - -
Ending balance 26,621 4,857 -

(3) The guideline for bad debt allowance for account receivables
- Calculation of bad debt allowance
Calculation of bad debt allowance by applying the expected credit loss model that considers the
expected bad debt in the future to the balance of trade and other receivables as of the reporting date.
- Calculation basis of write-off experience rate and future expected bad debt
1. Write off experience rate is calculated using credit loss rate of all account receivables for all
historical period
2. Future expected bad debt is determined taking into consideration cases of debtor bankruptcy,
compulsory execution, death, disappearance, credit information of debtor and forward-looking
information.
(4) The outstanding period of account receivables

Less than 6 months ~ 1 year ~ More than 3

Classification Total
6 months 1 year 3 years years
Amount 656,815 14,329 50,771 186 722,101
Ratio 90.96% 1.98% 7.03% 0.03% 100.00%
※ Consolidation basis in accordance with K-IFRS.

※ Receivables amount in net present value.
C. Inventory
(1) Inventory status for the past three years

Division Classification 2022 2021 2020
Finished goods 336,222,872 236,941,382 92,867,573

Work in
320,578,145 277,567,820 196,982,909
progress
CDMO Raw material 449,531,561 305,886,540 208,859,070
Material in
231,319,778 192,475,049 147,250,544
transit
Subtotal 1,337,652,356 1,012,870,791 645,960,096
Finished goods 414,799,472 - -

Work in
Biopharmaceutical 464,254,906 - -
progress
development and
commercialization Raw material 159,112,227 - -
Subtotal 1,038,166,605 - -
Total 2,375,818,961 1,012,870,791 645,960,096

Inventory ratio (%)
14.3% 12.7% 10.1%
[Inventory / Total Assets]
Inventory turnover (times)
[Yearly COGS /
0.9 1.0 1.4
{Beginning inventory + Ending inventory}
/ 2]
※ The inventory status does not include unrealized inventory on intercompany transactions (Consolidation basis)
(2) Inventory counts
① Inspection date
[Samsung Biologics]
• External auditors join and observe the inspection once a year near year-end (Late Dec. -
Early Jan.). In accordance with the internal regulation, internal inspection is carried out once
a month.
• For the difference in inventories between the inspection date and the end of the year, the
Company checks using warehouse record to confirm the inventories as the date of financial
statements.
[Samsung Bioepis]
• External auditors join and observe the inspection once a year near year-end (Late Dec. -
Early Jan.). In accordance with the internal regulation, internal inspection is carried out once
a month.
• The difference in inventories between the inspection date and the end of the year is
warehousing/shipping of the outsourcing company(CMO etc.)
② Inspection methodology
[Samsung Biologics]
• All items for monthly internal inspection.
• External auditors join and observe the inspection and carry out sample test to check the
existence and completeness of inventory.
[Samsung Bioepis]
• The external auditor confirms the inventory due diligence of the factory for some of the
inventory and confirms its actuality and completeness.
• Rest of the inventory’s existence and completeness is checked by comparing the result of the
inventory inquiry reply from the outsourcing company (CMO, etc.) with our company's books.
③ Obsolete Inventory
• If the net realizable value of inventories falls below the acquisition cost, the valuation loss
allowance is recognized to determine the value of the inventory assets in the statement of
financial position;
• The evaluation details of inventories as of December 31, 2022 are as follows.
(As of December 31, 2022) (Unit: KRW Thousand)
Inventory Ending
Classification Acquisition cost Gross inventory
write-down Balance
Finished goods 752,104,606 752,104,606 (1,082,262) 751,022,344
Work in progress 802,745,931 802,745,931 (17,912,880) 784,833,051
Raw material 615,162,962 615,162,962 (6,519,174) 608,643,788

Material in transit 235,593,730 235,593,730 (4,273,952) 231,319,778
Total 2,405,607,229 2,405,607,229 (29,788,268) 2,375,818,961
D. Fair Value Evaluation Details
(1) Financial Assets
① Classification
The Group classifies its financial assets in the following measurement categories
- Financial assets measured at amortized cost
- Financial assets measured at fair value through other comprehensive income, and
- Financial assets measured at fair value through profit or loss.
The classification depends on the Group’s business model for managing the financial assets and the
contractual terms of the cash flows. For financial assets measured at fair value, gains and losses will
either be recorded in profit or loss or other comprehensive income. For investments in debt instruments,
this will depend on the business model in which the investment is held. The Group reclassifies debt
investments when, and only when its business model for managing those assets changes.
For investments in equity instruments that are not held for trading, this will depend on whether the
Group has made an irrevocable election at the time of initial recognition to account for the equity
investment at fair value through other comprehensive income. Changes in fair value of non-designated
equity investment are recognized in profit or loss.
② Measurement
At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial
asset not at fair value through profit or loss, transaction costs that are directly attributable to the
acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit
or loss are expensed in profit or loss. Financial assets with embedded derivatives are considered in
their entirety when determining whether their cash flows are solely payment of principal and interest.
②-① Debt Instruments
Subsequent measurement of debt instruments depends on the Company’s business model for
managing the asset and the cash flow characteristics of the asset. The Company classifies its debt
instruments into one of the following three measurement categories:
A. Amortized cost
Assets that are held for collection of contractual cash flows where those cash flows represent solely
payments of principal and interest are measured at amortized cost. A gain or loss on a debt investment
that is subsequently measured at amortized cost and is not part of a hedging relationship is recognized
in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets
is included in ‘finance income’ using the effective interest rate method.
B. Fair value through other comprehensive income

Assets that are held for collection of contractual cash flows and for selling the financial assets, where
the assets’ cash flows represent solely payments of principal and interest, are measured at fair value
through other comprehensive income. Movements in the carrying amount are taken through other
comprehensive income, except for the recognition of impairment loss (reversal of impairment loss),
interest income and foreign exchange gains and losses which are recognized in profit or loss. When
the financial asset is derecognized, the cumulative gain or loss previously recognized in other
comprehensive income is reclassified from equity to profit or loss.
C. Fair value through profit or loss

Assets that do not meet the criteria for amortized cost or fair value through other comprehensive income
are measured at fair value through profit or loss. A gain or loss on a debt investment that is subsequently
measured at fair value through profit or loss and is not part of a hedging relationship is recognized in
‘finance income or costs’.
②-② Equity instruments
The Company subsequently measures all equity investments at fair value. Where the Company’s
management has elected to present fair value gains and losses on equity investments, which are held
for long-term investments or strategic purposes, in other comprehensive income, there is no subsequent
reclassification of fair value gains and losses to profit or loss following the derecognition of the
investments. Dividend income from such investments continue to be recognized as ‘finance income’
when the right to receive payments is established.
Changes in the fair value of financial assets at fair value through profit or loss are recognized in ‘finance
income and expenses’. Impairment loss (reversal of impairment loss) on equity investments measured
at fair value through other comprehensive income are not reported separately.
③ Impairment
The Company assesses on a forward-looking basis the expected credit losses associated with its debt
instruments carried at amortized cost and fair value through other comprehensive income. The
impairment methodology applied depends on whether there has been a significant increase in credit
risk. For trade receivables and lease receivables, the Company applies the simplified approach, which
requires expected lifetime credit losses to be recognized from initial recognition of the receivables.
④ Recognition and derecognition
Regular way purchases and sales of financial assets are recognized or derecognized on the trade-date,
the date on which the Company commits to purchase or sell the asset. Financial assets are
derecognized when the rights to receive cash flows from the financial assets have expired or have been
transferred and the Company has transferred substantially all the risks and rewards of ownership.
If a transfer does not result in derecognition because the Company has retained substantially most of
the risks and rewards of ownership of the transferred asset, the Company continues to recognize the
transferred asset in its entirety and recognizes a financial liability for the consideration received.
⑤ Offsetting of financial instruments
Financial assets and liabilities are offset and reported in the statement of financial position where there
is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a
net basis or realize the assets and settle the liability simultaneously. The legally enforceable right must
not be contingent on future events and must be enforceable in the normal course of business and even
in the event of default, insolvency or bankruptcy of the Group or the counterparty.
(2) Financial Liabilities
① Classification and measurement
The Group’s financial liabilities at fair value through profit or loss are financial instruments held for
trading. A financial liability is held for trading if it is incurred principally for the purpose of repurchasing
in the near term. A derivative that is not designated as a hedging instrument and an embedded
derivative that is separated are also classified as held for trading.
The Group classifies non-derivative financial liabilities, except for financial liabilities at fair value through
profit or loss, financial guarantee contracts and financial liabilities that arise when a transfer of financial
assets does not qualify for derecognition, as financial liabilities carried at amortized cost and present
as ‘trade and other payables’ and ‘debentures and borrowings’ in the statement of financial position.
② Derecognition
Financial liabilities are removed from the statement of financial position when it is extinguished; for
example, when the obligation specified in the contract is discharged or cancelled or expired or when
the terms of an existing financial liability are substantially modified. The difference between the carrying
amount of a financial liability extinguished or transferred to another party and the consideration paid
(including any non-cash assets transferred or liabilities assumed) is recognized in profit or loss.
(3) Derivative Instruments

Derivatives are initially recognized at fair value on the date when a derivative contract is entered into
and are subsequently re-measured at their fair value at the end of each reporting period. Changes in
the fair value of any derivative instrument that does not qualify for hedge accounting are recognized
immediately in profit or loss based on the nature of transactions.
(4) Financial Instruments by Category
(1) Financial assets

Details of financial instruments by category as of the end of 2022 and 2021, are as follows :

Financial Financial Financial Financial
assets at fair assets assets at fair assets
Total Total
value through measured at value through measured at
profit or loss amortized cost profit or loss amortized cost
Current assets
Cash and
cash - 890,819,571 890,819,571 - 47,410,384 47,410,384
equivalents
Short-term
financial - 2,168,901,000 2,168,901,000 - 450,000,000 450,000,000
instruments
Financial
assets at fair
value 98,505,712 - 98,505,712 850,039,877 - 850,039,877
through profit
or loss
Account
receivable
- 684,321,895 684,321,895 - 350,187,893 350,187,893
and other
receivables
Deposits
- 35,310,984 35,310,984 - 23,984,945 23,984,945
provided
Derivatives
13,478,488 - 13,478,488 - - -
assets(*)
Subtotal 111,984,200 3,779,353,450 3,891,337,650 850,039,877 871,583,222 1,721,623,099
Non-current
assets
Long-term
financial - 7,335,813 7,335,813 - 189,491 189,491
instruments
Account
receivable
- 10,635,002 10,635,002 - 4,428,344 4,428,344
and other
receivables
Deposits
- 27,432,729 27,432,729 - 22,827,408 22,827,408
provided
Derivative
instrument 4,658,970 - 4,658,970 4,091,971 - 4,091,971
assets
Subtotal 4,658,970 45,403,544 50,062,514 4,091,971 27,445,243 31,537,214
Total 116,643,170 3,824,756,994 3,941,400,164 854,131,848 899,028,465 1,753,160,313
(*) Currency interest rate swaps and interest rate swaps contract concluded into for foreign and won currency borrowings, details
of which are as follows.

Currency
USD Libor(3M)
30,000,000 + 1.70
swap
Currency
USD Libor(3M)
30,000,000 + 1.80
swap
Currency
USD Libor(3M)
Trading interest Woori bank 2021.08.30 2024.08.30 USD KRW 1,164 2.15
30,000,000 + 1.20
swap
Interest rate(%)
Received Paid
Interest KRW CD(91Days)

Trading Woori bank 2020.09.28 2023.10.02 2.25
swap 50,000,000,000 + 1.23
(2) Financial liabilities

Details of financial instruments by category as of the end of 2022 and 2021, are as follows :

Financial
liabilities Cost
measured measureme Financial
at fair nt financial Other liabilities at Other
Total Total
value liabilities liabilities amortized liabilities
through after cost
profit or amortization
loss
Current
liabilities
Trade and
other - 1,624,767,738 - 1,624,767,738 342,930,338 - 342,930,338
payables
Debentures - 39,978,721 - 39,978,721 - - -
Short-term
- 582,783,298 - 582,783,298 50,000,000 - 50,000,000
borrowings
Current
portion of
- 516,038,000 - 516,038,000 109,855,000 - 109,855,000
long-term
borrowings
Lease
- - 142,247,058 142,247,058 - 7,537,132 7,537,132
liabilities
Subtotal - 2,763,567,757 142,247,058 2,905,814,815 502,785,338 7,537,132 510,322,470
Non-current
liabilities
Trade and
other - 532,829,743 - 532,829,743 2,648,496 - 2,648,496
payables(*)
Debentures - 499,052,332 - 499,052,332 538,553,996 - 538,553,996
Long-term
- 466,038,000 - 466,038,000 576,130,000 - 576,130,000
borrowings
Derivative
22,733,991 - - 22,733,991 - - -
liabilities
Lease
- - 267,895,530 267,895,530 - 10,671,166 10,671,166
liabilities
Subtotal 22,733,991 1,497,920,075 267,895,530 1,788,549,596 1,117,332,492 10,671,166 1,128,003,658
Total 22,733,991 4,261,487,832 410,142,588 4,694,364,411 1,620,117,830 18,208,298 1,638,326,128
(*)This is the amount excluding annual allowances and performance bonuses to be paid to employees.
(3) Fair value of financial assets
Carrying amount and fair value of financial assets as of the end of 2022 and 2021 are as follows :

Description
Carrying amount Fair value Carrying amount Fair value
Financial assets measured at fair value :
Financial
assets at fair
98,505,712 98,505,712 850,039,877 850,039,877
value through
profit or loss
Derivative
18,137,458 18,137,458 4,091,971 4,091,971
assets
Subtotal 116,643,170 116,643,170 854,131,848 854,131,848
Financial assets not measured at fair value :
Cash and
cash 890,819,571 890,819,571 47,410,384 47,410,384
equivalents(*)
Short-term
financial 2,168,901,000 2,168,901,000 450,000,000 450,000,000
instruments
Long-term
financial 7,335,813 7,335,813 189,491 189,491
instruments
Trade and
other 694,956,897 694,956,897 354,616,237 354,616,237
receivables
Deposits
62,743,713 62,743,713 46,812,354 46,812,354
provided
Subtotal 3,824,756,994 3,824,756,994 899,028,466 899,028,466
Total 3,941,400,164 3,941,400,164 1,753,160,314 1,753,160,314
Financial liability carried at fair value :
Derivative
22,733,991 22,733,991 - -
liabilities
Financial liability carried at amortized cost :
Trade and
other 2,157,597,481 2,157,597,481 345,578,834 345,578,834
payables
Debentures 539,031,053 539,031,053 538,553,996 538,553,996
Borrowings 1,564,859,298 1,564,859,298 735,985,000 735,985,000
Subtotal 4,261,487,832 4,261,487,832 1,620,117,830 1,620,117,830
Total 4,284,221,823 4,284,221,823 1,620,117,830 1,620,117,830
(4) Fair value hierarchy

The following presents financial instruments measured and recognized at fair value as of the end of
2022 and 2021, are as follows :
① End of 2022
Level 1 Level 2 Level 3 Total
Financial assets :
Financial assets at
fair value through - 98,505,712 - 98,505,712
profit or loss
Derivative financial
- 18,137,458 - 18,137,458
instrument assets
Financial liabilities :
instrument - - 22,733,991 22,733,991
liabilities
② End of 2021
Level 1 Level 2 Level 3 Total
Financial assets :
Financial assets at
fair value through 850,039,877 - 850,039,877
profit or loss
4,091,971 - 4,091,971
instrument assets
(5) Valuation techniques and inputs
Valuation techniques and significant inputs used in measuring the fair value of financial instruments
classified as level 2 of the fair value hierarchy, are as follows :

Fair Value
Fair value Significant
Level
End of 2022 End of 2021 measurement unobservable inputs
Financial assets at
Market
fair value through 98,505,712 850,039,877 2 -
approach
profit or loss
Derivative financial Currency forward
instrument assets rate, interest rate,
17,019,024 3,475,382
(currency interest Discounted discount rate, and
swap) 2 cash flow others
Derivative financial model Interest rate,
instrument assets 1,118,434 616,589 discount rate, and
(interest swap) others
Derivative financial Interest rate,
Option pricing
instrument liabilities 22,733,991 - 3 discount rate, and
model
(stock warrants) others
(6) Valuation Process for Fair Value Measurements Classified as Level 3
The financial departments of each segment of the Group are responsible for measuring fair value for
financial reporting purposes, and these fair value measurements include fair value measurements
classified as level 3. The department in charge of fair value measurement regularly reports on the fair
value evaluation process and results according to the reporting schedule at the end of each reporting
period.
(7) Sensitivity analysis of financial products is conducted by classifying them into favorable and
unfavorable changes based on changes in the value of financial products due to changes in
unobservable input variables using statistical techniques. And, if fair value is affected by more than one
input variable, it is calculated based on the most advantageous or most unfavorable amount.
Input variable (*) Volatility Favorable fluctuations Adverse fluctuations
Discount rate 0.50% 715,268 (722,390)

(*) The amount of change in the fair value of derivative liabilities was calculated by increasing or decreasing significant but
unobservable inputs among the inputs used to calculate the fair value of the underlying assets.
(8) Net gains or losses by category of financial instruments
Net gains or losses on each category of financial instruments as of the end of 2022 and 2021, are as
follows :
Interest income
Gain on valuation(loss) Other income (*) Net income (loss)
(expenses)
2022 2021 2022 2021 2022 2021 2022 2021
Financial
assets at
53,292,640 9,655,916 - - (63,012,030) 8,836,759 (9,719,390) 18,492,675
amortized
cost
Financial
assets at
fair value
- - 476,889 86,523 7,757,719 182,600 8,234,608 269,123
through
profit or
loss
Derivative
- - 7,763,431 5,356,983 (339,354) - 7,424,077 5,356,983
assets
Financial
liabilities
at (61,368,955) (14,021,318) - - (491,296) 9,036,852 (61,860,251) (4,984,467)
amortized
cost
Derivative
- - (2,192,006) - - - (2,192,006) -
liabilities
Other
(2,695,391) (685,864) - - - - (2,695,391) (685,864)
liabilities
Total (10,771,706) (5,051,266) 6,048,314 5,443,506 (56,084,961) 18,056,211 (60,808,353) 18,448,450
(*) Other income and expenses include gain (loss) on foreign currency translations and transactions, and gain (loss) on
disposal of financial assets at fair value through profit or loss.
(5) Re-measurement details of fixed assets
No re-measurement of fixed assets was carried out during the reporting period.
IV. Directors’ Management Discussion & Analysis
1. Notes to forecasts
This annual report includes forward-looking statements that relate to future events. The statements can
be generally identified by phrases containing words such as ‘forecast’, ‘predict’, ‘plan’, ‘anticipate’ or
other words or phrases of similar meaning.
Forward-looking statements involve uncertain events that could positively or negatively affect the
Company’s management condition and financial performance include, but are not limited to:
· Trends of domestic/international financial markets including changes in exchange rate and interest
rate
· The Company’s strategic decision-making including business acquisition or disposal
· Unexpected sudden change of conditions in the Company’s core business areas
· Other domestic/international changes that may affect management status and financial performance
Please note that because of such uncertainties, the Company’s actual future performance may be
materially different from the statements expressed or implied in forecasts. The Company is not liable to
disclose a corrective report that modifies the details of forecasts to reflect risks or uncertainties that may
occur after the forecasts were created.
2. Overview
In 2022, Samsung Biologics achieved all business objectives set for the year and successfully
expanded businesses for sustainable growth. Plants 1, 2, and 3 have been maintaining high capacity
utilization rates close to 100%, and the world's largest Plant 4 successfully began partial operations
(60,000 liters) within 23 months of construction. The Company achieved annual sales of KRW 3 trillion
1.3 billion on a consolidated basis, and KRW 2 trillion 437 billion on a separate basis. The cumulative
contract orders amount reached USD 9.5 billion with accumulated number of contract orders of 74 in
CMO and 101 in CDO. In addition, with the completion of the sales contract for District 11 in Songdo,
Incheon, which will be used as the site for the second Bio campus, all preparations for further expansion
of production capacity have been completed.
The CMO division established an mRNA drug substance (DS) production facility and started end-to-
end service from DS to drug products (DP), while the CDO division expanded its business portfolio by
launching 'S-DUAL', a platform for bispecific antibody, and 'DEVELOPICK', a platform for screening
new drug candidates.
Through the Life Science Fund created together with Samsung C&T, the Company started fostering
innovative technologies in earnest by investing in technology companies related to gene therapy and
nanoparticles as drug carriers, and is accelerating the expansion into the biosimilar market by acquiring
the entire stake in Samsung Bioepis.
Samsung Biologics has also strengthened Environmental, Social, and Governance (ESG) management
to realize sustainable workplaces. Currently, the Company entered into ESG partnerships with partners
and published reports related to the Task Force on Climate-Related Financial Disclosures (TCFD), is
serving as the supply chain champion for the Healthcare Systems Task Force within the Sustainable
Markets Initiative (SMI), led by the British Crown, and is working to achieve carbon neutrality (Net Zero)
in its operations and supply chains by 2050 and have joined the RE100 initiative. Samsung Biologics'
ESG efforts are also being recognized in various fields. The Company obtained Grade B in the Carbon
Disclosure Project (CDP), received a Carbon Management Sector Honor, earned a Gold status in
EcoVadis' ESG Assessment 2022, acquired Grade A in the comprehensive evaluation of the Korea
Institute of Corporate Governance and Sustainability (KCGS) for two consecutive years, and has been
included in the Dow Jones Sustainability Index for the second consecutive year.
Samsung Biologics will further maximize its financial performance based on three growth axes of
improving production capacity (Capacity), expanding business portfolio (Portfolio), and securing a
geographical base (Geography).
When the world's largest Plant 4 (240,000 liters) is fully GMP-ready this year, Samsung Biologics will
have a total production capacity of 604,000 liters, positioning ourselves as the world's No. 1 Contract
Development and Manufacturing Organization (CDMO) with an overwhelming capacity gap above the
competition. Also, the Company plans to invest a total of KRW 7.5 trillion to build an open innovation
center on the second Bio campus.
This year, Samsung Biologics will expand its CDMO portfolio with not only antibody-drug conjugates
(ADC), but also with next-generation treatments such as gene therapy to respond timely to changes
and demands in the market, and continue investing in innovative companies with excellent technologies
through the Life Science Fund.
Samsung Biologics opened an R&D center in San Francisco, USA in 2020, and has since established
sales offices in Boston and New Jersey, USA, to strengthen our communication channels with
customers. In the future, the Company will expand not only in North America but also in important
overseas regions to increase accessibility to customers and provide timely and reliable services.
3. Financial status & Sales Performance (Consolidated basis)
A. Financial status
(Unit: KRW Mil)
Increase &
2022 2021 Change(%)
Decrease
Assets
I. Current assets 6,457,657 2,823,175 3,634,482 128.74%
Cash and cash equivalent 890,820 47,410 843,410 1,778.97%
Short-term financial instrument 2,168,901 450,000 1,718,901 381.98%

Financial assets at fair value through
98,506 850,040 -751,534 -88.41%
profit or loss
Current Assets - Derivatives 13,478 - 13,478 100.00%
Trade and other receivables 732,839 366,331 366,508 100.05%
Inventories 2,375,819 1,012,871 1,362,948 134.56%
Other current financial assets 35,311 23,985 11,326 47.22%
Other current assets 54,667 8,627 46,040 533.67%
Contract assets 87,316 63,911 23,405 36.62%
II, Non-current assets 10,124,394 5,146,836 4,977,558 96.71%
Long-term financial instruments 7,336 190 7,146 3,761.05%

Investments in associates and joint
30,775 2,661,309 -2,630,534 -98.84%
ventures
Property, plant, and equipment 3,416,529 2,207,064 1,209,465 54.80%
Intangibles assets 5,961,307 32,172 5,929,135 18,429.49%
Right-of-use asset 454,923 20,624 434,299 2,105.79%
Trade and other receivables 10,635 4,428 6,207 140.18%
Defined benefit asset 29,646 3,572 26,074 729.96%
Other non-current financial assets 32,092 26,919 5,173 19.22%
Other non-current assets 3,524 1,227 2,297 187.20%
Contract assets 177,627 189,331 -11,704 -6.18%
Total assets 16,582,051 7,970,011 8,612,040 108.06%
Liabilities
I. Current liabilities 4,181,543 1,107,295 3,074,248 277.64%
II. Non-current liabilities 3,416,034 1,871,614 1,544,420 82.52%
Total liabilities 7,597,577 2,978,909 4,618,668 155.05%
Total equity 8,984,474 4,991,102 3,993,372 80.01%
Total liabilities and equity 16,582,051 7,970,011 8,612,040 108.06%

※ Consolidated financial statements of 2022 pending the authorization from the Annual General Meeting.
The Company will publish amendment reports, presenting summaries and explanations, if any items regarding the financial
statements get rejected or amended at the Annual General Meeting.
- The Company’s total assets in 2022 were KRW 16.5821 trillion, an increase of KRW 8.612 trillion
(108.06%) from the previous year. The effect of business combination and consolidation adjustment
was KRW 5,033.5 billion.
Current assets increased by KRW 3,634.5 billion (128.74%) from the previous year to KRW 6,457.7
billion. Short-term financial instruments increased by KRW 1,718.9 billion due to subscription to
deposit products after paid-in capital increase, and inventory assets increased by KRW 1,362.9 billion
due to business combinations.
Non-current assets increased by KRW 4,977.6 billion (96.71%) from the previous year to KRW
10,124.4 billion. Investment stocks in affiliates and joint ventures decreased by KRW 2,630.5 billion
due to consolidation after additional acquisition of Samsung Bioepis Co., Ltd., However, increase in
book value of tangible assets by KRW 1,207.1 billion due to the construction of the 4th plant, and
increase in book value of intangible assets, such as development costs due to business combination,
etc. by KRW 5,929.1 billion would be the the main impact.
- The Company’s total liabilities in 2022 were KRW 7,597.6 billion, an increase of KRW 4,618.7 billion
(155.05%) from the previous year. The effect of Bioepis business combination and consolidation
adjustment was KRW 2,237.1 billion.
Current liabilities decreased by KRW 3.0742 trillion (277.64%) from the previous year. Increase in
account payable and other payables by KRW 289.8 billion due to an increase in operating expenses
such as raw material purchases, and increase in private loans and borrowing by KRW 978.9 billion
due to the construction of the 4th plant would be the main impact.
Non-current liabilities increased by KRW 1.5444 trillion (82.52%) year-on-year. This is mainly due to
an increase in the purchase amount of shares in the business combination by KRW 542.2 billion and
an increase in deferred tax liabilities by KRW 809.8 billion due to temporary differences in the
business combination.
- Capital rose 3.9934 trillion (80.01%) year-on-year to KRW 8.9845 trillion, mainly due to an increase
in capital and capital surplus of KRW 3.1883 trillion from paid-in capital increase.
B. Sales Performance
(Unit: KRW Mil)
Increase & Rate of Increase

2022 2021
Decrease and Decrease
I. Revenue 3,001,295 1,568,007 1,433,288 91.41%
II. Cost of revenue 1,532,847 841,556 691,291 82.14%
III. Gross profit 1,468,448 726,451 741,997 102.14%
IV. Selling, general and administrative
484,821 189,141 295,680 156.33%
expense
V. Operating profit(loss) 983,627 537,309 446,318 83.07%
Increase & Rate of Increase
2022 2021
Decrease and Decrease
VI. Non-operating profit(loss) 25,397 23,972 1,425 5.94%
VII. Profit(loss) before income tax 1,009,024 561,283 447,741 79.77%
VIII. Income tax expense(benefit) 210,968 167,693 43,275 25.81%
IX. Net profit(loss) for the period 798,056 393,589 404,467 102.76%
※ Consolidated financial statements of 2022 pending the authorization from the Annual General Meeting.
The Company will publish amendment reports, presenting summaries and explanations, if any items regarding the financial
statements get rejected or amended at the Annual General Meeting.
※ Samsung Biologics has a single business sector.
- In 2022, revenue increased by KRW 1.4333 trillion (91.41%) to KRW 3.0013 trillion, and gross
profit increased by KRW 742.0 billion (102.14%). This is mainly due to the full operation of Plants
1, 2 and 3 and the increase in sales due to business combinations.
Samsung Biologics is a bio contract manufacturing organization (CMO) that provides biologics
product manufacturing services. Therefore, sales are linked according to the production schedule
of each plant based on the number of orders received by the clients.
- Selling, general and administrative expense increased by KRW 295.7 billion (156.33%) from the
previous year. The change is attributable to an increase in labor cost due to a rise in employee
number and an increase in partner marketing expenses and current research expenses from
business combination.
- Operating profit was KRW 983.6 billion, an increase of KRW 446.3 billion (83.07%) from the
previous year, largely due to increased sales and a rise in the exchange rate.
- In 2022, all major financial ratios showed slight decrease as follows: Operating profit ratio of
32.8% (34.3% in 2021), EBITDA of 43.0% (44.6% in 2021), and Interest coverage ratio of 15.4
times (36.5 times in 2021).
C. New Business
The Company is currently widening the scope of business to CDO services, mRNA and cell/gene
therapy to transform into a global biopharmaceutical company.
The CDO business provides cell line and process development and characterization services for small
and medium-size Biotechs with no development facilities. The Company launched high-performing cell
line ‘S-CHOice’, which delivers high productivity and viability, and ‘S-Cellerate’, which is a platform that
innovatively shortens the development period through a standardized process for each development
stage. In September 2022, 'S-DUAL', a next-generation bispecific antibody platform with improved
safety and binding ability with a structure similar to human antibodies, and 'DEVELOPICK', a technology
for screening new drug candidates has been launched from CDO field. We will continue to develop our
own new technology in .
Furthermore, the Company opened its first global CDO R&D center in the renowned San Francisco
Biopharma Cluster in October 2020 and currently plans to widen the scope of the market to Boston,
Europe, and China. In order to meet the demand of the rapidly emerging market in Songdo, Korea, the
Company has completed the expansion of the mRNA production facility in the existing manufacturing
plant, which is cGMP ready in April 2022. Additionally, the Company signed a contract to purchase the
Land to build additional plants in Songdo, Korea in July 2022.
D. Reorganization
- Not applicable
E. Currency risk
- Exposure to foreign exchange risk

The Company’s level of exposure to foreign exchange risk is as follows :

Description
USD EUR JPY GBP Others USD EUR JPY GBP
Assets:
Cashable
211,388,497 173,584 - 3,067,221 196,680 2,609 - - -
asset
Short-term
financial 468,901,000 - - - - - - - -
instruments
Trade receivable
and other 668,368,288 2,517,962 - 971,501 495,285 320,350,462 100,535 - 608,143
receivables
Contract asset 47,141,315 - - - - 27,999,271 - - -
Subtotal 1,395,799,100 2,691,546 - 4,038,722 691,965 348,352,342 100,535 - 608,143
Liability:
Borrowings
116,821,298 - - - - 11,855,000 - - -
(*)
Trade payables
and other 1,576,202,706 23,509,157 2,500,456 682,508 599,154 4,839,226 2,362,327 2,001 142,920
payables
Subtotal 1,693,024,004 23,509,157 2,500,456 682,508 599,154 16,694,226 2,362,327 2,001 142,920
Total (297,224,904) (20,817,611) (2,500,456) 3,356,214 92,811 331,658,116 (2,261,792) (2,001) 465,223
(*) Swap-covered borrowings are excluded as they are not exposed to currency risk.
- Sensitivity analysis
The Company regularly estimates the foreign exchange risk for fluctuations in KRW exchange rates.
The impact of fluctuations in exchange rates on income before income taxes when KRW exchange
rates changes by 10% to each foreign currency as of the end of 2022 and 2021 are as follows :

Category
Increase of 10% Decrease of 10% Increase of 10% Decrease of 10%
USD (29,722,490) 29,722,490 33,165,812 (33,165,812)

EUR (2,081,761) 2,081,761 (226,179) 226,179
JPY (250,046) 250,046 (200) 200
GBP 335,621 (335,621) 46,522 (46,522)
Others 9,281 (9,281) - -
Total (31,709,395) 31,709,395 32,985,955 (32,985,955)
4. Liquidity, financing, and expenditures
A. Liquidity Index
The Company’s liquidity is as follows :

(Unit: KRW Mil)
2022 2021
Cash equivalents 890,819 47,410
Short-term financial instruments 2,168,901 450,000
Financial assets at fair value
98,506 850,040
through profit or loss
Total 3,158,226 1,347,450
※ The company has current funds of KRW 3,158.2 billion at the end of the current term, an increase of KRW 1,810.7 billion
from KRW 1,347.5 billion at the end of the previous year.
※ The main reason for the change is the inflow of KRW 953.0 billion from cash flow from operating activities, KRW 3.2008
trillion from paid-in capital increase, KRW 956.8 billion from the acquisition of tangible assets, and KRW 1.818 trillion from
the acquisition of stocks in subsidiaries.
B. Financing and redemption plan
Total borrowings as of the end of the current term were KRW 2,104.9 billion, an increase of KRW
828.9 billion from KRW 1,276.0 billion at the end of the previous year. At the end of 2022, current
funds exceed borrowings and net cash holdings.
The Company’s financing details for 2022 are as follows :
(Unit: KRW Mil)
Financial institution Issuance date Maturity date Interest rate(%) Amount
Facility Korean Kookmin

2022-08-30 2023-08-30 CD(91day)+1.16% 50,000
Loan currency Bank
borrowings
Korean
Facility
currency Korea Eximbank 2022-10-13 2024-11-04 1.55% 55,000
Loan
borrowings
Korean
Facility Bank of Australia
currency 2022-04-18 2025-04-18 LIBOR_3M+1.30% 38,019
Loan and New Zealand
borrowings
Foreign Sumitomo
General
currency Mitsui 2022-03-18 2023-03-13 LIBOR_3M +1.38% 13,940
Loan
borrowings Bank
Foreign Sumitomo
General LIBOR_3M
currency Mitsui 2022-03-18 2023-03-13 7,410
Loan +1.736%
borrowings Bank
Korean
General BNP
currency 2022-09-16 2023-03-16 CD(91day)+1.49% 45,000
Loan Paribas
borrowings
Foreign Sumitomo
General
currency Mitsui 2022-04-18 2023-04-13 LIBOR_3M +1.38% 19,433
Loan
borrowings Bank
Korean
General Shinhan
currency 2022-07-02 2023-07-02 CD(91day)+1.55% 55,000
Loan Bank
borrowings
Korean
General Woori
currency 2022-07-28 2023-07-28 CD(91day)+1.42% 100,000
Loan Bank
borrowings
Korean
General Kookmin
currency 2022-07-29 2023-07-29 CD(91day)+1.60% 10,000
Loan Bank
borrowings
Korean
General Shinhan
currency 2022-09-19 2023-09-19 CD(91day)+1.40% 45,000
Loan Bank
borrowings
Korean
General Hana
currency 2022-10-02 2023-10-02 CD(91day)+1.47% 30,000
Loan Bank
borrowings
Korean
General Hana
currency 2022-10-02 2023-10-02 CD(91day)+1.47% 10,000
Loan Bank
borrowings
Korean
General Hana
currency 2022-10-02 2023-10-02 CD(91day)+1.47% 10,000
Loan Bank
borrowings
Korean Sumitomo
General
currency Mitsui 2022-10-26 2023-10-26 CD(91day)+1.30% 27,000
Loan
borrowings Bank
Korean Sumitomo
General
Loan
borrowings Bank
Korean
General Standard Chartered
currency 2022-10-28 2023-10-29 CD(91day)+1.60% 15,000
Loan Bank
borrowings
Korean
General
currency NH Bank 2022-11-12 2023-11-12 MOR(6mths)+1.81% 50,000
Loan
borrowings
Korean Sumitomo
General
Loan
borrowings Bank
Korean
General
currency Korea Eximbank 2022-09-26 2024-09-26 CD(91day)+1.70% 45,000
Loan
borrowings
Korean
General Hana
currency 2022-09-23 2025-09-23 CD(91day)+1.67% 75,000
Loan Bank
borrowings
Total 795,802
The year-based borrowing redemption plan as of December 31, 2022 is as follows :

(Unit: KRW Mil)
Time period Foreign bonds Borrowings Foreign Borrowings Total
2023.01.01 ~
40,000 582,783 516,038 1,138,821
2023.12.31
2024.01.01 ~
380,000 - 353,019 733,019
2024.12.31
2025.01.01 ~
- - 113,019 113,019
2025.12.31
2026.01.01 ~ 120,000 - - 120,000
Total 540,000 582,783 982,076 2,104,859
※ Redemption is made based on actual repayments (face value) excluding discounts on bond issuance of KRW 969 million.
※ Among the balance of short-term borrowings at the end of 2022, liquid long-term borrowings were classified as long-term
borrowings.
5. Other matters required for investment decision
A. Important accounting policies and estimates
- The consolidated financial statements of the Company have been prepared in accordance with
K-IFRS. The International Accounting Standards adopted by Korea refer to the content adopted
by the Republic of Korea from the International Accounting Standards Board (“IASB”) standards
and interpretations. The Korean International Accounting Standards allow the use of important
accounting estimates in the preparation of financial statements and require management's
judgment in applying accounting policies. Important accounting policies and estimates applied to
the preparation of the consolidated financial statements are described in Note 2 and Note 3 in the
consolidated financial statements.
B. Matters relating to environment and employees
- For matters relating to environmental sanctions or administrative measures, refer to 3. Other

matters including sanctions under XI. Other Information.
- There is no significant change in employees including the transfer of key human resources during
2022.
C. Matters relating to legal regulations
- For major legal regulations relating to the Company’s business, refer to 3. Other matters
including sanctions under XI. Other Information.
D. Matters regarding derivatives & risk management policy
The Company enters into derivative financial instruments contracts with financial institutions for the
purpose of hedging foreign currency bonds/debt exchange rates and interest rate risks, and the
details are as follows.
[Samsung Biologics]
As of 2022, the Company has entered into derivative financial product contracts with financial
institutions for the purpose of hedging foreign currency bonds/debt exchange rate and interest rate
risks.
(1) Currency interest swap contract

Financial Contracted Contract Maturity
institution Amount Date Date Sell Buy Received Paid
rate
Currency
Hana USD 2018- 2023- Libor(3M)
Trading interest USD KRW 1,080 3.70
Bank 30,000,000 05-31 05-31 +1.70
swap
Currency
Hana USD 2021- 2024- Libor(3M)+
Trading interest USD KRW 1,164 2.15
Bank 30,000,000 08-30 08-30 1.20
swap
(*) Contents were prepared at the time of borrowing.
(2) Interest rate swap contract

(Unit: KRW)
Financial Contracted Contract Maturity Interest rate(%)

institution Amount Date Date Received Paid
Interest CD(91days)
Trading Woori Bank 50,000,000,000 2020-09-28 2023-10-02 2.25
swap +1.23
(3) Derivatives liabilities related to the acquisition of equity securities of other corporations (conditional
consideration)
On January 28, 2022, the Company entered into a stock purchase contract to acquire an additional
10,341,852 shares of Samsung Bioepis Co., Ltd. held by Biogen Therapeutics Inc. Whether or not to
pay contingent consideration in 2027 after the end of the relevant period will be determined after
determining whether or not the satisfaction is met on a yearly basis. The range of the pre-discount
value that we are likely to pay in the future under the foregoing is 0 to 50,000,000 USD. On the date
of acquisition, the fair value of the obligation, KRW 20,541,985 thousand, was estimated using the
option valuation model and recognized as contingent consideration (derivative liabilities).
(4) Gain and loss on valuation
(Unit: KRW)
Accumulated other
Classification Gain on valuation Loss on valuation
comprehensive income
Currency interest swap 7,168,254,287 - -
Interest swap 501,845,017 - -
Equity purchase conditions - 2,192,006,326 -
[Samsung Bioepis]
As of 2022, the Company has entered into derivative financial instrument contracts with financial
institutions for the purpose of hedging foreign currency bonds/debt exchange rate and interest rate risks,
and the details are as follows.

Currency
USD Libor(3M)
30,000,000 + 1.80
swap

- Not applicable
(3) Gain and Loss Valuation of Derivative Liabilities

(Unit: KRW)
Accumulated Other
Currency Interest swap 111,659,231 - -
Interest swap - - -
V. Auditor’s Report
1. Matters Regarding Independent Auditor
A. Auditor’s name and opinion
Business
Auditor Auditor’s opinion Emphasis, etc. Key Audit Matters
year
- Appropriateness of CMO revenue

- Securities & Futures
recognition
Unqualified Commission’s ruling and
2022 Samil PwC - Appropriateness of distribution of
opinion administrative litigation and
acquisition cost in business
prosecution investigation
combination
- Inspect investment stocks in

associates and joint ventures for
- Securities & Futures impairment
Unqualified Commission’s ruling and - Appropriateness of CMO revenue
2021 Samil PwC
opinion administrative litigation and Recognition
prosecution investigation - Construction in Progress asset’s
existence and the occurrence of the
acquisition transaction
- Securities & Futures

- Inspect investment stocks in
Commission’s ruling and
associates and joint ventures for
Unqualified administrative litigation and
2020 Samil PwC impairment
opinion prosecution investigation
- Appropriateness of CMO revenue
- Initial adoption of K-IFRS in
recognition
separate financial statements
(*) A review of the quarterly financial statements was conducted and all matters were presented fairly, in all material respects.
※ 2022 is a review opinion on both separate and consolidate financial statements. 2021 and 2020 are audit opinions on both
separate and consolidated financial statements.
[2022 Audit Schedule]

Item Date
Preliminary Review '22.03.21 ~ 03.25
1Q
Review '22.04.18 ~ 05.13

1H
Review '22.07.11 ~ 08.12

3Q
Review '22.10.11 ~ 11.11
Audit of IT systems and automated internal controls '22.07.04 ~ '23.02.12

Annual audit and Assessment of design and
'22.03.21 ~ 12.31
operation of Internal Control over Financial Reporting
Early substantive audit procedures '23.01.02 ~ 01.20
Audit of Financial Statement and Internal Control over

'23.01.27 ~ 03.02
Financial Reporting
※ The schedule above is for the audit and review of separate and consolidated financial statements.
As of the end of 2022, the auditors of subsidiaries are as follows.

Subsidiaries Auditor
Samsung Bioepis Co., Ltd. KPMG Samjong Accounting Corp
SAMSUNG BIOEPIS IL LTD GUBERMAN
SAMSUNG BIOEPIS HK Limited Korchina TNC CPA Limited
B. Audit service contract

(Unit: KRW Thousand, hour)
Contract Actual
Business
Auditor Details
year Audit Audit Audit Audit
fee hour fee hour
- Review of the interim separate/consolidated financial statements
Samil
2022 - Audit of separate/consolidated financial statements 1,594,000 10,588 1,594,000 10,197
PwC
- Audit of Internal Control over Financial Reporting (ICFR)

Samil
PwC

Samil
PwC
C. Status of signing audit services related to the investee under the equity method with auditors
(Unit: KRW Thousand, hour)
Business year Contract date Service details Service period Service fee Remarks
Audit of specific financial ‘22.03 ~

2022 2022.04.15 300,000 -
information for consolidated purpose ‘23.02
Audit of financial information of equity ‘21.03 ~

2021 2021.03.18 190,000 -
method investees ‘22.02
Audit of financial information of equity ‘20.03 ~

2020 2020.03.31 150,000 -
method investees ‘21.02
D. Non-audit service contract

(Unit: KRW Thousand, USD)
Business year Contract date Service details Service period Service fee Remarks
Tax consulting service on the '22.09 ~

2022 2022.09.19 30,000- -
establishment of overseas subsidiary '22.10
Consulting service on matters regarding ‘21.02 ~
2021 2021.02.23 USD 295,000 -
overseas manufacturing plants ‘21.03
Consulting service on the establishment ‘20.01 ~

2020 2020.01.02 490,000 -
of overseas subsidiary ‘20.12
E. Contents of discussions about financial statements
Date Attendees Type Contents of discussion

Audit committee : 3 members
- Progress of key audit matters
Independent director: 1 director
1 2022.01.24 Face-to-face - Progress of annual accounting audit (financial
Company : Audit team leader & 4 others
statements/internal control over financial reporting)
Auditor : 1 Partner & 2 others
Audit committee : 3 members & 2 external
experts
- Interim report on the progress of Investigation
2 2022.02.04 Independent director: 1 director Face-to-face
committee
- Conclusion of management and governing body
based on the results of Investigation Committee's
Audit committee : 3 members, 3 external
diagnosis
experts
investigation
3 2022.02.25 Independent director: 1 director Face-to-face
- Results of key audit matters
- Year-End audit result and other essential
Auditor : 1 Partner & 1 other
communication factors at the completion stage of the
audit
Audit committee : 3 members
- Key audit matters from 1Q Review
4 2022.04.27 Company : Audit team leader & 1 other Face-to-face
- Plan of annual accounting audit
experts - Key audit matters from 1H Review
5 2022.07.27 Face-to-face - Audit plan for key audit items
Company : Audit team leader & 1 other
- Annual audit progress status
experts - Discussion of the work scope of Investigation
6 2022.10.17 Face-to-face
Company : Audit team leader & 2 others Committee
Audit committee : 3 members - Discussion of 3Q review focus areas
7 2022.10.26 Company : Audit team leader & 5 others Face-to-face - Audit plan for key audit maters
Auditor : 1 Partner & 2 others - Annual audit plan and its progress
Audit committee : 3 members - Audit plan for key audit maters
8 2023.01.27 Company : Audit team leader & 5 others Face-to-face - Year-end audit progress status (financial
Auditor : 1 Partner & 2 others statements/internal accounting management system)
- Conclusion of management and governing body
based on the results of Investigation Committee's
Audit committee : 3 members & 4 external experts diagnosis
9 2023.02.15 Company : Audit team leader & 2 others Face-to-face - Results of key audit matters
Auditor : 1 Partner & 2 others - Year-End audit result and other essential
communication factors at the completion stage of the
audit
※ The company operates the following pre-sessions so that the internal audit body and the auditor can have sufficient discussions
regarding the financial statements without the management.
- As of the end of December 2022, a total of 3 sessions (April 19, July 21, October 24) were held.
F. Change of external auditor
On July 12, 2018 and November 14, 2018, the Company was notified of the designation of auditors for
3 years as a result of actions by the Securities and Futures Commission, and concluded an audit
contract with Samjong KPMG LLC and the external auditor of the 7th and 8th business years, while
signing a new contract with the designated auditor, Hanyoung EY. The Company has appointed Samil
PwC as an external auditor for three consecutive business years since 2019 in line with the Audit
committee's evaluation process in accordance with the Audit committee's operational regulations, as
the application to suspend the ruling of a request to withdraw the measure recommended by the
Securities & Futures Commission has been cited.
In accordance with Article 10 (4) of the Act on external audits of corporations and others and Article 12
(1) of the Enforcement Decree of the Same Act, the audit committee held a face-to-face meeting on
November 19, 2021 to appoint Samil Accounting Firm as the external auditor for 2022 and three
consecutive business years. Accordingly, the Company signed the audit contract to appoint Samil
Accounting Firm as the 12th~14th external auditor.
2. Matters Regarding Internal Control
The independent auditor has audited the Company’s Internal Control over Financial Reporting as of
December 31, 2022. From the audit result, the auditor expressed ‘unqualified opinion’ that the Company
maintained, in all material respects, effective Internal Control over Financial Reporting based on the
‘Internal Control-Integrated Framework’.
The Company’s Internal Control over Financial Reporting is subject to annual audit by an external auditor.
Business
Auditor Audit opinions Remarks
year
As of December 31, 2022, the Company maintained, in all material

Samil
2022 respects, effective Internal Control over Financial Reporting based on -
PwC
the ‘Internal Control-Integrated Framework’

Samil
PwC

Samil
PwC
VI. Matters Regarding Executive Organizations
Including the Board of Directors
1. Matters Regarding the Board of Directors
A. Overview of the Board of Directors

The Company's Board of Directors (BOD) consists of three Executive directors (Kim Taehan, John Rim,
and Kim Dongjoong) and four Independent directors (Heo Geunnyoung, Eunice Kim, Lee Changwoo,
and Bahk Jaewan).
The BOD consists of the Management Committee, Audit Committee, Compensation Committee,
Independent Director Recommendation Committee, Related Party Transaction Committee, and ESG
Committee.
The Company currently separates the CEO and the Chairman position to enhance the independence
and transparency of the BOD. The board appointed the former CEO Kim Taehan as the Chairman, as
his managerial experiences enable him to mediate different opinions of Directors and make himself
most qualified to manage board activities.
The Company is undergoing a mid- and long-term review of whether to increase board members, as
the scale of business continuously expands.
Changes in Independent Directors

(Unit: person)
No. of independent Changes in independent directors

No. of directors
directors Appointment Dismissal Resignation
7 4 2 2 0
B. Agendas and Voting Results

Director
(Attendance rate)
No Date Agenda Result Kim John Kim Jeong Kwon Heo Eunice Lee Bahk
Tae Rim Dong Seok Soon Geun Kim Chang Jae
han joong woo jo nyung woo Wan
(92%) (100%) (92%) (100%) (100%) (100%) (100%) (100%) (100%)
※ Reported items:
- - - - - - - - N/A N/A
1. Plan for the Shareholder dividend policy
※ Resolution Items:
1st ‘22.01.24 1. Approval of FY2021 financial Approved For For For For For For For N/A N/A
statements and annual business report
2. Approval of transactions with related Approved For For For For For For For N/A N/A
parties
3. Approval of charitable contribution of idle Approved For For For For For For For N/A N/A
raw materials
Approved For For For For For For For N/A N/A
2nd ‘22.01.27 1. Signed stock purchase agreement Approved For For For For r For For For N/A N/A
2. Paid-in capital increase
1. Cancellation of signed stock purchase
3rd ‘22.01.27 agreement and paid-in capital increase Approved Absent For Absent For For For For N/A N/A
resolution
1. Signed stock purchase agreement Approved For For For For For For For N/A N/A
4th ‘22.01.28
2. Paid-in capital increase Approved For For For For For For For N/A N/A
※ Reported items:
5th ’22.02.25
1. FY2021 Audit Committee activities - - - - - - - - - -
Director
(Attendance rate)
No Date Agenda Result Kim John Kim Jeong Kwon Heo Eunice Lee Bahk
Tae Rim Dong Seok Soon Geun Kim Chang Jae
han joong woo jo nyung woo Wan
(92%) (100%) (92%) (100%) (100%) (100%) (100%) (100%) (100%)
2. Operation status of internal
accounting management system
3. Evaluation and audit report of internal - - - - - - - - - -
accounting management system
4. FY2021 Audit performance report - - - - - - - - - -
5. Approval of payment of legal services fee - - - - - - - - - -
for management’s litigation
6. Assignment of employee stock ownership - - - - - - - - - -
1. Approval of meeting and objectives of Approved For For For For For For For N/A N/A
general meetings of shareholders.
1. Nomination of Board of Director's Approved For For For N/A N/A For For For For
6th ’22.03.29
committee members
1. Participation in paid-in capital increase by Approved For For For N/A N/A For For For For
related parties
2. Review of compensation limit for directors Approved For For For N/A N/A For For For For
7th ‘22.03.29
3. Signed contract to purchase 2nd Approved For For For N/A N/A For For For For
4. Approval of 2022 Health and Safety Approved For For For N/A N/A For For For For
management system
※ Reported items:
- - - - N/A N/A - - - -
1. 1Q 2022 interim business result
- - - - N/A N/A - - - -
2. Progress of important matters
8th '22.04.27 ※ Resolution Items:

1. Approval of transactions with related Approved For For For N/A N/A For For For For
parties
2. Approval of transaction with major Approved For For For N/A N/A For For For For
shareholders
※ Reported items:
- - - - N/A N/A - - - -
1. 1H 2022 interim business result
- - - - N/A N/A - - - -
2. Progress of important matters
9th '22.7.27
1. Approval of implementation of Anti-bribery Approved For For For N/A N/A For For For For
management systems (ISO37001)
shareholders
3. Approval of transactions with related Approved For For For N/A N/A For For For For
parties
※ Reported items:
1. 3Q 2022 interim business result - - - - N/A N/A - - - -
1. Subscription of Samsung Fire & Marine Approved For For For N/A N/A For For For For
10th '22.10.26 Property Comprehensive Insurance
2. Approval of transactions with major Approved For For For N/A N/A For For For For
shareholder
3. Approval of anti-corruption guidelines Approved For For For N/A N/A For For For For
4. Approval of 2022 Charitable Contribution Approved For For For N/A N/A For For For For
5. Revision of the operating regulations of the Approved For For For N/A N/A For For For For
ESG Committee
※ Reported items:
11th '22.10.26 1. Litigation related to accounting issues - - - - N/A N/A - - - -
legal expenses
1. Approval of year-end donation to needy Approved For For For N/A N/A For For For For
neighbors
12th '22.11.30
shareholders
※ Reported items:
1. 2022 Incentive payment plan report - - - - N/A N/A - - - -
13th '22.12.21 ※ Resolution Items:

1. Approval of transactions with major
Approved For For For N/A N/A For For For For
shareholder
2. Approval of transactions with related
Approved For For For N/A N/A For For For For
parties
※ From 11th Board of Directors meeting held on March 29, 2022, independent directors Kwon Soonjo and Jeong Seokwoo
resigned, and Lee Changwoo and Bahk Jaewan were newly appointed as independent directors.
※ Jan 24, 2022 (1st round), Details of “Approval of transactions with related parties”
- Company name : Samsung Engineering

- Content : P5, P6 project basic design service contract
- Amount : KRW 100 million
- Period : Feb. 2022 ~ Jun. 2022
※ Jan 28, 2022 (4th round), Details of “Approval of stock purchase agreement resolution”
- Company name : Biogen Therapeutics Inc.

- Content : Acquired 10,341,852 shares of Samsung Bioepis
- Amount : USD 2,300,000,000
(Purchase amount USD 2,250,000,000 and contingent consideration amount USD 50,000,000)
※ Mar 29, 2022 (7th round), Details of “Participation of paid-in capital with related parties”
- Company name : Samsung C&T Corporation, Samsung Electronics

- Content : Preemptive subscription rights due to paid-in capital increase
- Amount : 1) Samsung C&T Corporation : KRW 1.2168 trillion
2) Samsung Electronics : KRW 882.1 billion
※ Apr 27, 2022 (8th round), Details of “Participation of paid-in capital with related parties”

- Content : Site suspension and installation of temporary facility of Plant 2
- Amount : KRW 24.4 billion
※ Apr 27, 2022 (8th round), Details of “Approval of transaction with major shareholders”
- Company name : Samsung C&T Corporation

- Content : Contract to change design service
※ Jul 27, 2022 (9th round), Details of “Approval of transaction with major shareholders”
- Company name : Samsung Electronics

- Content : Consulting of improvement of working environment of production facility PCO
※ Jul 27, 2022 (9th round), Details of “Participation of paid-in capital with related parties”

- Content : Investment in P5
※ Oct 26, 2022 (10th round), Details of “Approval of transaction with major shareholders”
- Company name : SAMOO Architects & Engineers

- Content : Contract to change design service contract
※ Nov 30, 2022 (12th round), Details of “Approval of transaction with major shareholders”
- Company name : Samsung Electronics

- Content : Consulting of enhancement of DP Manufacturing Competitiveness
※ Dec 21, 2022 (13th round), Details of “Approval of transactions with major shareholder”
Company name Transaction Contract date

Samsung Electronics Group disclosure system '23.1
Disclosure system '23.1
Purchase training '23.1
Electronic equipment purchase and
If needed
maintenance service
Lease in-house mobile phone store '23.1
Samsung Electronics Sales
Purchase of electronic equipment If needed
After service fee for electronic
Samsung Electronics Service If needed
equipment
Landscape management '23.1
Samsung C&T
Use of Anyang CC Membership '23.3
SAMOO Architects & Engineers Ki-10 Site licensing design service '22.12
Operation of in-house restaurant,
Samsung Welstory '23.1
Lease in-house café
Facility parts and maintenance
Samsung C&T Deutschland GmbH If needed
materials
Samsung Bioepis CMO contract During '23
※ Dec 21, 2022 (13th round), Details of “Approval of transactions with related parties”
Company name Transaction Contract Amount

S-1 Corporation Building maintenance KRW 27.63 billion
Construction of 1st Bio Campus
KRW 5.1 billion
green center
Non GMP Pilot process/detail lay out KRW 0.42 billion
Samsung Engineering
Detailed design of new ADC
KRW 0.97 billion
production facility
Ki-10 Site licensing design service KRW 0.12 billion
C. Committees of the BOD
(1) Committees
Committee
Composition Name Purpose & authority Remarks
Name
[Purpose]
To deliberate the matters entrusted by the BOD out of
the Company’s material management information,
matters often entrusted by the BOD, and matters
(Chairperson) entrusted by the BOD as other material management
Management information
2 Executive John Rim
committee -
directors
(‘11.04.22) [Main authorities]
Kim Dongjoong
① General management
② Matters regarding finance
③ Other related matters
Committee
Composition Name Purpose & authority Remarks
Name
[Purpose]
To secure objectivity and transparency in determining
director compensation
(Chairperson) [Main authorities]

3 Independent Bahk Jaewan
Compensation
directors ① Matters regarding the compensation limit of
committee registered directors -
1 Executive Heo Geunnyung
(‘16.08.10) ② Matters regarding performance evaluation criteria
director Eunice Kim
Kim Dongjoong of registered directors
③ Matters regarding the compensation system of
registered directors
④ Matters entrusted by the Board of Directors
regarding director compensation
[Purpose]
To deliberate large-scale related party transactions in
order to strength internal control over related party
transactions and external control over shareholders
and to enhance the efficiency of supervision over
(Chairperson) illegal support
Related party
Heo Geunnyung
transaction 3 Independent
-
committee directors [Main authorities]
Lee Changwoo
(‘16.08.10)
Bahk Jaewan ① To approve related party transactions
② To listen to the report of related party transactions
③ To order an ex-offcio investigation of related party
transactions
④ To suggest a corrective action against related
party transactions
[Purpose]
To deliberate policies regarding Environmental,
Social, and Corporate Governance issues including
(Chairperson) Corporate Social Responsibilities, shareholder value
Eunice Kim enhancement, customer value enhancement and
ESG
4 Independent shareholding structure.
Committee -
directors Heo Geunnyung
(‘21.02.26)
Lee Changwoo
Bahk Jaewan [Main authorities]
① Matters regarding ESG strategy and policy
② Annual donation plan
③ Other important matters delegated by the Board
※ The composition of committees is as of December 31, 2022.

※ On March 29, 2022, independent directors Kwon Soonjo and Jeong Seokwoo’s terms expired, and Lee Changwoo and Bahk
Jaewan were newly appointed as independent directors.
※ The Audit Committee and Independent Director Recommendation Committee were excluded according to Corporate
Disclosure Guidelines set forth by the Financial Supervisory Service Authority of the Republic of Korea.
(2) Committee activities
※ The Audit Committee and Independent Director Recommendation Committee were excluded
according to Corporate Disclosure Guidelines set forth by the Financial Supervisory Service
Authority of the Republic of Korea.
① Management committee
Director
(Attendance rate)
Date Details of agendas Result
John Rim Kim Dongjoong
(100%) (100%)
1. Extension of the due date of Woori Approved For For
Bank credit limit
2. Extension of the due date of Shinhan Approved For For
'22.05.13
Bank credit limit
3. Extension of the due date of Hana Approved For For
Bank credit limit
'22.06.07 1. Approval of new manufacturing contract Approved For For
'22.07.04 1. Approval of new manufacturing contract Approved For For
1. Extension of the due date of Kookmin
'22.07.13 Approved For For
Bank credit limit
1. Extension of the due date of Kookmin
Bank credit limit
1. Extension of maturity of SMBC credit
limit
② Compensation committee
Director
(Attendance rate)
Kwon Bahk Heo Eunice Kim
Soonjo Jae Geun Kim Dong
Wan nyung joong
(100%) (100%) (100%) (100%) (100%)
1. Assignment of employee stock ownership Approved For N/A For For For
2. Review of 2022 individual annual income Approved For N/A For For For
‘22.02.25 of executive directors
3. Review of 2022 compensation limit for Approved For N/A For For For
registered directors
'22.04.27 1. Appointment of compensation chairman Approved N/A For For For For
[Written Report] Report on TAI payment in - N/A - - - -
'22.07.06
the 1H of 2022
※ Reported items:
1. Report on target incentives and - N/A - - - -
'22.10.26
performance incentive payment plans for
the 2H of 2022
※ Reported items:
1. Incentive for executive director - - - - - -
2. Compensation B/M result report - - - - - -
'22.12.21
1. Deliberation on payment of incentives to Approved N/A For For For For
the CEO
※ As of March 29, 2022, independent directors Kwon Soonjo resigned, and Bahk Jaewan were newly appointed as independent
directors.
③ Related party transaction committee
Director
(Attendance rate)
Date Details of agendas Result Heo Lee Bahk
Geunnyung Changwoo Jaewan
(100%) (100%) (100%)
1. Appointment of chair of related party Approved For For For
transaction committee
‘22.03.29
2. Participation in paid-in capital increase by Approved For For For
related parties
'22.04.27 1. Landscaping of Plant 4 Approved For For For
'22.10.26 1. Contract regarding SAMOO Architects & Approved For For For
Engineers design services
2. Joining property insurance with Samsung Approved For For For
Fire & Marine Insurance Co., Ltd.
1. Contract regarding in-house restaurant Approved For For For
'22.12.21
consignment management
※ Details of March 29, 2022 agendas
- Content : Participation in paid-in capital increase by related parties

- Company name : Samsung C&T Corporation, Samsung Electronics
- Amount : 1) Samsung C&T Corporation : KRW 1,216.8 billion
2) Samsung Electronics : KRW 882.1 billion
※ Details of April 27, 2022 agendas
- Content : Landscaping of Plant 4

- Company name : Samsung C&T Corporation
※ Details of October 26, 2022 agendas
① Joining property insurance with Samsung Fire & Marine Insurance Co., Ltd
- Company name : Samsung Fire & Marine Insurance Co., Ltd.
- Period : 1 year('22.12.01~'23.11.30)
② Contract to change SAMOO Architects & Engineers design service contract

- Company name : SAMOO Architects & Engineers
- Period : '20.10.22~'23.09.30
※ Details of October 26, 2022 agendas
- Content : Contract for operation of In-house restaurant with Samsung Welstory

- Period : 1 year('23.01.01~'23.12.31)
④ ESG committee
Director
(Attendance rate)
Eunice Jeong Kwon Heo Lee Bahk
Kim Seok Soonjo Geun Chang Jae
woo nyung woo wan
(100%) (100%) (100%) (100%) (100%) (100%)
1. Approval of charitable
‘22.01.24 contribution of idle Approved For For For For N/A N/A
raw materials
※ Reported items
'22.04.27 - - N/A N/A - - -
ESG plan for 2022
※ Reported items
1. Result of Frontier-
'22.06.07 1.5D - - N/A N/A - - -
2. Progress of ESG
initiatives and plan
※ Reported items
'22.07.27 1. Participation - - N/A N/A - - -
programs in social
contribution activities
※ Reported items
'22.09.14 1. Promotion and - - N/A N/A - - -

declaration of carbon
neutrality
1. Approval of charitable Approved For N/A N/A For For For
'22.10.26
contribution
2. Amendment of ESG Approved For N/A N/A For For For
the operating
regulations of the
ESG Committee
1. Approval of charitable Approved For N/A N/A For For For
contribution
2. Promoting carbon Approved For N/A N/A For For For
'22.11.30
neutrality (Net Zero) and
changing the
declaration
※ Reported items
'22.12.31 1. Result of ESG - - N/A N/A - - -
assessment
※ On March 29, 2022, independent directors Kwon Soonjo and Jeong Seokwoo’s terms expired, and Lee Changwoo and Bahk
Jaewan were newly appointed as independent directors.
D. Independence of Directors
(1) Independence of directors

Directors are appointed at the general meeting of stockholders, and director candidates to be appointed
by the general meeting of stockholders are recommended by the Board of Directors, which is decided
as a bill to be submitted to the general meeting of stockholders. The Company ensures directors’
independence to make them objectively oversee the company business.
Consec Business Relationship

Term utive relationship with the
Name Appointment background Nominator Responsibility
expiration terms with a largest/major
(No.) company shareholder
- A professional enterpriser who

has been working as the CEO
since the foundation of the
Company and has been
improving the Company by
making important decisions with
a long-term view Executive
Kim ‘23 O Board of Affiliate
- Representative of South Korea’s Director, -
Taehan AGM (3) Directors Executive
bio industry with high awareness Chair of BOD
and reliability in relation to global
pharmaceutical companies
- The company expects to lead
the company’s future contracts
and new business projects
- Served as CFO through sales /

marketing, production / RM /
SCM at global
biopharmaceutical companies
Genentech, Roche, etc., and the CEO,
John ‘23 possesses world's best global Board of Chair of Affiliate
X network and expertise -
Rim AGM Directors Management Executive
- Based on a high understanding committee
of the industry as a whole, he is
expected to contribute to
strengthening business
capabilities and competitiveness
and expanding new orders.
- Contributed to the
transplantation of advanced
company management system
to the Company based on past
experience of working for
Samsung Electronics
Executive
Kim ‘25 O Board of Affiliate
- Expected to contribute to the Director -
Dongjoong AGM (2) Directors Executive
Company's continued growth by CFO
overseeing HR, IT, Finance,
Business planning and Business
Innovation departments, which
are the company's key
management functions.
- As a legal expert (lawyer),

Served as presiding judge at the
Seoul Central District Court and
a professor at the Judicial Independent
Independe
Research and Training institute director,
nt director
Heo ‘25 O Chair of Affiliate
- As a legal expert with recommen -
Geunnyung AGM (1) Related party Executive
considerable experience in legal dation
transaction
practice and academic fields, the committee
committee
Company looks forward to the
inspection and reinforcement of
existing legal system
- Global leader with excellent

knowledge in legal services and
communication skills based on
her experience as an in-house
lawyer, an executive and
independent director in a
number of financial companies Independe
Independent
nt director
Eunice ‘23 - In the process of collaborating director, Affiliate
X recommen -
Kim AGM with global pharmaceutical Chair of ESG Executive
dation
companies, communication skills Committee
committee
and legal knowledge will be a
great asset, and she is expected
to reflect diversity in the
operation of the Board of
Directors as female independent
director.
- As an accounting expert (CPA)

and professor of business
administration major served as
chair of ethics committee at the
Korea Institute of Certified Public
Accountants
Independent
Independe
- Expected to perform objective director,
nt director
Lee ‘25 management role based on Chair of Affiliate
X recommen -
Changwoo AGM accounting and management Related party Executive
dation
expertise, and the Company transaction
committee
looks forward to enhancing committee
financial soundness and
management transparency
based on financial management
and risk management
knowledge
- Possess a high level of

understanding of the operation
of the Board of Directors from
experience as multiple
independent directors
Independe Independent
- Based on the experience of
nt director director,
Bahk ‘25 serving as the chairman of the Affiliate
X recommen Chair of -
Jaewan AGM Board of Directors of global Executive
dation Compensation
companies and high-ranking
committee Committee
political positions, preemptive
risk review for business growth
and rational presentation of
management strategy for
business growth are expected.
※ From 11th Board of Directors meeting held on March 29, 2022, executive director Kim Dongjoong and independent director
Heo Geunnyung were re-appointed, and audit committee member Lee Changwoo and independent director Bahk Jaewan
were newly appointed.
(2) Independent director recommendation committee

The Company has created the independent director recommendation committee on August 10, 2016
for the recommendation of independent director candidates, and the committee will review their
competence and recommend qualified persons.
Director
(Attendance rate)
Name of Details of Kwon Jeong Kim Lee Bahk Eunice Kim
Date Result
committee agendas Soon Seok Tae Chang Jae Kim Dong
jo woo han woo Wan Joong
(100%) (100%) (100%) (100%) (100%) (100%) (100%)
※ Reported items:
1. Establishment of
- - - - N/A N/A - N/A
internal operating
standards for a
recommendation of
’22.02.25 candidates for
independent director
※ Bill
1. Recommendation of Approved For For For N/A N/A For N/A
Independent an independent
director candidate director candidate
Recommendation
※ Bill
committee
1. Appointment of the
chairman of the
'22.04.27 independent director Approved N/A N/A N/A For For For For
candidate
recommendation
committee
※ Bill
1. Recommendation of
'22.12.21 Approved N/A N/A N/A For For For For
indepdent director
candidates
E. Expertise of Independent Directors
The Company operates the Board of Directors Secretariat consisting of 6 full-time staff, to support
independent directors perform their professional duties. The staff provide the directors with reference
materials corresponding to the meeting agendas well in advance the meeting. This enables directors
study and review each agenda discussed during the Board of Directors/Committee meetings. If
necessary, the Directors are provided with separate information sessions on any agenda and they are
also frequently provided updates on other key management issues.
(1) Secretariat for Independent directors

Name Number Department/Position Task
1 Team Leader, 1 Group Leader,

General management and
HR Support Center 4 and 2 Pros
operation of Secretariat
(Average 3 years)
※ Average years refer to time performing work relevant to support activity
(2) Education program for Independent Directors

Reasons for
Date Educator Attendant Education contents
absence
Heo Geungnyeong
Korea Health Industry Eunice Kim
2022.05.11 - - BIO KOREA 2022(Online)(~05.13)
Development Institute Lee Changwoo
Bahk Jaewan
2. Audit System
A. Profile of the Member of the Audit Committee

Indepen Accounting and Finance expertise
Name dent Career Applicable
director Expert type Related experience
status
- Basic qualifications:
Acquisition of a
master's degree or
higher related to
accounting and finance
ㆍDoctor of Business
Administration, UC
- Chair of ethics committee, Korea Institute of Certified
Berkeley (1987)
Public Accountants (2020~present)
ㆍMaster of accounting
- Professor, Seoul National University Business School ② Degree
science, University
(1992~present) holder in of Illinois Urbana-
Lee - Chairman of Board of Director, Korea Institute the field of
Chang Yes Yes Champaign (1982)
Association (2011~2013) accounting - Work experience :
woo and
- Ministry of Economy and Finance, Head of Over five years of
management evaluation team of Quasi-Government finance overall work experience
Institution (2009-2011) (Type 2) as a researcher or
- President, Korea Accounting Association (2008-2009) assistant professor in
accounting or finance
fields at a research
institute or a university
ㆍProfessor, Seoul
National University
Business School
(1992~present)
Indepen Accounting and Finance expertise
Name dent Career Applicable
director Expert type Related experience
status
- Legal Advisor, Pyeongan Law Firm (2019~Present)

- Managing Partner, Pyeongan Law Firm (2016~2019)
- Lawyer, GILDO Law Firm (2011~2016)
Heo
Yes - Senior Judge, Seoul Central District Court
Geun - - -
(2004~2007)
nyung
- Professor, Judicial Research and Training Institute
(2001~2004)
- Chief Judge, Cheongju District Court (1999~2001)
- Committee member of ESG Standards Committee,

Korea Corporate Governance Service
(2017~Present)
- Professor, Ewha W. University Law School
(2010~2021)
Eunice
Yes - Vice President/Chief Compliance Officer, Hana - - -
Kim
Financial Group (2008~2010)
- Chief Compliance Officer, Japan Citi Bank
(2007~2008)
- Executive Vice President, Deputy Minister for Legal
Affairs, Korea Citi Bank (2004~2007)
※ On March 29, 2022, the audit committee member Jeong Seokwoo and independent director Kwon Soonjo's terms expired.
※ On March 29, 2022, independent director Heo Geungnyeong was re-appointed as an audit committee member, and Lee
Changwoo and Eunice Kim were newly appointed as independent directors.
B. Independence of Audit Committee Members
Relati
onship Relationship
Reappoi
Recommend with with the
Name Appointment Background Term ntment
ation the largest/major
(No.)
Comp shareholder
any
- As an accounting expert (KICPA and AICPA) and

doctorate of Business Administration, he has high
level of understanding in corporation from multiple Independent
independent director experiences. director Affiliate
Lee 2022.03
candidate Executive
Chang - Expects contribution to enhancement of ~ X -
recommend (SBL)
woo competitiveness and increasing the rights and 2025.03
ation
interests of stakeholders, including shareholders, by committee
performing objective management supervisory roles
based on expertise and active board activities
- As an expert in legal field (lawyer), he served as

presiding judge at the Seoul Central District Court Independent
and a professor at the Judicial Research and Training director Affiliate
Heo institute 2022.03
candidate O Executive
Geun ~ -
- With considerable experience in legal practice and recommend (1) (SBL)
nyung 2025.03
academic fields, he will play a crucial role in ation
inspection and reinforcement of the Company’s legal committee
system
- Successfully performed various positions such as

compliance attorney at the global company,
independent director, and professor. Independent
director Affiliate
- Expects high contribution in inspection and 2022.03
Eunice candidate Executive
reinforcement of the Company’s compliance ~ X -
Kim recommend (SBL)
monitoring system and practice of ethical 2025.03
ation
management system. Expects diverse and committee
strengthened internal control system as a first female
independent director.
※ Independent director Lee Changwoo was recommended by Independent Director Recommendation Committee and appointed
at the General Meetings of Shareholders.
The Company’s Audit committee is formed in accordance with Article 542-11 of the Commercial Act,
and three independent directors who constitute the Audit committee as stated above meet eligibility
requirements for both Independent directors and Audit committee members.
Details Qualifications Remarks
Consists of 3 directors Qualified(3) Article 415-2 Clause 2
More than 2/3 of Qualified
Article 415-2 Clause 2
independent directors (All independent directors)
More than one member must be an
Qualified
accounting or financial specialist
(1, Independent director: Article 542-11 Clause 2
prescribed by Presidential Decree.
Lee Changwoo)
Qualified
Representative of Audit committee must
(Independent director: Article 542-11 Clause 2
be an independent director
Lee Changwoo)
Other qualification
(Related parties of the largest Qualified Article 542-11 Clause 3
shareholders, etc)
One member of the Audit Committee is
Qualified
appointed by the resolution of the general
(Independent director: Article 542-12 Clause 2
meeting of shareholders after being
Lee Changwoo)
separated from other directors
Meanwhile, the Audit committee is eligible to request reports on business performance and financial
status from Directors and requests additional reviews and supplementation of data as needed.
C. Activities of Audit Committee
Director
(Attendance rate)
Date Details of agendas Result Heo Lee Eunice
Jeong Kwon
Geung Changwoo Kim
Seokwoo Soonjo
(100%) (100%) nyeong (100%) (100%)
(100%)
※ Reported Items:
1. 2021 financial statements and annual - - - -
‘22.01.24
business report
2. Audit activities by external auditor - - - -
※ Reported Items:
1. 2nd interim report from 3rd Assessment - - - -
committee
2. Audit activities by external auditor - - - -
3. Results of internal accounting - - - -
performance evaluation by the CEO
‘22.02.04 4. Performance and independence of - - - -
the Audit committee
5. Assessment result of the internal audit - - - -
department
6. Report on audit results of 1H 2021 - - - -
7. Report on the progress of major
issues - - - -
※ Reported Items:
‘22.02.15 1. 2nd Report on the progress of major - - - - Not Not
issues Applicable Applicable
(Newly (Newly
※ Reported Items: appointed) appointed)
1. 2nd Report on the results of internal - - -
-
accounting performance evaluation by
the CEO
2. 2nd Report on performance and - - -
‘22.02.21 -
independence of the Audit committee
3. 2nd Report on assessment result of - - -
-
the internal audit department
4. 3rd Report on the progress of major - - -
-
issues
※ Reported Items:
1. Operation status of internal control - - - -
over financial reporting
2. Progress of the assessment on - - - -
‘22.02.25 internal control over financial reporting
by PA
3. Progress of the end-of-year audit - - - -
1. Approval of agenda for the 11th AGM Approved For For For
※ Reported Items:
1. Entry education for newly appointed - - - -
auditors
2. Annual operation plan of the Audit - - - -
committee
‘22.03.29 - -
3. Annual plan of Internal accounting - -
management system
Approved Not Not For For For
1. Appointment of chairman of audit
Applicable Applicable
committee
(End of (End of
※ Reported Items: term) term)
-
1. 1Q 2022 interim business result
- - -
2. 2022 annual audit plan -
- - -
'22.04.27 3. Progress of 1Q 2022 accounting -
review
1. Establishment of internal audit Approved
performance indicators For For For
※ Reported Items:
'22.04.27
1. Annual plan of internal audit team - - - -
2. Evaluation of 2021 external audit firm - - - -
3. Appointment of audit committee as PA - - - -
4. Establishment of phase 2 of - - - -
consolidated internal accounting
management system
'22.07.27 ※ Reported Items:
1. 1H 2022 interim business report - - - -
2. Report on assessment of internal - - - -
accounting control system
3. Assessment on internal accounting - - - -
control system by PA
4. Progress of 1H 2022 accounting - - - -
review and control system
1.1H 2022 Audit performance of - - - -
Samsung Biologics and Bioepis and
audit plan of 2H 2022
2. Current activity status of information - - - -
security/compliance
3. Improvement in Audit Committee work - - - -
4. Audit progress of subsidiary company - - - -
1. Start of the 4th assessment committee - - - -
2. Samsung Biologics' internal audit - - - -
Team's annual audit performance
3. Samsung Bioepis' audit team's annual - - - -
audit performance
4. 2022 1H internal control over financial - - - -
reporting evaluation
5. Selection of evaluator of internal - - - -
control performer
1. 3Q 2022 interim business report - - - -
2. Progress of 3Q 2022 accounting - - - -
review
3. Progress of audit of internal - - - -
4. Project result of consolidated internal - - - -
development
1. Amendment of internal accounting - - - -
management guidelines
2. Performance evaluation of Audit - - - -
Committee's internal accounting
management system
1. Evaluation of the person in charge of Approved For For For
2022 Audit Committee
※ According to Article 415-2 (Audit Committee) (5) of the Commercial Act and Article 7 (1) 8 of the operating regulations of our
audit committee, the audit committee operates a diagnostic committee with external auditors to examine the impact of ongoing
lawsuits on internal control as of the end of each business year ('19~’22).
D. Education Plan & Status of Audit Committee
(1) 2022 Education program for Audit Committee
Education plan
Name of education Educator
‘22.04 - Audit and Inspection conference Audit Committee Forum
‘22.05 - BIO KOREA 2022 Korea Health Industry Development Institute
‘22.07 - Audit committee seminar with external experts Internal Control Operation Group
(2) Previous education program
Reasons for
Date Educator Attendant Education contents
absence
Lee Changwoo
Internal
Heo - Entry education for newly appointed
2022.03.29 Accounting -
Geungnyeong auditors
Operation Group
Eunice Kim
Lee Changwoo
(Personal reason)
Audit Committee - Disclosure of ESG and audit committee
2022.04.19 Eunice Kim Heo
Forum supervising points
Geungnyeong
(Personal reason)
Korea Health Lee Changwoo

Industry Heo
2022.05.11 - - BIO KOREA 2022(Online)(~05.13)
Development Geungnyeong
Institute Eunice Kim
Lee Changwoo
Heo
2022.07.27 Anjin Deloitte - - FY2022 key accounting issues
Geungnyeong
Eunice Kim
Heo
Audit Committee Lee Changwoo - Global status and implications related
2022.09.14 Geungnyeong
Forum (Personal reason) to the audit committee's ESG response
Eunice Kim
E. Support Team for Audit committee

No. of Position
Department Details
employee (Average service period)
1 Group Leader, 1 Pro - Operation of Audit Committee

Internal Control Operation Group 2
(3.5years) - Assessment of Internal Control
1 Team leader, 4 Pros - Support operation for Audit Committee

Audit Team 5
(1.5years) - Inspection of Internal Control process
※ Service years refer to time performing work relevant to support activity.
F. Compliance Officer
Name Career Qualification
- Master degree in Laws, Seoul National University (1996),
Moon 45th bar exam. Qualified
Hyung - Lawyer, Law firm KIM CHANG & LEE (2006~2017) (Article 542-13 Clause 5
Woo - Team leader, Legal Compliance Team, No. 1 of Commercial Act)
Samsung Biologics Co., Ltd. (2017~present)
G. Major Compliance Activities

The Company conducts regular/non-regular compliance activities at the workplace, and based on the
results of the activities, the Company is effectively supporting compliance activities so that the Company
and its employees can comply with all laws and regulations by reflecting the issues that need
improvement.
Dates Major Inspection & Activity details
2022.01 - Compliance education for experienced employees
2022.02 - Compliance education for entrance-level employees
- Compliance education for experienced employees
2022.03
- Compliance PR(Capital Markets Act, etc.)
2022.04 - Compliance PR(In-house broadcasting/Quiz)
2022.05 - Risk evaluation(anti-corruption)
2022.06 - Compliance education(ISO37001, anti-corruption)
2022.07 - Compliance education for summer interns
- Compliance inspection(ISO37001)
2022.08
- Compliance education for entrance-level employees and industry-academia interns
- Compliance education and a pledge of action(online, all employees)
2022.10
- Inspection and improvement of internal processes (Mutually Cooperation Act, Subcontracting Act)
2022.12 - Compliance education for experienced employees
H. Support Team for the Compliance Officer

Department No. Position (Service Period) Details
Legal - Inspection and education of CPs such as fair

10 Lawyers (3.3years)
Compliance 15 trade and anti-graft law
5 Pros (3.6years)
Team - Review of contracts and in-house regulations
3. Matters Regarding the Exercise of Shareholders’ Voting Rights
A. Voting System
Type Cumulative voting. Paper voting Electronic voting
Introduction Not Applicable Not Applicable Applicable
Since 10th
Implementation - - Annual General Meeting held
on March 19, 2021
B. Minority Shareholders’ Rights

No minority shareholders' rights were exercised during the reporting period.
C. Competition over Management Rights

No competition over management rights occurred during the reporting system.
D. Voting Shares
The Company has 71,174,000 shares of common stock outstanding, which account for 14.23% of the
total number of authorized shares (500 million shares). The number of shares available for exercising
the voting right is 71,124,482 shares excluding 49,518 shares in a special account of Samsung Life
Insurance, the Company’s financial affiliate company.
Number of
Classification Remarks
shares
Common stock 71,174,000 -
Number of outstanding shares (A)
Preferred stock - -
Number of shares with no voting rights Common stock - -

(B) Preferred stock - -
Common stock - -
Number of shares with no voting rights
according to articles of incorporation (C) Preferred stock - -
Restricted by the
Insurance Business Act
Common stock 49,518
Number of shares with limited voting (Special account -
rights under relevant laws (D) Samsung Life Insurance)
Preferred stock - -
Common stock - -
Number of shares with revived voting
rights(E) Preferred stock - -
Number of shares with voting rights Common stock 71,124,482 -

(F = A - B - C - D + E) Preferred stock - -
E. Stock affairs
Article 11 (Issuance and allocation of shares)
① The Company may issue new shares with a resolution of the BOD by:
1. Granting the shareholders opportunities to subscribe for new shares in proportion to their
respective shareholding;
2. Granting specific persons (including the shareholders of the Company) opportunities to
subscribe for new shares to the extent of not exceeding 30/100 of the total number of
issued and outstanding shares (the total number of issued and outstanding shares herein
shall include new shares to be issued under this Sub-Paragraph) by a method other than
that under Sub-Paragraph 1 (i.e. private placement) for managerial purpose of the
Company such as improvement of financial structure, introduction of new technology,
strategic partnership, etc.;
3. Granting general public (including the shareholders of the Company) opportunities to
subscribe for new shares and allocating new shares to those who subscribe for such
shares to the extent of not exceeding 50/100 of the total number of issued and
outstanding shares (the total number of issued and outstanding shares herein shall
Details of stock include new shares to be issued under this Sub-Paragraph) by a method other than that
warrants in the under Sub-Paragraph 1.
articles of ② When allocating new shares under Sub-Paragraph 3 of Paragraph 1 above, the Company
incorporation shall allocate new shares with a resolution of the BOD by::
1. Allocating new shares to unspecified subscribers without differentiating the types of
persons who are granted opportunities to subscribe for new shares;
2. Allocating new shares to the members of the Employee Stock Ownership Association
pursuant to applicable laws and granting general public opportunities to subscribe for new
shares, including unsubscribed shares;
3. Granting the shareholders opportunities to subscribe for new shares first and, if there are
any unsubscribed shares, then to general public opportunities to be allocated;
4. Granting specific types of persons opportunities to subscribe for new shares in accordance
with reasonable standards stipulated in applicable statutory provisions, such as demands
forecast to be made by investment trader or investment broker as underwriter or arranger.
③ When new shares are allocated under Sub-Paragraph 2 or 3 of Paragraph 1 above, the
items set forth in Section 416 (1), (2), (2-2), (3) and (4) of the Commercial Code shall be
notified to shareholders by way of individual or public notices no later than two (2) weeks
prior to the date of payment of the subscription price; provided, however, that such an
individual notice and public notice may be substituted by publishing a Report of Major Items
to the Financial Services Commission and the stock exchange under Article 165-9 of the
Financial Investment Services and Capital Markets Act.
④ The class, number, and issuance price of the new shares that are to be issued under any of
the provisions in Paragraph 1 shall be determined by a resolution of the BOD.
⑤ Any of the new shares that are not subscribed for or paid therefor by applicable payment
date shall be handled by a resolution of the BOD in accordance with applicable laws and
regulations.
⑥ Disposal of fractional shares created in the course of allocation of new shares shall be
determined by a resolution of the BOD.
⑦ In case of allocation of new shares under Sub-Paragraph 1 of Paragraph 1 above, the
Company shall issue the certificates of preemptive rights to the shareholders.
General Shareholders’ Within 3 months after the
Closing date December 31
Meeting business year ends
Closing date of
December 31
stockholders’ list
Closure of
From January 1 to January 31
stockholders’ list
Type of share
-
certificates
Transfer agent Korea Securities Depository
Privileges of
Not Applicable
shareholders
Homepage (https://www.samsungbiologics.com)
Public notice
In unavoidable circumstances, related information is published on Joongang Daily
※ With Act on Electronic Registration of Stocks, Bonds, etc. (“Electronic Securities Act”) taking effect Sep 16, 2019, rights
specified on stocks and subscription warrants are subject to mandatory electronic registration, therefore, “Stock types” are no
longer applicable.
F. Summary of Annual General Meeting Minutes

Date Agenda Result
- Approval of 11th period (2021.01.01~2021.12.31) financial statement
- Appointment of directors (Executive director – Kim Dongjoong; &
Independent directors –Heo Geungnyeong and Bahk Jaewan)
- Appointment of independent director to serve as an Audit
2022.03.29 Approved
Committee member (Independent director – Lee Changwoo)
- Appointment of Audit Committee member (Heo Geungnyeong and
Eunice Kim)
- Approval of compensation limit for Directors
2021.03.19 Approved
- Appointment of directors (Executive director – Kim Taehan and
2020.03.20 Approved
John Rim; & Independent director – Eunice Kim)
VII. Matters Regarding Shareholders
1. Stocks Held by the Largest Shareholder and Related Parties
A. Stocks held by the largest shareholder and related parties

(As of December 31, 2022) (Unit: Share, %)
Share number and ratio
Class of Beginning of period End of period

Name Relationship Remarks
stock
Shares Ratio Shares Ratio
Samsung C&T Largest Common Participation in

28,742,466 43.44 30,646,705 43.06
Corporation shareholder stock capital increase
Samsung Common Participation in

Related party 20,836,832 31.49 22,217,309 31.22
Electronics stock capital increase
Participation in
Samsung Life
Common capital increase,
Insurance Related party 56,026 0.08 49,518 0.06
stock Open market
(special account)
transactions
Participation in
Common capital increase,
Kim Taehan Related party 16,400 0.02 4,200 0.01
stock Open market
transactions
Common Participation in
Kim Dongjoong Related party 4,300 0.01 4,632 0.01
stock capital increase
Common
49,656,024 75.04 52,922,364 74.36 -
stock
Total
Preferred
- - - - -
stock
B. Overview of the largest shareholder
(1) Corporation information
Number of Chief Executive Officer Business Executive Largest Shareholder

Investors (Representative Member) (Business Member) (Largest Investor)
Name
(Number of
persons) Name Share(%) Name Share(%) Name Share(%)
Lee Jae Yong

Koh Jung Suk 0.00 - - 33.47
and others
Samsung
C&T 186,329 Oh Se Chul 0.00 - - - -
Corporation
Han Seung Hwan 0.00 - - - -
※ The number of investors above is the number of common stock shareholders of Samsung C&T Corporation recorded up to
the latest shareholder list closure date which is December 31, 2022. The shares of Chief Executive Officer, Business
Executive, and Largest Shareholder are recorded up to the disclosure date of December 31, 2022.
Details of changes in Chief Executive Officer, Business Executive, and Largest Shareholder
Chief Executive Officer Business Executive Largest Shareholder

Date of (Representative Member) (Business Member) (Largest Investor)
change
Name Share(%) Name Share(%) Name Share(%)
2021.03.19 Lee Youngho - - - - -
2021.03.19 Chung Keumyong - - - - -
2021.03.19 Koh Jung Suk - - - - -
2021.03.19 Oh Se Chul 0.00 - - -

2021.03.19 Han Seunghwan 0.00 - - - -
※ On March 19, 2021, Co-Chief Executive Officers Lee Young Ho and Chung Keum Yong resigned. Oh Se Chul and Han Seung
Hwan were newly appointed as new Co-Chief Executive Officers.
※ For changes in the share ownership status during the period of public disclosure, changes in ownership and statement by
dates are separately disclosed in the electronic disclosure system, so please refer to the "2022 Annual report" by Samsung
C&T Corporation.
(2) Financial status

(Unit: KRW Mil)
Samsung C&T Corporation

Total assets 58,981,492
Total liabilities 27,017,371
Total stockholder’s equity 31,964,121
Sales 43,161,653
Operating income 2,528,524
Current net income 2,544,957
※ The values above are based on the consolidated financial statements as of December 31, 2022.
(3) Business status
Samsung C&T Corporation, the largest shareholder of Samsung Biologics Co., Ltd., is located in 26,
Sangil-ro 6-gil, Gangdong-gu, Seoul, Republic of Korea, and engages mainly in business areas at home
and abroad: the engineering & construction sector including building, civil infrastructure, plant, and
housing; the trading & investment sector including natural resources, steel, chemical & industrial
materials, and living industrial; the fashion sector including apparel products manufacturing, sales
business and textile processing; the resort sector including landscaping and Everland (drier park),
Caribbean Bay (water park), golf club, and catering (Samsung Welstory) and the biopharmaceutical
outsourcing & biosimilar sector.
※ For more details regarding largest shareholders, please refer to the "2022 report" by Samsung &T Corporation disclosed in
the electronic disclosure system.
2. Changes of the Largest Shareholder
Changes of the largest shareholder during the time period subject to disclosure are as follows:
(As of December 31, 2022) (Unit: share, %)
No. of stocks Cause of
Date Largest shareholder Share ratio Remarks
held Change
2011.04.22 (Old) Cheil Industries 600,000 40,00% Establishment -
2011.04.22 Samsung Electronics 600,000 40.00% Establishment -
2015.09.02 Samsung C&T Corporation 14,069,833 51.04% Note1) Note2)

Note1) Samsung C&T Corporation is the sole largest shareholder, as Cheil Industries Inc., a survival corporation after merger
between Samsung C&T Corporation and (old) Cheil Industries Inc. which was the largest shareholder was renamed to
Samsung C&T Corporation.
Note2) Currently, the largest shareholder Samsung C&T Corporation has 30,646,705 shares which is 43.06% stake.
3. Distribution of Shares
A. Shareholders with over 5% ownership and stocks held by the employee stock
ownership association
(As of December 31 2022) (Unit: share)
Number of shares
Classification Name of shareholders Share ratio Remarks
owned
Samsung C&T Corporation 30,646,705 43.06% -
Shareholders with
Samsung Electronics 22,217,309 31.22% -
over 5% ownership
National Pension Service 4,819,468 6.77% -
Employees Share Ownership Association 627,532 0.88% -
B. Minority shareholders
Shareholders Shares owned
Category No. of No. of Remarks
No. of total No. of total
Minority Ratio Minority Ratio
shareholders shares
shareholders shares
Shareholders
Minority holding stocks
102,110 102,146 99.97 14,720,864 71,174,000 20.69
shareholders below 1/100 of total
stocks issued
4. Share Price and Stock Transactions

(Unit: KRW, share)
Class '22.12 '22.11 '22.10 '22.9 '22.8 '22.7
Highest 884,000 907,000 896,000 841,000 910,000 865,000

Share
Lowest 806,000 870,000 802,000 754,000 828,000 781,000
price
Common
Average 830,000 888,409 839,947 802,150 868,727 822,571
stock
Highest
92,016 73,570 155,954 179,902 85,143 108,584
Trading (day)
volume Lowest
20,757 23,456 30,976 24,846 29,782 28,450
(day)
Class '22.12 '22.11 '22.10 '22.9 '22.8 '22.7
Monthly
913 1,041 1,235 1,271 1,112 1,209
(thousand)
※ The Company was listed on the stock market as of November 10, 2016.
VIII. Matters Regarding Executives and Employees
1. Executives and Employees
A. Registered executives
Date of Registered Full/ No. of shares held Length of Term

Name Gender Position Responsibility Career
birth Executive Part-time service expiration
Common Preferred
- Center Leader, CMO2 Center, Samsung

Executive Biologics 4 years
John Rim M 1961.10 President Full-time CEO - - 2023.03.20
Director - Master of Business Administration, 4 months
Northwestern University
- Former CEO, Samsung Biologics

Residing Executive Chair of the 11 years
Kim Taehan M 1957.11 Full-time - Doctor of Chemical Engineering, University 4,200 - 2023.03.20
Advisor Director Board 10 months
of Texas, Austin
- Head of Office, Corporate Management
Office, Samsung Biologics
Executive Business - Head of Planning Support Team,
Kim Executive Mechatronics & Manufacturing Technology 8 years
M 1965.02 Vice Full-time Support Center 4,632 - 2025.03.21
Dongjoong Director Center, Samsung Electronics 2 months
President Leader
- Master of Business Administration, Ajou
University
- Chair of ESG - Member, Korea Corporate Governance
Committee Service
Eunice Independent 2 years
W 1959.03 Director Part-time - Audit - - 2023.03.20
Kim Director - Professor, Ewha W. University Law School 9 months
Committee
Member - Juris Doctor, Yale University Law School
Chair of
Compensation
Committee/ - Honorary professor, Public Administration
Chair of department, Sungkyunkwan University
Bahk Independent
M 1955.01 Director Part-time Independent - - 10 months 2025.03.21
Jaewan Director - Chairman of the director, Hansun Foundation
Director
Candidate - Doctor of Public Policy , Harvard University
Recommendati
on
- Honorary professor, Seoul National
University Business School
Lee Independent Chair of Audit
M 1954.01 Director Part-time - Chair of Ethic Committee, Korean Institute of - - 10 months 2025.03.21
Changwoo Director Committee
Certified Public Accounts
- Doctor of Business Administration, UC
Date of Registered Full/ No. of shares held Length of Term
Name Gender Position Responsibility Career
birth Executive Part-time service expiration
Common Preferred
Berkeley
- Chair of
Related Party
Heo Transaction - Managing Partner, Pyeong An Law Firm
Independent 3 years
Geungnyeo M 1956.10 Director Part-time Committee, - Senior Judge, Seoul Central District Court - - 2025.03.21
Director 9 months
ng - Audit - Master of Law, Seoul National University
Committee
Member
※ Relationship with the major shareholder status was listed in accordance with Article 3 Paragraph 1 of Enforcement Decree of the Act on Corporate Governance of Financial Companies.
※ From 11th Board of Directors meeting held on March 29, 2022, Lee Changwoo and Bahk Jaewan were newly appointed as independent directors, and independent directors Kwon Soonjo and
Jeong Seokwoo resigned due to end of term.
※ Number of shares held by executives as of December 31, 2022. For subsequent changes, please refer to the ownership report of executives and major shareholders at the DART (Data Analysis,
Retrieval and Transfer System
※ The Independent director Bahk Jaewan resigned as of January 18, 2023.
Current status of candidates for appointment and dismissal of registered executives

(As of February 15, 2023) (Unit: share)
Date of
Date of Relationship to largest
Name Gender Candidate Position Career appointment or
Birth shareholder
dismissal
- CEO, Samsung Biologics

Affiliate Executive
Appointment John Rim M 1961.10 Executive director - Center Leader, CMO2 Center, Samsung Biologics 2023.03.17
(SBL)
- Master of Business Administration, Northwestern University
- Center Leader, EPCV center

Affiliate Executive
Appointment Lo Kun M 1963.01 Executive director - Center Leader, DS center, Samsung Biologics 2023.03.17
(SBL)
- Ph.D. in Chemical Engineering, Seoul National University
- Independent director, Samsung Biologics

Affiliate Executive
Appointment Eunice Kim F 1959.03 Independent director - Member, Korea Corporate Governance Service 2023.03.17
(SBL)
- Professor, Ewha W. University Law School
- Senior Research Fellow, National Future Strategy Institute, Seoul
National University
Appointment Ahn Dogeol M 1965.01 Independent director 2023.03.17 -
- Gwangju Metropolitan City Finance and Economy Advisory Station
- 2nd Vice Minister of Strategy and Finance
※ As an agenda for the 12th annual general meeting of shareholders scheduled to be held after the reporting date. In the event of a rejection or amendment at the annual general meeting of
shareholders, the content reason will be reflected in the correction report.
B. Unregistered executives
No. of shares Relationship
owned with the
Date of Registration Employment Term of
Name Gender Position Responsibility Career With Without largest
birth status status service
voting voting shareholder
rights rights
Affiliated
- Center Leader, DS center, Samsung Biologics company
Executive EPCV Center 2 years
Lo Kun M 1963.01 Unregistered Full-time - Ph.D. in Chemical Engineering, Seoul National - - executives
Vice President Leader 1 month
University (Company
Executive)
- Center Leader, Quality center, Samsung Biologics Affiliated
company
Sam Executive Quality Center - Quality Executive, Lonza 3 years
M 1963.03 Unregistered Full-time 3.724 - executives
MacHour Vice President Leader - M.A. in Atomic Nucleophysics, Concordia 7 months
(Company
University Executive)
Affiliated
- Vice President, Vesalius Therapeutics company
Chung Executive Bio R&D
M 1967.03 Unregistered Full-time - Ph.D. in pharmacology and oncology, Duke - - executives 1 month
Namjin Vice President Center Leader
University (Company
Executive)
- Center leader, Global BD team, Samsung
Biologics Affiliated
company
Executive Global Sales - Team Leader, Global BD Team 2, Samsung 7 years
James Park M 1966.04 Unregistered Full-time 1,900 - executives
Vice President Center Leader Biologics 2 months
(Company
- M.A. in Industrial Engineering, Columbia Executive)
University
- Center leader, Global information and marketing Affiliated

team, Samsung Biologics company
James Executive Sales Support 8 years
M 1967.08 Unregistered Full-time - Team Leader, GIO Team, Samsung Biologics 796 - executives
Choi Vice President Center Leader 5 months
- M.A. in Business Administration, University of (Company
Southern California Executive)
Affiliated
- DS Center, Samsung Biologics company
Pierre Executive Manufacturing 1 year
M 1968.09 Unregistered Full-time - Site Head, Lonza - - executives
Catignol Vice President Center Leader 4 months
- M.A. in Industrial Engineering, ECAM Lyon (Company
Executive)
- CDO Division, Samsung Biologics Affiliated
company
Kang CDO Division - CEO, Lumebio 1 year
W 1972.09 Vice President Unregistered Full-time - - executives
Jahoon Center Leader - M.A. in Medicine, Sookmyung Women’s 2 months
(Company
- Executive, Industrial environment business Affiliated

team1, Samsung Engineering company
Koo EPM
M 1969.08 Vice President Unregistered Full-time - - executives 1 month
Younghan Team Leader - B.A. in Architectural engineering, Chonnam (Company
- Global client support team, Samsung Biologics Affiliated
- Group Leader, Information Security company
Kim Kijoong M 1969.08 Vice President Unregistered Full-time ISA Team Leader Group(Mobile), Samsung Electronics 20 - executives 3 years
- B.A. in Inorganic Material Engineering, (Company
Kyoungbuk National University Executive)
Affiliated
- Part Leader, USP2, Samsung Biologics company
Kim MFG Support 1 year
W 1981.09 Vice President Unregistered Full-time - Ph.D. in food science and biotechnology, Seoul 2 - executives
Heejung Department 1 month
National University (Company
Executive)
Affiliated
- Business Unit Leader, DS, Samsung Biologics company
Daniel Manufacturing 9 years
M 1951.01 Vice President Unregistered Full-time - - executives
Slone Center Executive - B.A. in biology, Florida International University 1 month
(Company
Executive)
Affiliated
- Head of CDMO, Takeda company
David PM
M 1974.12 Vice President Unregistered Full-time - B.A. in Biochemistry, University of California, - - executives 1 month
Lee Team Leader
Berkeley (Company
Executive)
Affiliated
- Lawyer, Kim Chang & Lee Law Firm company
Moon Compliance Team
M 1970.01 Vice President Unregistered Full-time - - executives 2 years
Hyungwoo Leader - M.A. in Law, Seoul National University (Company
Executive)
Affiliated
- Team Leader, DS3 Cell Culture Team, Samsung company
Park Biologics 2 years
M 1973.12 Vice President Unregistered Full-time EPM Team Leader 356 - executives
Segang 11 months
- B.A. in Chemical Engineering, Inha University (Company
Executive)
- Team Leader, Human Resource Team (North Affiliated
America), Samsung Electonics company
Park HR Support Center 1 year
Yong Leader - Ph.D. in Business Administration, Chung-ang 1 month
(Company
- Group Leader, Process Engineering, Samsung Affiliated
Corporate Biologics company
Son
F 1978.02 Vice President Unregistered Full-time Engineering - - executives 1 month
Boyun - Team Leader, Automation, Samsung Biologics
Team Leader (Company
- M.A. in Biochemistry, Korea University Executive)
Affiliated
- Team Leader, Corporate Engineering Team, company
Seo Business Strategy Samsung Biologics
M 1979.01 Vice President Unregistered Full-time 755 - executives 2 years
Sangwon Team Leader
- M.A. in Life Science, POSTECH (Company
Executive)
Affiliated
- Team Leader, PI Team, Samsung Biologics company
Shim 4 years
M 1968.01 Vice President Unregistered Full-time CSR T/T Leader - - executives
Byunghwa - B.A. in Economics, Sogang University 10 months
(Company
Executive)
Affiliated
- Managing Director, Global Operations Division, company
Lee Celltrion 1 year
M 1972.11 Vice President Unregistered Full-time MSAT Department - - executives
Sangyoon 1 month
- Ph.D. in biotechnology, Inha University (Company
Executive)
Affiliated
- Part Leader, USP2, Samsung Biologics company
Lee CDO Development 1 year
M 1973.12 Vice President Unregistered Full-time 324 - executives
Jaesun Team Leader - M.A. in Biochemistry, Chungbuk University 1 month
(Company
Executive)
Affiliated
- Team Leader, Facility Maintenance Team, company
Lee Facility Samsung Biologics 5 years
Chungwoo Team Leader 7 months
- B.A. in Electrical Engineering, Hanyang University (Company
Executive)
Affiliated
Business - Team Leader, Business Strategy Team, Samsung company
Lim Biologics
M 1975.06 Vice President Unregistered Full-time Assessment - - executives 2 years
Heekyun
Team Leader - B.A. in Life Science, POSTECH (Company
Executive)
Affiliated
- Quality Operations Team, Samsung Biologics company
Jo Beth 1 year
W 1965.12 Vice President Unregistered Full-time QA Department - M.A. in Neuroscience, University of California, - - executives
DeFreitas 1 month
San Francisco (Company
Executive)
Affiliated
- Team Leader, Global IT, Samsung Biologics company
Cho Business Innovation
M 1972.03 Vice President Unregistered Full-time - M.A. in Information and Communication executives 1 month
Seongil Team Leader
department(Certificate of completion) (Company
Executive)
- DS1 Division, Samsung Biologics Affiliated
company
Jo - DS Division, Samsung Biologics 1 year
M 1975.01 Vice President Unregistered Full-time DS Division 268 - executives
Youngjin - M.A. in Food Engineering, Seoul National 1 month
(Company
- Business Unit Leader, DP, Samsung biologics Affiliated
- Team Leader, Process Support Team, Samsung company
Jin 2 years
M 1966.10 Vice President Unregistered Full-time DP Division Biologics 182 - executives
Yonghwan 11 months
- Ph.D. in Molecular Biology, Seoul National (Company
- Team Leader, Strategic Operations, Samsung

BIologics Affiliated
company
Kevin CMO Sales - Team Leader, Alliance Management, Samsung 1 year
Sharp Team Leader Biologics 1 month
(Company
- M.A. in Business Administration, Temple Executive)
University
- Corporate QA, Samsung Biologics Affiliated
company
- Quality & Compliance Executive Director, Arkon 1 year
Keith Ellis M 1967.08 Vice President Unregistered Full-time QA Division - - executives
Pharma 6 months
(Company
- B.A. in Microbiology, University of Memphis Executive)
Affiliated
- Business Support Group, Samsung Electronics company
Heo Finance Team 1 year
Doyoung Leader - MBA, Indiana University 1 month
(Company
Executive)
※ Number of shares held by executives is as of December 31, 2022. For subsequent changes, refer to the ownership report of executives and major shareholders at the DART (Data Analysis,
Retrieval and Transfer System)
※ As of December 31, 2022, Executive Vice President James Park, Vice President Daniel Slone, and Vice President Jo Beth DeFreitas resigned.
C. Registered executives with concurrent positions
Interlocking executive Interlocking company
Name Position Name Position

Lo Kun Executive vice president Samsung Bioepis Other non-executive director 2022.02 ~ present
Eunice Kim Independent director U-young Industrial Executive director 2018.06 ~ present
Hanwha General
Lee Changwoo Independent director Independent director 2021.03 ~ present
Insurance
Bahk Jaewan Independent director Hankook & Company Independent director 2022.03 ~ present
※ As of February 9, 2022, President John Rim's term as an interlocking executive of the Company has expired, and Vice
President Lo Kun has been appointed as a non-executive director of Samsung Bioepis Co., Ltd.
D. Changes of unregistered executives after reporting date

Change of
Position Name Date of birth Responsibility Reason
date
Business
Newly
Vice president Christina Kim 1972.08 Development Newly hire 2023.01.06
appointed
Team
US Sales
Resigned Vice President Kevin Sharp 1976.01 SBA-S Office 2023.02.26
arrangement
※ Relationship with the major shareholder status was listed in accordance with Article 3 Paragraph 1 of Enforcement Decree of
the Act on Corporate Governance of Financial Companies.
E. Employees
Employee Non-Employee
No. of employees
Per Remar
Regular Average Gross
Business Fixed-term workers capita ks
Gender workers Total length of annual M W Total
unit average
(Part-time (Part-time service salary
All All salary
worker) worker)
Manufacturing M 1,353 - 134 - 1,487 3.7 - - -
Manufacturing F 656 - 83 - 739 3.0 - - -
Research M 516 - 97 - 613 3.7 - - -
Research F 730 - 58 - 788 4.0 - - -
Support M 535 - 25 - 560 4.4 - - 487 298 785 -
Support F 330 - 15 - 345 4.1 - - -
Total no. of M 2,404 - 256 - 2,660 3.8 241,599 95 -
employees F 1,716 - 156 - 1,872 3.6 152,237 87 -
Total 4,120 - 412 - 4,532 3.8 393,836 92 -
※ Gross annual salary is based on gross salary in the statement of earned income payments to be submitted to a competent tax
office in accordance with Article 20 of the Income Tax Act.
※ The number of employees above is based on headquarters and registered executives (7 members) are excluded.
The number of employees includes those on leave of absence.
※ The average salary per person was calculated based on the annual average number of employees of 4,294 (male: 2,548,
female: 1,746).
F. Compensation of unregistered executives

No. Gross annual salary Per capita average salary Remarks
Unregistered executives 29 12,493 431 -
※ In the case of unregistered executives who were elected in the current year, only the compensation paid after the date of
election was calculated.
2. Executive Compensation
<Compensation of Directors and auditors>
(1) Compensation approved at the Annual General Meeting of shareholders

(Unit: KRW Mil)
Category No. Amount approved Remarks

Executive directors
(Excluding independent
3 - -
directors, member of audit
committee)
Independent directors
(excluding member of audit 1 - -
committee)
Members of Audit committee 3 - -
Total 7 15,000 -
※ The approval amount at the shareholders’ general meeting is compensation limit for directors approved through the
resolution by the shareholders’ general meeting on March 29, 2022 in accordance with Article 388 of the Commercial Act
and the articles of incorporation.
(2) Compensation paid

2-1. Total compensation paid for directors and auditors
Average compensation
Number of persons Total compensation Remarks
per person
7 12,928 1,847 -
※ Registered director Kim Taehan's retirement income is included in the total compensation amount.
2-2. Compensation paid, by Director type

(Unit: KRW Mil)
Avg. compensation
Category Number of persons Total compensation Remarks
per person
Executive directors 3 12,554 4,185 -
Independent directors 1 95 95 -
Members of Audit
3 279 93 -
committee
Auditors - - - -
※ The Audit committee consists of three independent directors.

※ The number of persons is as of December 31, 2022.
※ Total compensation is the amount of income paid based on the Income Tax Act to registered directors in office or retired,
independent directors, and members of Audit committee as the status of registered executive during the business year in
accordance with Article 159 of the Financial Investment Services and Capital Market Act and Article 168 of the Enforcement
Decree of the Act.
※ Average compensation per person is calculated by dividing total compensation by number of persons.
(3) Criteria and methodology

- Compensation for registered directors (3 Executive directors and 4 Independent directors) is paid
within the compensation limit approved by the Annual General Meeting in accordance with Article
40 of the Company’s Articles of Incorporation.
- Total compensation is the amount exclusive of labor costs for appropriation. Average
compensation per capital is calculated by dividing total compensation by number of persons.
<Compensation for Executive Directors and Auditors>

1. Individual compensation paid
(Unit: KRW Mil)
Compensation not included in total
Name Position Total compensation
compensation
John Rim CEO 4,556 -
Kim Taehan Residing Advisor 7,196 -
Executive
Kim Dongjoong 802 -
Vice President
※Registered director Kim Taehan's retirement income is included in the total compensation amount.
2. Calculation criteria and method

(Unit: KRW Mil)
Total
Name Type of compensation Calculation criteria and method
amount
In accordance with separate service contract,
compensation is determined based on his position
Gross payroll 1,005
(CEO), responsibilities, and performance results. He
was paid USD 64,286 on a monthly basis.
- Traditional holiday bonus: 100% of monthly wage
- Target incentive:
Decided by CEO based on the level of target
attainment by division; and paid twice a year to the
extent of 0~200% of monthly wage (vary depending
on organization’s performance)
- Performance incentive:
Earned Decided by CEO and funded with 20% of profits if
CEO Bonus 3,462
Income revenues exceed the company’s break-even point
John and paid once a year to the extent of 0~50% of
Rim annual base salary (vary depending on individual
performance.
- Special bonus:
Paid in accordance with the executive treatment
regulation(Board resolution) and Compensation
Committee’s resolution from January 2023
Stock option
- -
execution profit
Other earned - Fringe benefits: Treatment is offered in line with the
89
income separate service contract.
Retirement income - -
Other income - -
In accordance with executive treatment regulations
(Board resolution), compensation is determined
Gross payroll 790 based on his position (Chairman), responsibilities,
Registered and performance results. He was paid KRW 65.8
Advisor million on a monthly basis.
Earned
Kim - Traditional holiday bonus: 100% of monthly wage
income
Taehan - Target incentive:
Bonus 1,279
Decided by CEO and funded with 20% of profits if
revenues exceed the company’s break-even point;
and paid once a year to the extent of 0~50% of
annual base salary (vary depending on individual
performance.
- Long-term performance incentive: Calculated to the
extent of compensation limit set by the General
Shareholders’ Meeting based on three-year
average annual salary by evaluating ROE, PER,
pre-tax profit ratio, etc.; and paid in installments for
three years
Stock option
- -
execution profit
Other earned - Fringe benefits: Treatment is offered in line the
27
income executive treatment regulations(Board resolution)
As of December 7, 2022, retirement payment was
Retirement income 5,100 settled due to conversion from a Chairman to a
registered advisor
Other income - -
In accordance with executive treatment regulations
(Board resolution), compensation is determined by
Gross payroll 347 based on his position (Executive Vice President),
responsibilities, and performance results. He was
paid KRW 28.9 million on a monthly basis.
- Target incentive:
Decided by CEO based on the l evel of target
Executive
Vice Earned - Personal Performance incentive:
income Bonus 437 Paid once a year within 0% to 50% of the base
President
salary based on individual performance
Kim
- Long-term performance incentive: Calculated to the
Dongjoong
extent of compensation limit set by the General
Shareholders’ Meeting based on three-year
average annual salary by evaluating ROE, PER,
pre-tax profit ratio, etc.; and paid in installments for
three years
Stock option
- -
execution profit
18
Other income - -
< Compensation status of top five individuals among individuals paid above KRW 500 million >
1. Individual compensation
(Unit: KRW Mil)
Total Compensation not included in

Name Title
compensation total amount
John Rim CEO 4,556 -

Kim Taehan Registed Advisor 7,196 -
Pierre Catignol Executive Vice President 1,450 -
James Park Executive Vice President 1,141 -
Sam MacHour Executive Vice President 1,139 -
※ Registered director Kim Taehan and Executive vice president James Park's retirement incomes are included in the total
compensation amount.
2. Calculation criteria and method

(Unit: KRW Mil)
Total
Name Type of compensation Calculation criteria and method
amount
Gross payroll 1,005
(CEO), responsibilities, and performance results. He
was paid USD 64,286 on a monthly basis.
- Target incentive:
extent of 0~200% of monthly wage (vary
depending on organization’s performance)
Earned
CEO Bonus 3,462 Decided by CEO and funded with 20% of profits if
Income
John revenues exceed the break-even point; and paid
Rim once a year to the extent of 0~50% of annual base
salary (vary depending on individual performance.
- Special bonus:
Paid in accordance with the executive treatment
regulation (Board resolution) and Compensation
Committee’s resolution from January 2023
Stock option
- -
execution profit
Other earned - Fringe benefits: Treatment is offered in line with
89
income the separate service contract.
Other income - -
In accordance with internal regulation for executive
treatment (Board resolution), the compensation is
Gross payroll 790 determined based on his position (Chairman),
responsibilities, and performance results. He was
paid KRW 65.8 million on a monthly basis.
- Target incentive:
extent of 0~200% of monthly wage (vary
depending on organization’s performance)
Earned
Registered Decided by CEO and funded with 20% of profits if
income Bonus 1,279
Advisor revenues exceed the break-even point; and paid
Kim once a year to the extent of 0~50% of annual base
Taehan salary (vary depending on individual performance.
- Long-term performance incentive:
Evaluate KPI (key performance indicator)
achievement every
year within the contract period and pay in two
installments
Stock option
- -
execution profit
27
As of December 7, 2022, retirement payment was
Retirement income 5,100 settled due to conversion from a Chairman to a
registered advisor
Other income - -
Executive Earned In accordance with separate service contract,
Gross payroll 478
Vice income compensation is determined based on his position
President (Executive Vice President), responsibilities, and
Pierre performance results. He was paid USD 30,600 on a
Catignol monthly basis.
- Personal Performance incentive:
Pay once a year based on individual performance
Bonus 914 - Long Term Incentive:
Calculated using KPI achievement rate, paid twice
a year
Stock option
- -
execution profit
58
Other income - -
Gross payroll 440 (Executive Vice President), responsibilities, and
performance results. He was paid USD 28,200 on a
monthly basis
Pay once a year based on individual performance
- Long Term Incentive:
Executive Earned Calculated using KPI achievement rate, paid twice
Vice income Bonus 261 a year
President - Sign on bonus: According to the terms and
James conditions of the contract, pay in installments
Park within the contract period after joining the
company.
Stock option
- -
execution profit
123
- On December 31, retirement income generated by
Retirement income 317
retired executives
Other income - -
In accordance with separate service contract, the
Gross payroll 521 (Executive Vice President), responsibilities, and
performance results. He was paid USD 34,100 on a
monthly basis.
Executive Earned Pay once a year based on individual performance
Vice Income Bonus 572 - Long Term Incentive:
President Calculated using KPI achievement rate, paid twice
Sam a year
MacHour Stock option
- -
execution profit
46
Other income - -
< Grant and execution of stock option>

Not applicable as of the date when the Annual Report is submitted.
IX. Matters Regarding Affiliates
A. Overview of Affiliates(Summary)
(1) Affiliated Company

As an affiliate belonging to the Samsung Group under the 「Monopoly Regulation and Fair Trade Act」,
as of the end of 2022, the Samsung Group had four companies (SHP Corporation, Ltd.,
Sungkyunkwan University Technology Holdings Co., Ltd., Samsung FN Consignment Management
Real Estate Investment Co., Ltd., and Hope Star Forest Co., Ltd.) have increased to 63 domestic
affiliates. Among them, a total of 16 listed companies, including our company, and 47 unlisted
companies.

Number of Affiliates
Name
Listed Unlisted Total
Samsung 16 47 63
※ For details, refer to XII. Table of Information – 2. Affiliate
(2) Equity investment between affiliated companies
Domestic
※ Percent of ownership as of December 31, 2022 based on common shares (Unit: %)
Investee Samsung Samsung Samsung Samsung Samsung

Samsung Samsung Samsung Samsung Samsung Samsung Samsung Multicampus
Investor C&T Life Electro- Heavy Fire & Marine
Biologics SDI SDS Engineering Electronics Securities Card Corporation
Corporation Insurance Mechanics Industries Insurance
Samsung C&T
- 43.1 19.3 - 17.1 7.0 - 5.0 0.1 - - - -
Corporation
Samsung Biologics - - - - - - - - - - - - -
Samsung Life Insurance 0.1 0.1 - 0.1 0.0 0.1 0.2 8.7 2.9 29.4 71.9 15.0 0.0
Samsung SDI - - - - - 11.7 - - 0.4 - - - -
Samsung SDS - - - - - - - - - - - - 47.2

Samsung Electro-
- - - - - - - - 2.1 - - - -
Mechanics
Samsung Electronics - 31.2 - 19.6 22.6 - 23.7 - 15.2 - - - -
Samsung Heavy
- - - - - - - - - - - - -
Industries
Samsung Securities - - - - - - - - - - - - -
Samsung Card - - - - - - - - - - - - -
Samsung Fire & Marine
- - - - - 0.2 - 1.5 - - - - -
Insurance
S-1 Corporation - - - - - - - - - - - - -
Cheil Worldwide - - - - - - - - 0.1 - - - -
Hotel Shilla - - - - - - - - - - - - -
Samsung Display - - - - - - - - - - - - -
Samsung Asset
- - - - - - - - - - - - -
Management
Samsung Electronics
- - - - - - - - - - - - -
Service
Miracom - - - - - - - - - - - - -
Samsung Economic
- - - - - - - - - - - - 15.2
Research Institute (SERI)
Harman International
- - - - - - - - - - - - -
Industries
Total 0.1 74.3 19.3 19.7 39.7 19.0 23.8 15.2 20.8 29.4 71.9 15.0 62.4
Samsung
Investee Samsung Life Samsung Samsung Samsung
S-1 Cheil Samsung Samsung Samsung Venture Samsung Samsung
Investor Hotel Shilla Service Claim Active Asset SRA Asset Asset
Corporation Worldwide Display Medison Bioepis Investment Futures Welstory
Adjustment Management Management Management
Corporation
Samsung C&T
- - - - - - 16.7 - - - - - 100.0
Corporation
Samsung Biologics - - - - - 100.0 - - - - - - -
Samsung Life Insurance 5.4 0.4 7.5 - - - - 99.8 - - 100.0 19.7 -
Samsung SDI 11.0 - 0.1 15.2 - - 16.3 - - - - - -
Samsung SDS - - - - - - - - - - - - -
Samsung Electro-
- - - - - - 17.0 - - - - - -
Mechanics
Samsung Electronics - 25.2 5.1 84.8 68.5 - 16.3 - - - - - -
Samsung Heavy
- - - - - - 17.0 - - - - - -
Industries
Samsung Securities 1.3 - 3.1 - - - 16.7 - 100.0 - - 3.6 -
Samsung Card 1.9 3.0 1.3 - - - - - - - - - -

1.0 - - - - - - - - - - 18.9 -
Insurance
S-1 Corporation - - - - - - - - - - - - -
Cheil Worldwide - - - - - - - - - - - - -
Hotel Shilla - - - - - - - - - - - - -
Samsung Display - - - - - - - - - - - - -
Samsung Asset
- - - - - - - - - 100.0 - - -
Management
Samsung Electronics
- - - - - - - - - - - - -
Service
Miracom INC - - - - - - - - - - - - -
Samsung Economic
- - - - - - - - - - - - -
- - - - - - - - - - - - -
Industries, Inc.
Total 20.7 28.6 17.1 100.0 68.5 100.0 100.0 99.8 100.0 100.0 100.0 42.1 100.0
Investee Samsung Samsung Samsung Samsung
Samsung Samsung Samsung Samsung Samsung Suwon
Electronics Card Corning Samsung Fire Claim
Asset Electronics Electronics Electronics Hedge Asset SEMES Samsung
Investor Logitech Customer Advanced Service Adjustment
Management Service Service CS Sales Management Football Club
Corporation Service Glass Service
Samsung C&T
- - - - - - - - - - - -
Corporation
Samsung Biologics - - - - - - - - - - - -
Samsung Life Insurance 100.0 - - - - - - - - - - -
Samsung SDI - - - - - - - - - - - -
Samsung SDS - - - - - - - - - - - -
Samsung Electro-
- - - - - - - - - - - -
Mechanics
Samsung Electronic - 100.0 99.3 - 100.0 - - - - - 91.5 -
Samsung Heavy
- - - - - - - - - - - -
Industries
Samsung Securities - - - - - - - - - - - -
Samsung Card - - - - - 100.0 - - - - - -

- - - - - - - - 100.0 100.0 - -
Insurance
S-1 Corporation - - - - - - - - - - - -
Cheil Worldwide - - - - - - - - - - - 100.0
Hotel Shilla - - - - - - - - - - - -
Samsung Display - - - - - - 50.0 - - - - -

Samsung Asset
- - - - - - - 100.0 - - - -
Management
Samsung Electronics
- - - 100.0 - - - - - - - -
Service
Miracom - - - - - - - - - - - -
Samsung Economic
- - - - - - - - - - - -
- - - - - - - - - - - -
Industries
Total 100.0 100.0 99.3 100.0 100.0 100.0 50.0 100.0 100.0 100.0 91.5 100.0
investee Shilla S1CRM HDC Shilla Cheil

Steco SD Flex SBTM SUMaterials S-Core STM Open Hands Fashion Miracom
Investor Stay Corporation Duty Free
Retail
Samsung C&T
- - - - - - - - - - 100.0 -
Corporation
Samsung Life Insurance - - - - - - - - - - - -
Samsung SDI - - 50.0 - - - - 100.0 - - - -
Samsung SDS - - - - - - 81.8 - - 100.0 - 83.6

Samsung Electro-
- - - - - - - - - - - -
Mechanics
Samsung Electronics 70.0 - - - - - - - - - - -
Samsung Heavy
- - - - - - - - - - - -
Industries
Samsung Card - - - - - - - - - - - -
- - - - - - - - - - - -
Insurance
S-1 Corporation - - - - 100.0 - 0.6 - - - - 0.6
Cheil Worldwide - - - - - - 5.2 - - - - 5.4
Hotel Shilla - 100.0 - 100.0 - - - - 50.0 - - -
Samsung Display - - - - - 50.0 - - - - - -

Samsung Asset
- - - - - - - - - - - -
Management
Samsung Electronics
- - - - - - - - - - - -
Service
Miracom - - - - - - 0.5 - - - - -
Samsung Economic
- - - - - - - - - - - -
- - - - - - - - - - - -
Industries
Total 70.0 100.0 50.0 100.0 100.0 50.0 88.1 100.0 50.0 100.0 100.0 89.6
Investee Samsung Fire

Samsung Samsung Life Samwoo Harman
Samsung & Marine Seoul Lake CVnet SHP
Global Financial Architects & SECUI International Human TSS Bear Better
Investor Lion Financial Side Corporation Corporation
Research Service Engineers Korea
Service
Samsung C&T
1.0 - - - 100.0 100.0 8.7 40.1 - - - -
Corporation
Samsung Life Insurance 14.8 - 100.0 - - - - - - - - -
Samsung SDI 29.6 - - - - - - - - - - -
Samsung SDS - - - - - - 56.5 9.4 - - - -

Samsung Electro-
23.8 - - - - - - - - - - -
Mechanics
Samsung Electronics 29.8 - - - - - - - - - - 100.0
Samsung Heavy
1.0 - - - - - - - - - - -
Industries
Samsung Card - - - - - - - - - - - -
- - - 100.0 - - - - - - - -
Insurance
S-1 Corporation - - - - - - - - - - 100.0 -
Cheil Worldwide - 67.5 - - - - - - - - - -
Hotel Shilla - - - - - - - - 100.0 - - -
Samsung Display - - - - - - - - - - - -
Samsung Asset
- - - - - - - - - - - -
Management
Samsung Electronics
- - - - - - - - - - - -
Service
Miracom - - - - - - - - - - - -
Samsung Economic
- - - - - - - - - - - -
- - - - - - - - - 100.0 - -
Industries
Total 100.0 67.5 100.0 100.0 100.0 100.0 65.2 49.5 100.0 100.0 100.0 100.0
Overseas
※ Percent of ownership as of December 31, 2022 based on common shares
Share
Investor Investee
Ratio(%)
Samwoo Architects & Engineers Co., Ltd. SAMOO AUSTIN INC 100.0
Samwoo Architects & Engineers Co., Ltd. SAMOO HU Designer and Engineering Services Limited 100.0
Samwoo Architects & Engineers Co., Ltd. SAMOO DESIGNERS & ENGINEERS INDIAPRIVATE LIMITED 100.0
Samwoo Architects & Engineers Co., Ltd. SAMOO (KL) SDN. BHD. 100.0
Samwoo Architects & Engineers Co., Ltd. SAMOO Design Consulting Co.,Ltd 100.0
Samsung C&T America Inc. Meadowland Distribution 100.0
Samsung C&T America Inc. Samsung Green repower, LLC 100.0
Samsung C&T America Inc. Samsung Solar Construction Inc. 100.0
Samsung C&T America Inc. QSSC, S.A. de C.V. 20.0
Samsung C&T America Inc. Samsung Solar Energy LLC 100.0
Samsung C&T America Inc. Equipment Trading Solutions Group, LLC 70.0
Samsung Renewable Energy Inc. SP Armow Wind Ontario LP 50.0
Samsung Renewable Energy Inc. SRE GRW EPC GP Inc. 100.0
Samsung Renewable Energy Inc. SRE GRW EPC LP 100.0
Samsung Renewable Energy Inc. SRE SKW EPC GP Inc. 100.0
Samsung Renewable Energy Inc. SRE SKW EPC LP 100.0
Samsung Renewable Energy Inc. SRE WIND PA GP INC. 100.0
Samsung Renewable Energy Inc. SRE WIND PA LP 100.0
Samsung Renewable Energy Inc. SRE GRS Holdings GP Inc. 100.0
Samsung Renewable Energy Inc. SRE GRS Holdings LP 100.0
Samsung Renewable Energy Inc. SRE K2 EPC GP Inc. 100.0
Samsung Renewable Energy Inc. SRE K2 EPC LP 100.0
Samsung Renewable Energy Inc. SRE KS HOLDINGS GP INC. 100.0
Samsung Renewable Energy Inc. SRE KS HOLDINGS LP 100.0
Samsung Renewable Energy Inc. SP Belle River Wind LP 42.5
Samsung Renewable Energy Inc. SRE Armow EPC GP Inc. 100.0
Samsung Renewable Energy Inc. SRE Armow EPC LP 100.0
Samsung Renewable Energy Inc. North Kent Wind 1 LP 35.0
Samsung Renewable Energy Inc. SRE Wind GP Holding Inc. 100.0
Samsung Renewable Energy Inc. South Kent Wind LP Inc. 50.0
Samsung Renewable Energy Inc. Grand Renewable Wind LP Inc. 45.0
Samsung Renewable Energy Inc. SRE North Kent 2 LP Holdings LP 100.0
Samsung Renewable Energy Inc. SRE Solar Development GP Inc. 100.0
Samsung Renewable Energy Inc. SRE Solar Development LP 100.0
Samsung Renewable Energy Inc. SRE Windsor Holdings GP Inc. 100.0
Samsung Renewable Energy Inc. SRE Southgate Holdings GP Inc. 100.0
Samsung Renewable Energy Inc. SRE Solar Construction Management GP Inc. 100.0
Samsung Renewable Energy Inc. SRE Solar Construction Management LP 100.0
Samsung Renewable Energy Inc. SRE BRW EPC GP INC. 100.0
Samsung Renewable Energy Inc. SRE BRW EPC LP 100.0
Samsung Renewable Energy Inc. SRE North Kent 1 GP Holdings Inc 100.0
Samsung Renewable Energy Inc. SRE North Kent 2 GP Holdings Inc 100.0
Samsung Renewable Energy Inc. SRE Belle River GP Holdings Inc 100.0
Samsung Renewable Energy Inc. SRE NK1 EPC GP Inc 100.0
Samsung Renewable Energy Inc. SRE NK1 EPC LP 100.0
Samsung Renewable Energy Inc. SRE Summerside Construction GP Inc. 100.0
Samsung Renewable Energy Inc. SRE Summerside Construction LP 100.0
Samsung Green repower, LLC Monument Power, LLC 100.0

Share
Investor Investee
Ratio(%)
SP Armow Wind Ontario GP Inc SP Armow Wind Ontario LP 0.0
Samsung C&T Oil & Gas Parallel Corp. PLL Holdings LLC 83.6
Samsung C&T Oil & Gas Parallel Corp. PLL E&P LLC 90.0
SRE GRW EPC GP Inc. SRE GRW EPC LP 0.0
SRE SKW EPC GP Inc. SRE SKW EPC LP 0.0
PLL Holdings LLC Parallel Petroleum LLC 61.0
SRE WIND PA GP INC. SRE WIND PA LP 0.0
SRE GRS Holdings GP Inc. Grand Renewable Solar GP Inc. 50.0
SRE GRS Holdings GP Inc. SRE GRS Holdings LP 0.0
SRE K2 EPC GP Inc. SRE K2 EPC LP 0.0
SRE KS HOLDINGS GP INC. KINGSTON SOLAR GP INC. 50.0
SRE KS HOLDINGS GP INC. SRE KS HOLDINGS LP 0.0
SP Belle River Wind GP Inc SP Belle River Wind LP 0.0
SRE Armow EPC GP Inc. SRE Armow EPC LP 0.0
SRE Wind GP Holding Inc. SP Armow Wind Ontario GP Inc 50.0
SRE Wind GP Holding Inc. South Kent Wind GP Inc. 50.0
SRE Wind GP Holding Inc. Grand Renewable Wind GP Inc. 50.0
South Kent Wind GP Inc. South Kent Wind LP Inc. 0.0
Grand Renewable Wind GP Inc. Grand Renewable Wind LP Inc. 0.0
North Kent Wind 1 GP Inc North Kent Wind 1 LP 0.0
SRE Solar Development GP Inc. SRE Solar Development LP 0.0
SRE Solar Construction Management GP Inc. SRE Solar Construction Management LP 0.0
SRE BRW EPC GP INC. SRE BRW EPC LP 0.0
SRE North Kent 1 GP Holdings Inc North Kent Wind 1 GP Inc 50.0
SRE North Kent 2 GP Holdings Inc SRE North Kent 2 LP Holdings LP 0.0
SRE Belle River GP Holdings Inc SP Belle River Wind GP Inc 50.0
SRE NK1 EPC GP Inc SRE NK1 EPC LP 0.0
SRE Summerside Construction GP Inc. SRE Summerside Construction LP 0.0
Samsung Solar Energy LLC Samsung Solar Energy 1 LLC 100.0
Samsung Solar Energy LLC Samsung Solar Energy 2 LLC 100.0
Samsung Solar Energy LLC Samsung Solar Energy 3, LLC 100.0
Samsung Solar Energy 1 LLC CS SOLAR LLC 50.0
Samsung Solar Energy 3, LLC SST SOLAR, LLC 50.0
Samsung Solar Energy 1 LLC 5S ENERGY HOLDINGS, LLC 100.0
Samsung Solar Energy 2 LLC SungEel Recycling Park Thuringen GmbH 20.0
Samsung C&T Deutschland GmbH POSS-SLPC, S.R.O 20.0
Samsung C&T Deutschland GmbH Solluce Romania 1 B.V. 99.9
Samsung C&T Deutschland GmbH S.C. Otelinox S.A 70.0
Samsung C&T Malaysia SDN. BHD WARIS GIGIH ENGINEERING AND TECHNOLOGY SDN. BHD. 48.3
Samsung C&T Singapore Pte., Ltd. Samsung Chemtech Vina LLC 0.2
Samsung C&T Singapore Pte., Ltd. Samsung C&T Thailand Co., Ltd 65.2
Samsung C&T Singapore Pte., Ltd. PT. INSAM BATUBARA ENERGY 30.0
Samsung C&T Singapore Pte., Ltd. Malaysia Samsung Steel Center Sdn.Bhd 12.6
Samsung C&T Singapore Pte., Ltd. S&G Biofuel PTE.LTD 95.0
S&G Biofuel PTE.LTD PT. Gandaerah Hendana 95.0
S&G Biofuel PTE.LTD PT. Inecda 100.0

VISTA CONTRACTING AND DEVELOPMENT BANGLADESH
Vista Contracting and Investment Global Pte. Ltd. 50.0
LTD.
CHEIL HOLDING INC. SAMSUNG CONST. CO. PHILS. 75.0
Samsung C&T Hongkong Ltd. Samsung C&T Thailand Co., Ltd 6.8
Samsung C&T Hongkong Ltd. SAMSUNG TRADING (SHANGHAI) CO., LTD 100.0
Share
Investor Investee
Ratio(%)
Samsung C&T Hongkong Ltd. Samsung Precision Stainless Steel(pinghu) Co.,Ltd. 45.0
Samsung Electronics Co., Ltd. Samsung Japan Corporation 100.0
Samsung Electronics Co., Ltd. Samsung R&D Institute Japan Co. Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics America, Inc. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Canada, Inc. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Mexico S.A. De C.V. 63.6
Samsung Electronics Co., Ltd. Samsung Electronics Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics (UK) Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Holding GmbH 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Iberia, S.A. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics France S.A.S 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Hungarian Private Co. Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Italia S.P.A. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Europe Logistics B.V. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Benelux B.V. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Overseas B.V. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Polska, SP.Zo.o 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Portuguesa, Unipessoal, Lda. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Nordic Aktiebolag 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Austria GmbH 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Slovakia s.r.o 55.7
Samsung Electronics Co., Ltd. Samsung Electronics Europe Holding Cooperatief U.A. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Display (M) Sdn. Bhd. 75.0
Samsung Electronics Co., Ltd. Samsung Electronics (M) Sdn. Bhd. 100.0
Samsung Electronics Co., Ltd. Samsung Vina Electronics Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Asia Pte. Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung India Electronics Private Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung R&D Institute India-Bangalore Private Limited 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Australia Pty. Ltd. 100.0
Samsung Electronics Co., Ltd. PT Samsung Electronics Indonesia 100.0
Samsung Electronics Co., Ltd. Thai Samsung Electronics Co., Ltd. 91.8
Samsung Electronics Co., Ltd. Samsung Malaysia Electronics (SME) Sdn. Bhd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Hong Kong Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Suzhou Samsung Electronics Co., Ltd. 69.1
Samsung Electronics Co., Ltd. Samsung (CHINA) Investment Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Suzhou Semiconductor Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Tianjin Samsung Electronics Co., Ltd. 48.2
Samsung Electronics Co., Ltd. Samsung Electronics Taiwan Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Tianjin Samsung Telecom Technology Co., Ltd. 90.0
Samsung Electronics Co., Ltd. Shanghai Samsung Semiconductor Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Suzhou Computer Co., Ltd. 73.7
Samsung Electronics Co., Ltd. Samsung Semiconductor (China) R&D Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung (China) Semiconductor Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung SemiConductor Xian Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Gulf Electronics Co., Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Egypt S.A.E 0.1
Samsung Electronics Co., Ltd. Samsung Electronics South Africa(Pty) Ltd. 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Latinoamerica(Zona Libre), S. A. 100.0
Samsung Electronics Co., Ltd. Samsung Eletronica da Amazonia Ltda. 87.0
Samsung Electronics Co., Ltd. Samsung Electronics Argentina S.A. 98.0

Share
Investor Investee
Ratio(%)
Samsung Electronics Co., Ltd. Samsung Electronics Chile Limitada 4.1
Samsung Electronics Co., Ltd. Samsung Electronics Rus Company LLC 100.0
Samsung Electronics Co., Ltd. Samsung Electronics Rus Kaluga LLC 100.0
Samsung Electronics Co., Ltd. Tianjin Samsung LED Co., Ltd. 100.0
Samsung Biologics Co., Ltd. Samsung Biologics America, Inc. 100.0
Samsung Bioepis Co., Ltd. Samsung Bioepis United States Inc. 100.0
Samsung Bioepis Co., Ltd. SAMSUNG BIOEPIS UK LIMITED 100.0
Samsung Bioepis Co., Ltd. Samsung Bioepis NL B.V. 100.0
Samsung Bioepis Co., Ltd. Samsung Bioepis CH GmbH 100.0
Samsung Bioepis Co., Ltd. Samsung Bioepis PL Sp z o.o. 100.0
Samsung Bioepis Co., Ltd. SAMSUNG BIOEPIS AU PTY LTD 100.0
Samsung Bioepis Co., Ltd. SAMSUNG BIOEPIS NZ LIMITED 100.0
Samsung Bioepis Co., Ltd. SAMSUNG BIOEPIS TW Limited 100.0
Samsung Bioepis Co., Ltd. Samsung Bioepis HK Limited 100.0
Samsung Bioepis Co., Ltd. SAMSUNG BIOEPIS IL LTD 100.0
Samsung Bioepis Co., Ltd. SAMSUNG BIOEPIS BR PHARMACEUTICAL LTDA 100.0
Samsung Display Co., Ltd. Intellectual Keystone Technology LLC 41.9
Samsung Display Co., Ltd. Samsung Display Slovakia, s.r.o. 100.0
Samsung Display Co., Ltd. Samsung Display Vietnam Co., Ltd. 100.0
Samsung Display Co., Ltd. Samsung Display Noida Private Limited 100.0
Samsung Display Co., Ltd. Samsung Display Dongguan Co., Ltd. 100.0
Samsung Display Co., Ltd. Samsung Display Tianjin Co., Ltd. 95.0
Samsung Display Co., Ltd. Novaled GmbH 9.9
SEMES Co., Ltd. SEMES America, Inc. 100.0
SEMES Co., Ltd. SEMES (XIAN) Co., Ltd. 100.0
Samsung Electronics America, Inc. NeuroLogica Corp. 100.0
Samsung Electronics America, Inc. Dacor Holdings, Inc. 100.0
Samsung Electronics America, Inc. Samsung HVAC America, LLC 100.0
Samsung Electronics America, Inc. SmartThings, Inc. 100.0
Samsung Electronics America, Inc. Samsung Oak Holdings, Inc. 100.0
Samsung Electronics America, Inc. Joyent, Inc. 100.0
Samsung Electronics America, Inc. TeleWorld Solutions, Inc. 100.0
Samsung Electronics America, Inc. Samsung Semiconductor, Inc. 100.0
Samsung Electronics America, Inc. Samsung Research America, Inc 100.0
Samsung Electronics America, Inc. Samsung Electronics Home Appliances America, LLC 100.0
Samsung Electronics America, Inc. Samsung International, Inc. 100.0
Samsung Electronics America, Inc. Harman International Industries, Inc. 100.0
Dacor Holdings, Inc. Dacor, Inc. 100.0
Samsung Semiconductor, Inc. Samsung Austin Semiconductor LLC. 100.0
Samsung Electronics Canada, Inc. AdGear Technologies Inc. 100.0
Samsung Research America, Inc SAMSUNG NEXT LLC 100.0
SAMSUNG NEXT LLC SAMSUNG NEXT FUND LLC 100.0
Samsung International, Inc. Samsung Mexicana S.A. de C.V 100.0
Samsung Electronics Mexico S.A. De C.V. Samsung Electronics Digital Appliance Mexico, SA de CV 100.0
Harman International Industries, Inc. Harman International Japan Co., Ltd. 100.0
Harman International Industries, Inc. Harman International Industries Canada Ltd. 100.0
Harman International Industries, Inc. Harman Becker Automotive Systems, Inc. 100.0
Harman International Industries, Inc. Harman Professional, Inc. 100.0
Harman International Industries, Inc. Harman Connected Services, Inc. 100.0
Harman International Industries, Inc. Harman Financial Group LLC 100.0

Share
Investor Investee
Ratio(%)
Harman International Industries, Inc. Harman Belgium SA 100.0
Harman International Industries, Inc. Harman France SNC 100.0
Harman International Industries, Inc. Red Bend Software SAS 100.0
Harman International Industries, Inc. Harman Inc. & Co. KG 66.0
Harman International Industries, Inc. Harman KG Holding, LLC 100.0
Harman International Industries, Inc. Harman Becker Automotive Systems Italy S.R.L. 100.0
Harman International Industries, Inc. Harman Finance International, SCA 100.0
Harman International Industries, Inc. Harman Finance International GP S.a.r.l 100.0
Harman International Industries, Inc. Harman Industries Holdings Mauritius Ltd. 100.0
Harman International Industries, Inc. Harman International Mexico, S. de R.L. de C.V. 99.9
Harman Becker Automotive Systems, Inc. Harman International Estonia OU 100.0
Harman Professional, Inc. Harman Singapore Pte. Ltd. 100.0
Harman Professional, Inc. Harman da Amazonia Industria Eletronica e Participacoes Ltda. 0.0
Harman Professional, Inc. Harman do Brasil Industria Eletronica e Participacoes Ltda. 0.0
Harman Connected Services, Inc. Harman Connected Services Engineering Corp. 100.0
Harman Connected Services, Inc. Harman Connected Services AB. 100.0
Harman Connected Services, Inc. Harman Connected Services UK Ltd. 100.0
Harman Connected Services, Inc. Harman Connected Services Corp. India Pvt. Ltd. 1.6
Harman Connected Services, Inc. Global Symphony Technology Group Private Ltd. 100.0
Harman Financial Group LLC Harman International (India) Private Limited 0.0
Harman Financial Group LLC Harman International Mexico, S. de R.L. de C.V. 0.1
Harman Financial Group LLC Harman de Mexico, S. de R.L. de C.V. 0.0
Samsung Electronics (UK) Ltd. Samsung Semiconductor Europe Limited 100.0
Samsung Electronics Holding GmbH Samsung Semiconductor Europe GmbH 100.0
Samsung Electronics Holding GmbH Samsung Electronics GmbH 100.0
Samsung Electronics Hungarian Private Co. Ltd. Samsung Electronics Czech and Slovak s.r.o. 31.4
Samsung Electronics Hungarian Private Co. Ltd. Samsung Electronics Slovakia s.r.o 44.3
Samsung Electronics Benelux B.V. Samsung Electronics Mexico S.A. De C.V. 36.4
Samsung Electronics Benelux B.V. SAMSUNG ELECTRONICS BALTICS SIA 100.0
Samsung Electronics Benelux B.V. Samsung Electronics West Africa Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics East Africa Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Saudi Arabia Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Egypt S.A.E 99.9
Samsung Electronics Benelux B.V. Samsung Electronics Israel Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Tunisia S.A.R.L 99.0
Samsung Electronics Benelux B.V. Samsung Electronics Pakistan(Private) Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics South Africa Production (pty) Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Turkey 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Industry and Commerce Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Semiconductor Israel R&D Center, Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Levant Co.,Ltd. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Maghreb Arab 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Venezuela, C.A. 100.0
Samsung Electronics Benelux B.V. Samsung Eletronica da Amazonia Ltda. 13.0
Samsung Electronics Benelux B.V. Samsung Electronics Chile Limitada 95.9
Samsung Electronics Benelux B.V. Samsung Electronics Peru S.A.C. 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Ukraine Company LLC 100.0
Samsung Electronics Benelux B.V. Samsung R&D Institute Ukraine 100.0
Samsung Electronics Benelux B.V. Samsung R&D Institute Rus LLC 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Central Eurasia LLP 100.0
Share
Investor Investee
Ratio(%)
Samsung Electronics Benelux B.V. Samsung Electronics Caucasus Co. Ltd 100.0
Samsung Electronics Benelux B.V. Samsung Electronics Uzbekistan Ltd. 100.0
Samsung Electronics Benelux B.V. Corephotonics Ltd. 100.0
Samsung Electronics Nordic Aktiebolag Samsung Nanoradio Design Center 100.0
AKG Acoustics Gmbh Harman Professional Denmark ApS 100.0
AKG Acoustics Gmbh Studer Professional Audio GmbH 100.0
Harman Professional Denmark ApS Martin Professional Japan Ltd. 40.0
Harman Becker Automotive Systems GmbH Harman International Romania SRL 0.0
Harman Becker Automotive Systems GmbH Apostera UA, LLC 100.0
Harman Holding Gmbh & Co. KG Harman Becker Automotive Systems GmbH 100.0
Harman Holding Gmbh & Co. KG Harman Deutschland GmbH 100.0
Harman Holding Gmbh & Co. KG Harman Becker Automotive Systems Manufacturing Kft 100.0
Harman Holding Gmbh & Co. KG Harman RUS CIS LLC 100.0
Harman Inc. & Co. KG Harman Holding Gmbh & Co. KG 100.0
Harman Inc. & Co. KG Harman Management Gmbh 100.0
Harman Inc. & Co. KG Harman Hungary Financing Ltd. 100.0
Harman Connected Services GmbH Harman Connected Services OOO 100.0
Harman KG Holding, LLC Harman Inc. & Co. KG 34.0
Harman Becker Automotive Systems Manufacturing Kft Harman Professional Kft 100.0
Harman Becker Automotive Systems Manufacturing Kft Harman Consumer Nederland B.V. 100.0
Harman Becker Automotive Systems Manufacturing Kft Harman International Romania SRL 100.0
Harman Becker Automotive Systems Manufacturing Kft Red Bend Ltd. 100.0
Harman Becker Automotive Systems Manufacturing Kft Harman do Brasil Industria Eletronica e Participacoes Ltda. 100.0
Harman Hungary Financing Ltd. Harman International Industries Limited 100.0
Harman Finance International GP S.a.r.l Harman Finance International, SCA 0.0
Harman Consumer Nederland B.V. AKG Acoustics Gmbh 100.0
Harman Consumer Nederland B.V. Harman Audio Iberia Espana Sociedad Limitada 100.0
Harman Consumer Nederland B.V. Harman Holding Limited 100.0
Harman Audio Iberia Espana Sociedad Limitada Harman France SNC 0.0
Harman Connected Services AB. Harman Finland Oy 100.0
Harman Connected Services AB. Harman Connected Services GmbH 100.0
Harman Connected Services AB. Harman Connected Services Poland Sp.zoo 100.0
Harman Connected Services AB. Harman Connected Services Solutions (Chengdu) Co., Ltd. 100.0
Harman International Industries Limited Harman Automotive UK Limited 100.0
Harman International Industries Limited Harman International Industries PTY Ltd. 100.0
Harman International Industries Limited Harman de Mexico, S. de R.L. de C.V. 100.0
Harman Connected Services UK Ltd. Harman Connected Services Morocco 100.0
Samsung Electronics Austria GmbH Samsung Electronics Switzerland GmbH 100.0
Samsung Electronics Europe Holding Cooperatief U.A. Samsung Electronics Czech and Slovak s.r.o. 68.6
Samsung Electronics Europe Holding Cooperatief U.A. Samsung Electronics Romania LLC 100.0
Samsung Electronics Europe Holding Cooperatief U.A. SAMSUNG Zhilabs, S.L. 100.0
Samsung Electronics Europe Holding Cooperatief U.A. Porta Nuova Varesine Building 2 S.r.l. 49.0
Samsung Electronics Europe Holding Cooperatief U.A. Samsung Electronics Poland Manufacturing SP.Zo.o 100.0
Samsung Electronics Europe Holding Cooperatief U.A. Samsung Electronics Greece S.M.S.A 100.0
Samsung Electronics Europe Holding Cooperatief U.A. Samsung Electronics Air Conditioner Europe B.V. 100.0
Samsung Electronics Europe Holding Cooperatief U.A. FOODIENT LTD. 100.0
Samsung Electronics Europe Holding Cooperatief U.A. Samsung Denmark Research Center ApS 100.0
Samsung Electronics Europe Holding Cooperatief U.A. Samsung Cambridge Solution Centre Limited 100.0
Samsung Electronics Europe Holding Cooperatief U.A. Novaled GmbH 40.0
Samsung Electronics Singapore Pte. Ltd. Samsung Electronics Display (M) Sdn. Bhd. 25.0
Share
Investor Investee
Ratio(%)
Samsung Electronics Singapore Pte. Ltd. iMarket Asia Co., Ltd. 11.4
Samsung Asia Private Ltd. Samsung Electronics Japan Co., Ltd. 100.0
Samsung Asia Private Ltd. Samsung Electronics Singapore Pte. Ltd. 100.0
Samsung Asia Private Ltd. Samsung Electronics New Zealand Limited 100.0
Samsung Asia Private Ltd. Samsung Electronics Philippines Corporation 100.0
Samsung Asia Private Ltd. Samsung R&D Institute BanglaDesh Limited 100.0
Samsung Asia Private Ltd. Samsung Electronics Vietnam Co., Ltd. 100.0
Samsung Asia Private Ltd. Samsung Electronics Vietnam THAINGUYEN Co., Ltd. 100.0
Samsung Asia Private Ltd. Samsung Electronics HCMC CE Complex Co., Ltd. 100.0
Samsung India Electronics Private Ltd. Samsung Nepal Services Pvt, Ltd 100.0
Samsung India Electronics Private Ltd. Red Brick Lane Marketing Solutions Pvt. Ltd. 100.0
PT Samsung Electronics Indonesia PT Samsung Telecommunications Indonesia 100.0
Thai Samsung Electronics Co., Ltd. Laos Samsung Electronics Sole Co., Ltd 100.0
Samsung Electronics Hong Kong Co., Ltd. iMarket Asia Co., Ltd. 11.3
Suzhou Samsung Electronics Co., Ltd. Samsung Suzhou Electronics Export Co., Ltd. 100.0
Samsung (CHINA) Investment Co., Ltd. Suzhou Samsung Electronics Co., Ltd. 19.2
Samsung (CHINA) Investment Co., Ltd. Samsung Mobile R&D Center China-Guangzhou 100.0
Samsung (CHINA) Investment Co., Ltd. Samsung R&D Institute China-Shenzhen 100.0
Samsung (CHINA) Investment Co., Ltd. Tianjin Samsung Electronics Co., Ltd. 43.1
Samsung (CHINA) Investment Co., Ltd. Beijing Samsung Telecom R&D Center 100.0
Samsung (CHINA) Investment Co., Ltd. Samsung Electronics Suzhou Computer Co., Ltd. 26.3
Samsung (CHINA) Investment Co., Ltd. Samsung Electronics China R&D Center 100.0
Harman International (China) Holdings Co., Ltd. Harman (Suzhou) Audio and Infotainment Systems Co., Ltd. 100.0
Harman International (China) Holdings Co., Ltd. Harman Technology (Shenzhen) Co., Ltd. 100.0
Harman International (China) Holdings Co., Ltd. Harman (China) Technologies Co., Ltd. 100.0
Harman Holding Limited Harman Commercial (Shanghai) Co., Ltd. 100.0
Harman Holding Limited Harman International (China) Holdings Co., Ltd. 100.0
Harman Holding Limited Harman Automotive Electronic Systems (Suzhou) Co., Ltd. 100.0
Samsung Gulf Electronics Co., Ltd. Samsung Electronics Egypt S.A.E 0.1
Samsung Electronics Maghreb Arab Samsung Electronics Tunisia S.A.R.L 1.0
Harman Industries Holdings Mauritius Ltd. Harman International (India) Private Limited 100.0
Global Symphony Technology Group Private Ltd. Harman Connected Services Corp. India Pvt. Ltd. 98.4
Red Bend Ltd. Red Bend Software Ltd. 100.0
Samsung Electronics Latinoamerica(Zona Libre), S. A. Samsung Electronics Latinoamerica Miami, Inc. 100.0
Samsung Electronics Latinoamerica(Zona Libre), S. A. Samsung Electronica Colombia S.A. 100.0
Samsung Electronics Latinoamerica(Zona Libre), S. A. Samsung Electronics Panama. S.A. 100.0
Samsung Eletronica da Amazonia Ltda. Samsung Electronics Argentina S.A. 2.0

Harman do Brasil Industria Eletronica e Participacoes Ltda.
Harman da Amazonia Industria Eletronica e Participacoes Ltda. 100.0
Samsung Electronics Central Eurasia LLP Samsung Electronics Caucasus Co. Ltd 0.0
Samsung SDI Co., Ltd. Intellectual Keystone Technology LLC 41.0
Samsung SDI Co., Ltd. Samsung SDI Japan Co., Ltd. 89.2
Samsung SDI Co., Ltd. Samsung SDI America, Inc. 91.7
Samsung SDI Co., Ltd. Samsung SDI Hungary., Zrt. 100.0
Samsung SDI Co., Ltd. Samsung SDI Europe GmbH 100.0
Samsung SDI Co., Ltd. Samsung SDI Battery Systems GmbH 100.0
Samsung SDI Co., Ltd. Samsung SDI Vietnam Co., Ltd. 100.0
Samsung SDI Co., Ltd. Samsung SDI Energy Malaysia Sdn, Bhd. 100.0
Samsung SDI Co., Ltd. Samsung SDI India Private Limited 100.0
Samsung SDI Co., Ltd. Samsung SDI(Hong Kong) Ltd. 97.6
Samsung SDI Co., Ltd. Samsung SDI China Co., Ltd. 100.0
Share
Investor Investee
Ratio(%)
Samsung SDI Co., Ltd. Samsung SDI-ARN (Xi'An) Power Battery Co., Ltd. 65.0
Samsung SDI Co., Ltd. Samsung SDI（Tianjin）Battery Co.,Ltd. 80.0
Samsung SDI Co., Ltd. Novaled GmbH 51.0
Samsung SDI Co., Ltd. SAMSUNG SDI WUXI CO.,LTD. 50.1
Samsung SDI Co., Ltd. iMarket Asia Co., Ltd. 100.0
Samsung SDI(Hong Kong) Ltd. Samsung SDI India Private Limited 8.7
Samsung SDI(Hong Kong) Ltd. Tianjin Samsung SDI Co., Ltd. 0.0
Samsung Electro-Mechanics Co., Ltd. Samsung Electro-Machanics Japan Co., Ltd. 80.0
Samsung Electro-Mechanics Co., Ltd. Samsung Electro-Mechanics America, Inc. 100.0
Samsung Electro-Mechanics Co., Ltd. Samsung Electro-Mechanics GmbH 100.0
Samsung Electro-Mechanics Co., Ltd. Samsung Electro-Mechanics Philippines, Corp. 100.0
Samsung Electro-Mechanics Co., Ltd. Calamba Premier Realty Corporation 100.0
Samsung Electro-Mechanics Co., Ltd. Samsung Electro-Mechanics Pte Ltd. 39.8
Samsung Electro-Mechanics Co., Ltd. Samsung Electro-Mechanics Vietnam Co., Ltd. 100.0
Samsung Electro-Mechanics Software India Bangalore Private
Samsung Electro-Mechanics Co., Ltd. 100.0
Limited
Samsung Electro-Mechanics Co., Ltd. Dongguan Samsung Electro-Mechanics Co., Ltd. 99.9
Samsung Electro-Mechanics Co., Ltd. Tianjin Samsung Electro-Mechanics Co., Ltd. 100.0
Samsung Electro-Mechanics Co., Ltd. Samsung High-Tech Electro-Mechanics(Tianjin) Co., Ltd. 81.8
Samsung Electro-Mechanics Co., Ltd. Samsung Electro-Mechanics (Shenzhen) Co., Ltd. 95.0
Samsung Electro-Mechanics Co., Ltd. Kunshan Samsung Electro-Mechanics Co., Ltd. 100.0
Samsung Electro-Mechanics Co., Ltd. iMarket Asia Co., Ltd. 100.0
Calamba Premier Realty Corporation Batino Realty Corporation 8.7

Samsung Electro-Mechanics Software India Bangalore Private
Samsung Electro-Mechanics Pte Ltd. 100.0
Limited
Samsung Fire & Marine Insurance Co., Ltd. Samsung Fire & Marine Management Corporation 0.1
SAMSUNG FIRE & MARINE INSURANCE COMPANY OF
Samsung Fire & Marine Insurance Co., Ltd. 100.0
EUROPE LTD.
Samsung Fire & Marine Insurance Co., Ltd. PT. Asuransi Samsung Tugu 100.0
Samsung Fire & Marine Insurance Co., Ltd. SAMSUNG VINA INSURANCE COMPANY LIMITED 70.0
Samsung Fire & Marine Insurance Co., Ltd. Samsung Reinsurance Pte. Ltd. 75.0
Samsung Fire & Marine Insurance Co., Ltd. Samsung Property & Casualty Insurance Company(China), Ltd 100.0
Samsung Fire & Marine Insurance Management Middle East
Samsung Fire & Marine Insurance Co., Ltd. 37.0
Limited
Samsung Heavy Industries Co., Ltd Camellia Consulting Corporation 100.0
Samsung Heavy Industries Co., Ltd Samsung Heavy Industries India Pvt.Ltd. 100.0
Samsung Heavy Industries Co., Ltd SAMSUNG HEAVY INDUSTRIES (M) SDN.BHD 100.0
Samsung Heavy Industries Co., Ltd Samsung Heavy Industries(Ningbo) Co., Ltd 100.0
Samsung Heavy Industries Co., Ltd Samsung Heavy Industries(Rongcheng) Co., Ltd 100.0
Samsung Heavy Industries Co., Ltd SAMSUNG HEAVY INDUSTRIES NIGERIA LIMITED 100.0
Samsung Heavy Industries Co., Ltd Samsung Heavy Industries Mozambique LDA 100.0
Samsung Heavy Industries Co., Ltd Samsung Heavy Industries Rus LLC 100.0
SAMSUNG HEAVY INDUSTRIES NIGERIA LIMITED SHI - MCI FZE 70.0
Samsung Life Insurance Co., Ltd. Porta Nuova Varesine Building 2 S.r.l. 51.0
Samsung Life Insurance Co., Ltd. Samsung Life Insurance (Thailand) Public Co., Ltd 48.9
Samsung Life Insurance Co., Ltd. Beijing Samsung Real Estate Co., Ltd 90.0
Samsung Asset Management Co., Ltd. Samsung Asset Management (New York), Inc. 100.0
Samsung Asset Management Co., Ltd. Samsung Global SME Private Equity Manager Fund Co., Ltd. 100.0
Samsung Asset Management Co., Ltd. Samsung Asset Management U.S. Holdings, Inc. 100.0
Samsung Asset Management Co., Ltd. Samsung Private Equity Fund 2022 GP, Ltd. 100.0
Samsung Asset Management Co., Ltd. Samsung Co-Investment 2021 GP, Ltd. 100.0
Samsung Asset Management Co., Ltd. Samsung Asset Management(London) Ltd. 100.0
Samsung Asset Management Co., Ltd. Samsung Private Equity Manager I Co., Ltd. 100.0
Share
Investor Investee
Ratio(%)
Samsung Asset Management Co., Ltd. Samsung Asset Management (Hong Kong) Ltd. 100.0
Samsung Asset Management (Hong Kong) Ltd. Samsung Asset Management (Beijing) Ltd. 100.0
Samsung C&T Corporation Samsung C&T Japan Corporation 100.0
Samsung C&T Corporation Samsung C&T America Inc. 100.0
Samsung C&T Corporation Samsung E&C America, INC. 100.0
Samsung C&T Corporation Samsung Renewable Energy Inc. 100.0
Samsung C&T Corporation QSSC, S.A. de C.V. 80.0
Samsung C&T Corporation Samsung C&T Oil & Gas Parallel Corp. 100.0
Samsung C&T Corporation Samsung C&T Lima S.A.C. 100.0
Samsung C&T Corporation Samsung C&T Deutschland GmbH 100.0
Samsung C&T Corporation Samsung C&T U.K. Ltd. 100.0
Samsung C&T Corporation Samsung C&T ECUK Limited 100.0
Samsung C&T Corporation Whessoe engineering Limited 100.0
Samsung C&T Corporation POSS-SLPC, S.R.O 50.0
Samsung C&T Corporation Solluce Romania 1 B.V. 80.0
Samsung C&T Corporation SAM investment Manzanilo.B.V 53.3
Samsung C&T Corporation Samsung C&T (KL) Sdn.,Bhd. 100.0
Samsung C&T Corporation Samsung C&T Malaysia SDN. BHD 100.0
Samsung C&T Corporation Erdsam Co., Ltd. 100.0
Samsung C&T Corporation Samsung Chemtech Vina LLC 51.7
Samsung C&T Corporation Samsung C&T Thailand Co., Ltd 93.0
Samsung C&T Corporation PT. INSAM BATUBARA ENERGY 34.8
Samsung C&T Corporation Samsung E&C India Private Limited 100.0
Samsung C&T Corporation Samsung C&T Corporation India Private Limited 100.0
Samsung C&T Corporation Malaysia Samsung Steel Center Sdn.Bhd 70.0
Samsung C&T Corporation Samsung C&T Singapore Pte., Ltd. 100.0
Samsung C&T Corporation S&G Biofuel PTE.LTD 50.5
Samsung C&T Corporation SAMSUNG C&T Mongolia LLC. 70.0
Samsung C&T Corporation Samsung C&T Eng.&Const. Mongolia LLC. 100.0
Samsung C&T Corporation S&WOO CONSTRUCTION PHILIPPINES,INC. 100.0
Samsung C&T Corporation VSSC STEEL CENTER LIMITED LIABILITY COMPANY 70.0
Samsung C&T Corporation Vista Contracting and Investment Global Pte. Ltd. 100.0
Samsung C&T Corporation SAMSUNG CONST. CO. PHILS. 25.0
Samsung C&T Corporation CHEIL HOLDING INC. 40.0
Samsung C&T Corporation Samsung C&T Renewable Energy Australia Pty Ltd 100.0
Samsung C&T Corporation Samsung C&T Hongkong Ltd. 100.0
Samsung C&T Corporation Samsung C&T Taiwan Co., Ltd. 100.0
Samsung C&T Corporation Samsung Precision Stainless Steel(pinghu) Co.,Ltd. 55.0
Samsung C&T Corporation SAMSUNG C&T (SHANGHAI) CO., LTD. 100.0
Samsung C&T Corporation Samsung C&T (Xi'an) Co., Ltd. 100.0
Samsung C&T Corporation WARIS GIGIH ENGINEERING AND TECHNOLOGY SDN. BHD. 30.0
Samsung C&T Corporation SAMSUNG C&T CORPORATION SAUDI ARABIA 100.0
Samsung C&T Corporation SAM Gulf Investment Limited 100.0
Samsung C&T Corporation Samsung C&T Chile Copper SpA 100.0
Samsung C&T Corporation SCNT Power Kelar Inversiones Limitada 100.0
Samsung C&T Corporation Samsung C&T Corporation Rus LLC 100.0
Samsung C&T Corporation Samsung SDI America, Inc. 8.3
Samsung C&T Corporation Samsung SDI(Hong Kong) Ltd. 2.4
Samsung C&T Corporation Beijing Samsung Real Estate Co.. Ltd 10.0
Samsung C&T Corporation CHEIL INDUSTRIES ITALY SRL 100.0

Share
Investor Investee
Ratio(%)
Samsung C&T Corporation Samsung Fashion Trading Co. ,Ltd 100.0
Samsung C&T Corporation SAMSUNG C&T CORPORATION VIETNAM CO., LTD 100.0
Samsung C&T Corporation Samsung C&T Corporation UEM Construction JV Sdn Bhd 60.0
Samsung C&T Corporation iMarket Asia Co., Ltd. 19.3
Samsung Welstory Co., Ltd. WELSTORY VIETNAM COMPANY LIMITED 100.0
Samsung Welstory Co., Ltd. Shanghai Ever-Hongjun Business Mgt Service Co.,LTD 85.0
Samsung Welstory Co., Ltd. Shanghai Welstory Food Company Limited 81.6
Multicampus Corporation LANGUAGE TESTING INTERNATIONAL, INC. 82.4
Pengtai Greater China Company Limited PENGTAI CHINA CO.,LTD. 100.0
Pengtai Greater China Company Limited PengTai Taiwan Co., Ltd. 100.0
PENGTAI CHINA CO.,LTD. PENGTAI E-COMMERCE CO.,LTD 100.0
PENGTAI CHINA CO.,LTD. PENGTAI MARKETING SERVICE CO.,LTD. 100.0
PENGTAI INTERACTIVE ADVERTISING CO.,LTD Medialytics Inc. 100.0
PENGTAI INTERACTIVE ADVERTISING CO.,LTD Beijing Pengtai Baozun E-commerce Co., Ltd. 51.0
iMarket Asia Co., Ltd. iMarket China Co., Ltd. 80.0
Samsung Securities Co., Ltd. Samsung Securities (America), Inc. 100.0
Samsung Securities Co., Ltd. Samsung Securities (Europe) Limited. 100.0
Samsung Securities Co., Ltd. Samsung Securities (Asia) Limited. 100.0
Samsung SDS Co., Ltd. iMarket Asia Co., Ltd. 40.6
Samsung SDS Co., Ltd. Samsung SDS America, Inc. 100.0
Samsung SDS Co., Ltd. SAMSUNG SDS GSCL Canada., Ltd. 100.0
Samsung SDS Co., Ltd. Neo EXpress Transportation (NEXT), Inc. 51.0
Samsung SDS Co., Ltd. Samsung SDS Europe, Ltd. 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Hungary, Kft. 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Slovakia, S.R.O. 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Poland Sp. Z.o.o. 100.0
Samsung SDS Co., Ltd. Samsung GSCL Sweden AB 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL France SAS 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Italy S.R.L. A Socio Unico 100.0
Samsung SDS Co., Ltd. Samsung SDS Global Supply Chain Logistics Spain S.L.U 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Netherlands Cooperatief U.A. 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Germany GmbH 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Romania S.R.L 100.0
Samsung SDS Co., Ltd. Samsung SDS Asia Pacific Pte, Ltd. 100.0
Samsung SDS Co., Ltd. Samsung Data Systems India Private Limited 100.0
Samsung SDS Co., Ltd. Samsung SDS Vietnam Co., Ltd. 100.0
Samsung SDS Co., Ltd. PT. Samsung SDS Global SCL Indonesia 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Philippines Co., Ltd.Inc. 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Thailand Co.,Ltd 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Malaysia SDN.BHD. 100.0
Samsung SDS Co., Ltd. SAMSUNG SDS Global SCL Austraila Pty.,Ltd. 100.0
Samsung SDS Co., Ltd. SDS-ACUTECH CO., Ltd. 50.0
Samsung SDS Co., Ltd. ALS SDS Joint Stock Company 51.0
Samsung SDS Co., Ltd. SDS-MP Logistics Joint Stock Company 51.0
Samsung SDS Co., Ltd. Samsung SDS China Co., Ltd. 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Hong Kong Co., Ltd. 100.0
Samsung SDS Co., Ltd. SAMSUNG SDS Global SCL Egypt 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL South Africa (PTY) Ltd. 100.0
Samsung SDS Co., Ltd. Samsung SDS Global SCL Nakliyat ve Lojistik Anonim Sirketi 100.0
Samsung SDS Global Supply Chain Logistics Middle East DWC-
Samsung SDS Co., Ltd. 100.0
LLC
Share
Investor Investee
Ratio(%)
Samsung SDS Co., Ltd. Samsung SDS Latin America Solucoes Em Tecnologia Ltda. 99.7
Samsung SDS Co., Ltd. INTE-SDS Logistics S.A. de C.V. 51.0
Samsung SDS Co., Ltd. Samsung SDS Rus Limited Liability Company 100.0
.Samsung SDS Global SCL America, Inc. Samsung SDS Mexico, S.A. DE C.V. 99.0
Samsung SDS Global SCL America, Inc. Samsung SDS Global SCL Panama S. A. 100.0
Samsung SDS Global SCL America, Inc. Samsung SDS Global SCL Chile Limitada 100.0
Samsung SDS Global SCL America, Inc. Samsung SDS Global SCL Peru S.A.C. 100.0
Samsung SDS Global SCL America, Inc. Samsung SDS Global SCL Colombia S.A.S. 100.0
Samsung SDS Global SCL America, Inc. Samsung SDS Latin America Solucoes Em Tecnologia Ltda. 0.3
Samsung SDS Europe, Ltd. Samsung SDS Global SCL Netherlands Cooperatief U.A. 0.0
Samsung SDS Global SCL Netherlands Cooperatief U.A. Samsung SDS Global SCL Poland Sp. Z.o.o. 0.0
Samsung SDS Global SCL Netherlands Cooperatief U.A. Samsung SDS Global SCL Romania S.R.L 0.0
Samsung SDS Global SCL Netherlands Cooperatief U.A. Samsung SDS Rus Limited Liability Company 0.0
Samsung IT Services (Beijing) Co., Ltd. Samsung SDS Global Development Center Xi'an 100.0
Samsung Engineering Co., Ltd. Samsung Engineering America Inc. 100.0
Samsung Engineering Co., Ltd. Samsung Project Management Inc. 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Hungary Ltd. 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Italy S.R.L. 100.0
Samsung Engineering Co., Ltd. Samsung Engineering (Malaysia) SDN. BHD. 100.0
Samsung Engineering Co., Ltd. PT Samsung Engineering Indonesia Co., Ltd. 100.0
Samsung Engineering Co., Ltd. Samsung Engineering (Thailand) Co., Ltd. 81.0
Samsung Engineering Co., Ltd. Samsung Engineering India Private Limited 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Vietnam Co., Ltd. 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Global Private Limited 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Construction(Shanghai) Co., Ltd 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Construction Xi' an Co., Ltd. 100.0
Samsung Engineering Co., Ltd. Samsung Saudi Arabia Co., Ltd. 100.0
Samsung Engineering Co., Ltd. Muharraq Wastewater Services Company W.L.L. 99.8
Samsung Engineering Co., Ltd. Muharraq STP Company B.S.C. 6.6
Samsung Engineering Co., Ltd. Muharraq Holding Company 1 Ltd. 65.0

Samsung Ingenieria Mexico Construccion Y Operacion S.A. De
Samsung Engineering Co., Ltd. 99.9
C.V.
Samsung Engineering Co., Ltd. Samsung Engineering Trinidad Co., Ltd. 100.0
Samsung Engineering Co., Ltd. Samsung Ingenieria Manzanillo, S.A. De C.V. 99.9
Samsung Engineering Co., Ltd. Grupo Samsung Ingenieria Mexico, S.A. De C.V. 100.0
Samsung Engineering Co., Ltd. Samsung Ingenieria Energia S.A. De C.V. 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Bolivia S.A 100.0
Samsung Engineering Co., Ltd. Samsung Ingenieria DUBA S.A. de C.V. 100.0
Samsung Engineering Co., Ltd. Samsung Engineering Kazakhstan L.L.P. 100.0
Samsung Engineering America Inc. SEA Construction, LLC 100.0
Samsung Engineering America Inc. SEA Louisiana Construction, L.L.C. 100.0
Samsung Engineering (Malaysia) SDN. BHD. Muharraq Wastewater Services Company W.L.L. 0.3
Samsung Engineering India Private Limited Samsung Engineering Global Private Limited 0.0
Samsung Engineering India Private Limited Samsung Saudi Arabia Co., Ltd. 0.0
Samsung Saudi Arabia Co., Ltd. Samsung EPC Company Ltd. 75.0
Muharraq Holding Company 1 Ltd. Muharraq Holding Company 2 Ltd. 100.0
Muharraq Holding Company 2 Ltd. Muharraq STP Company B.S.C. 89.9
Samsung Ingenieria Manzanillo, S.A. De C.V. Asociados Constructores DBNR, S.A. de C.V. 49.0
S-1 Corporation S-1 CORPORATION HUNGARY LLC 100.0
S-1 Corporation S-1 CORPORATION VIETNAM CO., LTD 100.0
S-1 Corporation Samsung Beijing Security Systems 100.0

Share
Investor Investee
Ratio(%)
Cheil Worldwide Inc. PENGTAI INTERACTIVE ADVERTISING CO.,LTD 100.0
Cheil Worldwide Inc. Cheil USA Inc. 100.0
Cheil Worldwide Inc. Cheil Central America Inc. 100.0
Cheil Worldwide Inc. Iris Worldwide Holdings Limited 100.0
Cheil Worldwide Inc. CHEIL EUROPE LIMITED 100.0
Cheil Worldwide Inc. Cheil Germany GmbH 100.0
Cheil Worldwide Inc. Cheil France SAS 100.0
Cheil Worldwide Inc. CHEIL SPAIN S.L 100.0
Cheil Worldwide Inc. Cheil Benelux B.V. 100.0
Cheil Worldwide Inc. Cheil Nordic AB 100.0
Cheil Worldwide Inc. Cheil India Private Limited 100.0
Cheil Worldwide Inc. Cheil (Thailand) Ltd. 100.0
Cheil Worldwide Inc. Cheil Singapore Pte. Ltd. 100.0
Cheil Worldwide Inc. CHEIL VIETNAM COMPANY LIMITED 99.0
Cheil Worldwide Inc. Cheil Integrated Marketing Philippines, Inc. 100.0
Cheil Worldwide Inc. CHEIL MALAYSIA SDN. BHD. 100.0
Cheil Worldwide Inc. Cheil New Zealand Limited 100.0
Cheil Worldwide Inc. Pengtai Greater China Company Limited 3.1
Cheil Worldwide Inc. CHEIL CHINA 100.0
Cheil Worldwide Inc. Cheil Hong Kong Ltd. 100.0
Cheil Worldwide Inc. Caishu (Shanghai) Business Consulting Co., Ltd 100.0
Cheil Worldwide Inc. Cheil MEA FZ-LLC 100.0
Cheil Worldwide Inc. Cheil South Africa (Pty) Ltd 100.0
Cheil Worldwide Inc. CHEIL KENYA LIMITED 99.0
Cheil Worldwide Inc. Cheil Communications Nigeria Ltd. 99.0
Cheil Worldwide Inc. Cheil Worldwide Inc./Jordan LLC. 100.0
Cheil Worldwide Inc. Cheil Ghana Limited 100.0
Cheil Worldwide Inc. Cheil Egypt LLC 99.9
Cheil Worldwide Inc. Cheil Brasil Comunicacoes Ltda. 100.0
Cheil Worldwide Inc. Cheil Mexico, S.A. de C.V. 98.0
Cheil Worldwide Inc. Cheil Chile SpA. 100.0
Cheil Worldwide Inc. Cheil Peru S.A.C. 100.0
Cheil Worldwide Inc. CHEIL ARGENTINA S.A. 98.0
Cheil Worldwide Inc. Cheil Rus LLC 100.0
Cheil Worldwide Inc. Cheil Ukraine LLC 100.0
Cheil Worldwide Inc. Cheil Kazakhstan LLC 100.0
Hotel Shilla Co., Ltd. Samsung Hospitality America Inc. 100.0
Hotel Shilla Co., Ltd. Shilla Travel Retail Pte. Ltd. 100.0
Hotel Shilla Co., Ltd. Samsung Shilla Business Service Beijing Co., Ltd. 100.0
Hotel Shilla Co., Ltd. Shilla Travel Retail Hong Kong Limited 100.0
HDC Shilla Duty Free Ltd. HDC SHILLA (SHANGHAI) CO., LTD 100.0
SBTM Co., Ltd. Samsung Hospitality U.K. Inc. 100.0
SBTM Co., Ltd. Samsung Hospitality Europe GmbH 100.0
SBTM Co., Ltd. SAMSUNG HOSPITALITY ROMANIA SRL 100.0
SBTM Co., Ltd. Samsung Hospitality Vietnam Co., Ltd. 99.0
SBTM Co., Ltd. Samsung Hospitality Philippines Inc. 100.0
SBTM Co., Ltd. Samsung Hospitality India Private Limited 100.0
삼성벤처투자(주) Samsung Venture Investment (Shanghai) Co., Ltd. 100.0
Iris Americas, Inc. Iris (USA) Inc. 100.0
Iris Americas, Inc. Iris Atlanta, Inc. 100.0

Share
Investor Investee
Ratio(%)
Iris Americas, Inc. 89 Degrees, Inc. 100.0
Cheil USA Inc. The Barbarian Group LLC 100.0
Cheil USA Inc. McKinney Ventures LLC 100.0
Cheil USA Inc. Cheil India Private Limited 0.0
Cheil USA Inc. Cheil Mexico, S.A. de C.V. 2.0
Iris Worldwide Holdings Limited Iris Nation Worldwide Limited 100.0
Iris Nation Worldwide Limited Iris Americas, Inc. 100.0
Iris Nation Worldwide Limited Irisnation Latina No.2, S. de R.L. de C.V. 100.0
Iris Nation Worldwide Limited Irisnation Latina, S. de R.L. de C.V. 100.0
Iris Nation Worldwide Limited Pricing Solutions Ltd 100.0
Iris Nation Worldwide Limited Iris London Limited 100.0
Iris Nation Worldwide Limited Iris Promotional Marketing Ltd 100.0
Iris Nation Worldwide Limited Iris Ventures 1 Limited 100.0
Iris Nation Worldwide Limited Founded Partners Limited 100.0
Iris Nation Worldwide Limited Iris Products (Worldwide) Limited 100.0
Iris Nation Worldwide Limited Iris Korea Limited 100.0
Iris Nation Worldwide Limited Iris Digital Limited 100.0
Iris Nation Worldwide Limited Iris Amsterdam B.V. 100.0
Iris Nation Worldwide Limited Iris Ventures (Worldwide) Limited 100.0
Iris Nation Worldwide Limited Iris Culture Limited 100.0
Iris Nation Worldwide Limited Concise Consultants Limited 100.0
Iris Nation Worldwide Limited Atom42 Ltd 49.0
Iris Nation Worldwide Limited WDMP Limited 100.0
Iris Nation Worldwide Limited Pricing Solutions (UK) Limited 100.0
Iris Nation Worldwide Limited Iris Services Limited Dooel Skopje 100.0
Iris Nation Worldwide Limited Irisnation Singapore Pte. ltd. 100.0
Iris Nation Worldwide Limited Iris Worldwide Integrated Marketing Private Limited 100.0
Iris Nation Worldwide Limited Iris Sydney PTY Ltd 100.0
Iris Nation Worldwide Limited Iris Worldwide (Thailand) Limited 100.0
Iris Nation Worldwide Limited Iris Beijing Advertising Company Limited 100.0
Iris London Limited Iris Partners LLP 100.0
Iris Promotional Marketing Ltd Holdings BR185 Limited 100.0
Iris Ventures 1 Limited Iris Germany GmbH 100.0
Founded Partners Limited Founded, Inc. 100.0
Iris Germany GmbH Pepper NA, Inc. 100.0
Iris Germany GmbH Pepper Technologies Pte. Ltd. 100.0
CHEIL EUROPE LIMITED Beattie McGuinness Bungay Limited 100.0
CHEIL EUROPE LIMITED Cheil Italia S.r.l 100.0
Cheil Germany GmbH Cheil Austria GmbH 100.0
Cheil Germany GmbH Centrade Integrated SRL 100.0
Centrade Integrated SRL Centrade Cheil HU Kft. 100.0
Centrade Integrated SRL Centrade Cheil Adriatic D.O.O. 95.7
Cheil India Private Limited Experience Commerce Software Private Limited 100.0
Cheil Singapore Pte. Ltd. Pengtai Greater China Company Limited 30.0
Cheil Singapore Pte. Ltd. PT. CHEIL WORLDWIDE INDONESIA 100.0
Cheil Integrated Marketing Philippines, Inc. Cheil Philippines Inc. 100.0
Shilla Travel Retail Pte. Ltd. Shilla Retail Plus Pte. Ltd. 100.0
Samsung Shilla Business Service Beijing Co., Ltd. Tianjin Samsung International Travel Service Co., Ltd 100.0
Shilla Travel Retail Hong Kong Limited Shilla Retail Limited 100.0
Shilla Travel Retail Hong Kong Limited Shilla Travel Retail Duty Free HK Limited 0.0
Share
Investor Investee
Ratio(%)
Cheil MEA FZ-LLC One Agency FZ-LLC 0.1
One RX Project Management Design and Production Limited
Cheil MEA FZ-LLC 1.0
Company
Cheil MEA FZ-LLC Cheil Egypt LLC 1.0
Cheil South Africa (Pty) Ltd CHEIL KENYA LIMITED 100.0
Cheil South Africa (Pty) Ltd Cheil Communications Nigeria Ltd. 100.0
One Agency FZ-LLC One RX India Private Limited 100.0

One RX Project Management Design and Production Limited
One Agency FZ-LLC 100.0
Company
One Agency FZ-LLC ONE RX INTERIOR DECORATION L.L.C 100.0
One Agency FZ-LLC ONE AGENCY PRINTING L.L.C 0.0
One Agency FZ-LLC One Agency South Africa (Pty) Ltd 100.0
ONE RX INTERIOR DECORATION L.L.C One RX India Private Limited 100.0
Holdings BR185 Limited Brazil 185 Participacoes Ltda 2.0
Brazil 185 Participacoes Ltda Iris Router Marketing Ltda 100.0
Cheil Brasil Comunicacoes Ltda. CHEIL ARGENTINA S.A. 100.0

(3) Regulations under related laws, etc
“Business groups with restrictions on mutual investment in the “Act on Monopoly Regulation and Fair
Trade”, etc.”
① Start date: May 1, 2021
② Detail of restriction
- Prohibition of mutual investment

- prohibition of debt guarantee by affiliates
- Restriction on voting rights of affiliates of financial and insurance companies
- Board resolution and disclosure of large-scale insider transactions
- Disclosure of important matters to unlisted companies
- Disclosure on the status of corporate groups, etc.
B. Equity investments in other corporations(Summary)

Number of investee Investment amount
Increase(Decrease)
Classification Beginning Ending
Listed Unlisted Total Acquisition Valuation
Book Value Book Value
(Disposal) gain(Loss)
Management
- 4 4 541,389 2,763,590 3,813 3,308,792
Participation
General
- - - - - - -
Investment
Simple
- - - - - - -
Investment
Total - 4 4 541,389 2,763,590 3,813 3,308,792
※ For details, refer to XII. Table of Information – 3. Investments in other companies
C. Concurrent position with other affiliates

Director Concurrent position
Name Position Company name Position Duration
Executive Other non-executive
Lo Kun Samsung Bioepis 2022.02 ~ present
Vice President director
※ As of February 9, 2022, President John Rim's term as an interlocking executive of the company has expired, and Vice President
Lo Kun has been appointed as a non-executive director of Samsung Bioepis Co., Ltd.
X. Transactions with Stakeholders
1. Credit Offerings for Affiliates and Subsidiaries
A. Provisional payments and loans (incl. securities loan)

- Not applicable
B. Collateral provided
- Not applicable
C. Debt guarantee
- Not applicable
2. Acquisitions and Disposals of Assets with Affiliates and Subsidiaries
A. Acquisitions and disposals of assets

- Not applicable
B. Purchase or sale of securities

- Not applicable
C. Investment and disposal of invested shares

- Not applicable
3. Business transactions with affiliates and subsidiaries

Type of
Name Relation Contract period Contract details Contract amount
transaction
Product/raw
Samsung Bioepis 2022.01 ~
Affiliate. Sales etc. materials/service 1,373
Co., Ltd 2022.12.
etc.
※ The values above are based on the separate financial statements.
※ Total contract amount is worth 5% or above of the Company’s revenue in 2021
4. Transactions with stakeholders other than affiliates and subsidiaries

- On January 28, 2022, 5,009,000 ordinary shares were allocated to shareholders through a
resolution of the Board of Directors and issued through general public offering.
The confirmed issuance price is KRW 639,000, and the details of participation in capital increase,
including major shareholders, are as follows :
(Unit: KRW thousand)
Contract
Name Relationship Number of share Amount Remarks
date
Shareholder
Samsung C&T
Majority shareholder 2022.04.16 1,904,239 1,216,808,721 Preferred
Corporation
Subscription
Shareholder
Samsung
Related party 2022.04.16 1,380,477 882,124,803 Preferred
Electronics
Subscription
Shareholder
Kim Taehan Executive director 2022.04.16 1,272 812,808 Preferred
Subscription
Shareholder
Kim Dongjoong Executive director 2022.04.16 332 212,148 Preferred
Subscription
Employee stock Priority allocation of
ownership Employee 2022.04.16 624,414 399,000,546 12.5% of total
association issued stocks
※ The above transaction date, April 16, 2022, is the day after the share purchase date.
5. Transactions with stakeholders other than major shareholders

- Not applicable
XI. Other Information
1. Public Disclosure and Shareholder Meetings
A. Progress and Change of Notices

Disclosure
Title Details Progress
date
◦ Overview
- Contract name : Outsourced drug manufacturing
Entering into - Contract amount : USD 373,047,549.55
‘16.11.15 Single Sales or - Counterpart : Cilag GmbH International In progress
Supply Contract - Contract period : 2016. 11. 15 ~ Contract end date
※ The disclosure of the confidential details of contract end
date is reserved.
◦ Overview
Entering into - Contract amount : USD 55,513,715
‘17.07.04 Single Sales or - Counterpart : Sun Pharma Global FZE In progress
date is reserved.
◦ Overview
‘17.07.21 Single Sales or - Counterpart : Pharmaceutical company in US In progress
date is reserved.
◦ Overview
‘17.12.21 Single Sales or - Counterpart : UCB In progress
date is reserved.
◦ Overview
Entering into - Contract name : Outsourced drug manufacturing
‘18.02.22 Single Sales or - Contract amount : USD 50,313,000 In progress
Supply Contract - Counterpart : TG Therapeutics, Inc.
- Contract period : 2018. 2. 21 ~ 2026. 12. 31
◦ Overview
‘18.04.30 Single Sales or - Counterpart : Pharmaceutical company in Swiss In progress
Supply Contract - Contract period : 2018. 4. 30 ~ 2025. 12. 31
date is reserved.
◦ Overview
‘18.06.01 Single Sales or - Counterpart : Ichnos Sciences In progress
date is reserved.
Disclosure
date
◦ Overview
Single Sales or - Counterpart : Pharmaceutical company in Asia
‘18.08.14 In progress
(자율공시)
date is reserved.
◦ Overview
Supply Contract - Counterpart : Gilead Sciences, Inc.
- Contract period : 2018. 9. 11 ~ 2025. 12. 31
◦ Overview
Supply Contract - Counterpart : CytoDyn Inc.
- Contract period: 2019. 4. 1 ~ 2027.12.31
◦ Overview
‘19.04.26 Single Sales or - Counterpart : Pharmaceutical company in Asia In progress
date is reserved.
◦ Overview
date is reserved.
◦ Overview
date is reserved.
◦ Overview
- Contract name: Outsourced drug manufacturing
‘19.05.17 Single Sales or - Counterpart : UCB In progress
date is reserved.
◦ Overview
date is reserved.
Disclosure
date
◦ Overview
‘19.12.03 Single Sales or - Counterpart : Pharmaceutical company in US In progress
※ The disclosure of the confidential details of contract
end date is reserved.
◦ Overview
Supply Contract - Counterpart : GlaxoSmithKline Trading Services Limited
- Contract period : 2020. 5. 21 ~ 2028. 12 31
◦ Overview
‘20.07.20 Single Sales or - Counterpart : H. Lundbeck A/S In progress
※ The disclosure of the confidential details of counterpart &
contract end date is reserved.
◦ Overview
Entering into - Contract name: Outsourced drug manufacturing
‘20.07.28 Single Sales or - Contract amount: USD 268,349,994 In progress
Supply Contract - Counterpart: Eli Lilly and Company
- Contract period: 2020. 7. 21 ~ 2026.08.30
◦ Overview
Supply Contract - Counterpart: Immunovant Sciences GmbH
- Contract period: 2018. 12. 18 ~ 2029. 12. 31
◦ Overview
Supply Contract - Counterpart: GlaxoSmithKline Trading Services Limited
- Contract period: 2020. 4. 9 ~ 2023. 12. 31
◦ Overview
Supply Contract - Counterpart: AstraZeneca AB
- Contract period: 2020. 6. 23 ~ 2028.12.31
◦ Overview
Supply Contract - Counterpart: AstraZeneca UK Ltd.,
- Contract period: 2020. 9. 21 ~ 2023.12.31
◦ Overview
Supply Contract - Counterpart: Checkpoint Therapeutics, Inc.,
- Contract period: 2020. 10. 02 ~ 2030. 10. 02
Disclosure
date
◦ Overview
Supply Contract - Counterpart: Pharmaceutical company in US
- Contract period: 2020. 10. 28 ~ 2030.12.31
◦ Overview
Supply Contract - Counterpart: F.Hoffmann-La Roche Ltd
- Contract period: 2020. 6. 1 ~ 2024.12.31
◦ Overview
Supply Contract - Counterpart: F.Hoffmann-La Roche Ltd
- Contract period: 2020. 6. 1 ~ 2024.12.31
◦ Overview
- Contract name: Outsourced drug manufacturing LOI
Important - Contract amount: USD 76,703,939
‘21.12.23 management - Counterpart: Pharmaceutical company in Europe In progress
matters - Contract period: 2021.10.30 ~ 2023.03.31
◦ Overview
'22.03.28 Single Sales or - Contract amount: USD 92,041,300 In progress
Supply Contract - Counterpart: Eli Lilly Kinsale Limited
- Contract period: 2019.12.20 ~ 2029.12.31
◦ Overview
- Contract name: Outsourced drug manufacturing LOI
Important - Contract amount: USD 124,099,000
'22.04.25 management - Counterpart: Pharmaceutical company in Europe In progress
matters - Contract period: 2022.04.25 ~ 2023.03.31
◦ Overview
Important - Contract name: Outsourced drug manufacturing LOI
'22.06.07 management - Contract amount: USD 81,000,000 In progress
matters - Counterpart: Novartis Pharma AG
- Contract period: 2022.06.04 ~ Contract date
◦ Overview
Supply Contract - Counterpart: MSD International Business GmbH
- Contract period: 2022.07.01 ~ 2030.12.31
◦ Overview
Important - Contract name: Outsourced drug manufacturing LOI
'22.08.12 management - Contract amount: USD 350,970,225 In progress
matters - Counterpart: AstraZeneca UK Ltd.
- Contract period: 2021.05.14 ~ Contract date
Disclosure
date
◦ Overview
Supply Contract - Counterpart: GlaxoSmithKline Trading Service Limited
- Contract period: 2022.10.11 ~ 2030.12.31
2. Contingent Liability
A. Litigations
The Company’s litigations in progress are as follows :
Plaintiff Defender Details Status

The Seoul
On October 8, 2018, the Company filed
Administrative Court
administrative litigation in the Seoul Administrative
ruled to cancel the
Court to withdraw the measure recommended by the
Securities & Securities and Futures
Samsung Securities & Futures Commission to designate an
Futures Commission's
Biologics auditor to the Company for three years and dismiss
Commission administrative
the responsible officer regarding that the details of
disposition imposed on
the joint venture agreement are not stated in the
SBL on September
notes to the financial statements.
24th, 2020.
On November 28, 2018, the Company filed
administrative litigation in the Seoul Administrative
Court to withdraw the measure recommended by the
Securities & Securities & Futures Commission to designate an Legal procedures in
Futures auditor to the Company for three years and dismiss progress after the
Samsung Commission, the responsible officer regarding that the details of litigation was filed in the
Biologics Financial the joint venture agreement are not stated in the Seoul Administrative
Services notes to the financial statements as well as the Court on November 27,
Commission measure ordered by the Financial Services 2018.
Commission to rewrite the financial statements
(2012~2018.6.30) and subsequently impose a fine of
KRW 8 billion.
On April 29, 2019, 355 people filed a suit in the
Seoul Central District Court for damages against the Legal procedures in
Samsung company and 4 other parties.(Amount : KRW progress after a suit was
Kang and
Biologics 8,449,205,474) The plaintiffs claimed that they have filed in the Seoul Central
354 others
and 4 others experienced financial losses, for the Company District Court on April 29,
disclosed business reports with false information 2019.
against the accounting standards.
32 people filed a suit in the Seoul Central District
Court for damages against Samsung C&T
Corporation and 19. (Amount: KRW 200,320,000) Legal procedures in
Shim Samsung C&T The plaintiffs claimed that they have experienced progress after a suit was
and Corporation and financial losses, for the Company concealed filed in the Seoul Central
31 others 19 others important information regarding its control over District Court on
Samsung Bioepis Co., Ltd., and that resulted in an February 17, 2020.
unfair swap ratio between Samsung C&T and Cheil
Industries.
Plaintiff Defender Details Status
9 people filed a suit in the Incheon District Court for

Legal procedures in
damages against the Company. (Amount: KRW
progress after a suit was
Chung and Samsung 437,944,500) The plaintiffs claimed that they have
filed in the Incheon
8 others Biologics experienced financial losses in form of a decline in
District Court on March
stock price, for the Company applied equity method
4, 2020.
of accounting against the accounting standards.
Company Y and 18 other parties filed a suit in the

Seoul Central District Court for damages against
Samsung C&T Corporation and 23. (Amount: KRW Legal procedures in
Company Y Samsung C&T 209,000,000) The plaintiffs claimed that they have progress after a suit was
and Corporation and experienced financial losses, for the Company filed in the Seoul Central
18 others 23 others concealed important information regarding its control District Court on January
over Samsung Bioepis Co., Ltd., and that resulted in 21, 2021.
an unfair swap ratio between Samsung C&T and
Cheil Industries.
The Incheon District

Court issued an
The company discovered that Kang and 2 others injunction against the
leaked company's trade secrets when they infringement of trade
Samsung Kang and 2
transferred to another company, and filed a secrets filed by
Biologics others
provisional injunction seeking a prohibition of Samsung Biologics on
infringement with the Incheon District Court. July 29. The decision is
final as the respondents
did not appeal against it.
- In December 2020, Biogen Therapeutics Inc. has filed an arbitration with the International Chamber of Commerce (ICC)
against the Company in connection with the interpretation of some of the terms of the Samsung Bioepis Co., Ltd. joint venture
agreement with the Company, but was suspended the current arbitration process in accordance with the agreement of both
companies in February 2022. In April 2022, Biogen and the Company agreed to terminate the arbitration procedure.
B. Other contingent liabilities
(1) Major agreements with financial institutions
Loan commitments signed with financial institutions as of the end of 2022 are as follows:
[Samsung Biologics]
(Unit: KRW Thousand, USD Thousand)
Limits Execution amount
Bank Type
Currency Amount Currency Amount
Bank overdraft KRW 10,000,000 KRW -
B2B Plus KRW 5,760,000 KRW -
Loans for equipment KRW 70,000,000 KRW 70,000,000
Woori Bank Loans for equipment KRW 50,000,000 KRW 50,000,000
General loan in foreign
USD 30,000 USD 30,000
currency
Corporate operation
KRW 159,900,000 KRW 100,000,000
general fund loan
B2B + Main contract KRW 50,000 KRW -
KEB Bank overdraft KRW 10,000,000 KRW -

Hana Bank Loans for equipment KRW 50,000,000 KRW 50,000,000
Comprehensive limit KRW 40,000,000 KRW -
General loan in foreign
USD 30,000 USD 30,000
currency
Corporate operation
KRW 125,000,000 KRW 125,000,000
general fund loan
Corporate operation
USD 30,000 USD 30,000
general fund loan
General loan KRW 17,000,000 KRW -
Bank overdraft KRW 10,000,000 KRW -
Shinhan Bank
General loan KRW 125,000,000 KRW 125,000,000
Corporate general facility
KB Bank KRW 13,500,000 KRW 13,500,000
loan
Corporate operation
KRW 10,000,000 KRW 10,000,000
general fund loan
NH Bank Loans for equipment KRW 100,000,000 KRW 20,000,000
The Export-
Import Bank of
Korea General loan KRW 50,000,000 KRW 50,000,000
The Export- Export Growth Loan KRW 110,000,000 KRW 110,000,000

Import Bank of
Korea
Mizuho Bank Overseas business loan KRW 95,000,000 KRW 95,000,000
Mizuho Bank Loans for equipment KRW 100,000,000 KRW 100,000,000

Corporate operation
USD 50,000 USD -
general fund loan
General loan) KRW 30,000,000 KRW -
Sumitomo Short-term foreign
Mitsui Banking USD 32,181
currency loan USD 150,000
Corporation
General loan(KRW) KRW 122,000,000
Australia New
Zealand Loans for equipment USD 100,000 USD 30,000
Banking Group
Crédit Agricole Loans for equipment KRW 100,000,000 KRW -
Corporate operation
BNP Paribas KRW 45,000,000 KRW 45,000,000
general fund loan
Standard
General loan KRW 130,000,000 KRW 15,000,000
Chartered
China
Construction General loan(KRW) KRW 56,500,000 KRW 11,500,000
Bank
Bank of China Operating fund loan(KRW) KRW 50,000,000 KRW 50,000,000
As of December 31, 2022, details of guarantees provided by financial institutions are summarized as
follows:
Limits Payment guarantee

Bank Type
Currency Amount Currency Amount
Woori
Korean currency payment guarantees KRW 39,500,000 KRW 2,861,661
Bank
Kookmin
Foreign currency payment guarantee KRW 30,000,000 KRW -
Bank
If the Company does not comply with the commitments below, financial institutions may require an early
redemption of long-term borrowings.
Financial institution Remarks Details of covenants
The ownership of the Samsung Group shall be over 50%, and

Shareholder
Sumitomo Mitsui Bank Samsung C&T Corporation shall maintain its ownership in the
composition ratio
Company in excess of 30%.
The ownership of the Samsung Group (Samsung C&T Corporation

Mizuho Bank Shareholder
and Samsung Electronics) shall maintain ownership of the Company
composition ratio
in excess of 60% (voting shares).
Sumitomo Mitsui Bank Shareholder The Samsung Group shall maintain its ownership of Samsung Bioepis
composition ratio in excess of 50%
Kookmin Bank Shareholder Maintaining as Samsung Group affiliates and the Samsung Group's
composition ratio ownership of the Samsung Bioepis shall be over 50%,
BNP Paribas Shareholder Maintaining as Samsung Group affiliates and the Samsung Group's
composition ratio ownership of the Samsung Bioepis shall be over 50%,
Maintaining the ratio of interest-bearing debt to equity capital of

Mizuho Bank Financial ratio
Samsung Bioepis less than 180%
(2) Free land use rights

In connection with a lease agreement with Incheon Metropolitan city (“Incheon”) related to the use of
land, the Company is exempt from the full amount of rent because the Company meets the
requirements for exemption of rent in accordance with the Common Property Management Ordinance
of Incheon. The Company recognized an intangible asset at the fair value of the rent that is exempt
from Incheon and government grant as a reduction of assets at the same value. The period of land use
without payment and exemption requirement of the full amount of rent are as follows:
Period
Lease terms are for a total of 50 years. The initial lease period is for 20 years from the land lease
contract date of April 28, 2011, and the Company can extend the contract by 10 years.
Exemption requirement
The Company whose foreign investment amounts to more than USD 20 million for 5 years since the
land lease contract date is subject to the exemption from Article 32 of Common Property Management
Ordinance of Incheon. Afterwards, the Company, including foreign invested enterprises that meet the
average daily employee count of above 300, is subject to exemption.
(3) A suit for damages from stock trading

There are a total of four pending lawsuits of stock transaction damages related to the Company’s
accounting and disclosure (Note 34), and the total amount of litigation is KRW 9,296 million.
(4) Provision for acquisition of tangible/non-tangible assets

As the end of 2022, the provision for the acquisition of tangible/non-tangible assets regarding the
construction of the fourth plant is KRW 939.9 billion, of which the amount committed to related parties
including Samsung Engineering Co., Ltd. is KRW 675.8 billion.
(5) SVIC 54 New Technology Investment Association

As of 2021, the Company entered into an investment agreement with a limit of total KRW 49,500 million
for SVIC 54 New Technology Investment Association. On August 13, 2021, the Company paid an initial
investments of KRW 12,375 million, paid KRW 3,135 million on June, 2022, and KRW 12,375 million
on August, 2022. The Company plans to pay additional investments in two installments by August 13,
2024.
(6) A land purchase agreement for 2nd Bio Campus

On July 18, 2022, Samsung Biologics has signed a land purchase agreement with the Incheon Free
Economic Zone(IFEZ) to purchase land for its second Bio Campus, and the purchase amount was KRW
426 billion. The company must fulfill the required procedures, such as the facility construction plan and
consent to use, within a certain period from the effective date of the sales contract, otherwise the sales
contract may be canceled.
3. Sanctions and Others
A. Sanctions
(1) Sanctions by Investigation agency and Jurisdiction

Regarding violations of Financial Investment Services and Capital Markets Act, Act on External Audit of
Stock Companies, Act on the Aggravated Punishment, etc. of Specific Economic Crimes and
Destruction of Evidence, the Prosecutor’s Office has investigated the Company’s Chief Executive
Officer and Chief Financial Officer. Following the investigation, with regards to Act on External Audit of
Stock Companies, Act on the Aggravated Punishment, etc. of Specific Economic Crimes and
Destruction of Evidence, the Prosecutor’s Office has filed an indictment of the Company’s Chief
Executive Officer and Chief Financial Officer, and the first trial is currently in progress.
Currently, there is no case settled by the Investigation agency and Jurisdiction.
(2) Sanctions by Regulator
Regulatory Financial Relevant

Date Subject Content Reason
Authority penalty regulation
- External auditor designation by the

regulator for three years Omission of Act on External
Securities &
Samsung - Recommendation to dismiss the note regarding Audit of Stock
2018.07.12 Futures -
Biologics director in charge joint venture Companies
Commission
- Prosecution charges agreement Article 13
(Company and CEO)
Securities &
- External auditor designation by the
2018.11.14 Futures -.
regulator for three years
Commission Act on External
- Recommendation to dismiss the Inappropriate
Samsung Audit of Stock
CEO and director in charge consolidation
Biologics Companies
- Correction of financial statements accounting
Financial Article 13
- Prosecution charges KRW
2018.11.21 Services
(Company and CEO) 8 billion
Commission
- On July 12, 2018, the Securities & Futures Commission(“SFC”) imposed the first administrative
measures in accordance with the Act on External Audit of Stock Companies against the Company for
alleged failure to disclose sufficient information in the Company’s Financial Statement from 2012 to
2015 regarding the Company’s joint venture agreement with Biogen Therapeutics Inc. The measures
(“First measures”) included external auditor designation by the regulator, recommendation of
dismissal of the Company’s directors in charge, and referral of the case against the Company and its
representative director (CEO) to the Prosecutors’ Office. On October 10, 2018, in order to prove
unfairness of the decisions and actions taken by the SFC, the company filed a lawsuit for cancellation
of aforementioned measures. (Seoul Administrative Court)
On September 24, 2020, the Court ruled to cancel the First measures imposed to the Company by
SFC and decided to suspend the First measures until the decision of the appeal trail is made. The
SFC appealed the Court’s first trial and the litigation is in progress at the Seoul High Court.
- On November 14, 2018, SFC determined a second measure, in accordance with the Act on External
Audit of Stock Companies against the Company for violation of accounting standards by
inappropriately applying separate method regarding investments in Samsung Bioepis from 2012 to
2018. The measures (“Second measures”) included imposition of administrative fine of KRW 8 billion,
external auditor designation by the regulator, recommendation of dismissal of the Company’s
representative director (CEO) and directors in charge, retrospective restatement of financial
statements, and referral of the case against the Company and its representative director (CEO) to the
Prosecutors’ Office. On November 21, 2018, following the procedure, the Financial Service
Commission(“FSC”) imposed a penalty of KRW 8 billion on the Company. On November 27, 2018, to
prove justification of the accounting treatment, the Company filed a lawsuit for cancellation of the
measures by the SFC and the FSC. (Seoul Administrative Court)
B. Return of short-swing profits
The Company has not been notified of the occurrence of short-swing profits in the past three fiscal
years as of December 31.
4. Subsequent Events
A. Important subsequent events

[Samsung Biologics]
- Not applicable
[Samsung Bioepis]
Samsung Bioepis Co., Ltd. decided to invest in the New Technology Business Investment Association
(SVIC 63) to discover new business opportunities in the life science field according to the board of
directors on January 18, 2023. The total amount of investment will be KRW 19,800 million, divided into
two rounds, and the first round will be KRW 11,880 million in January 2023 and the second round will
be KRW 7,920 million in August 2023.
B. Follow-up information including mergers
(1) Overview of stock acquisition of other companies

Details
Name Samsung Bioepis
Acquisition Acquired shares 10,341,852

details Acquisition cost(KRW) 2,765,520,000,000
Acquisition cost(USD) 2,300,000,000
Strengthening global business competitiveness by enhancing biopharmaceutical
Acquisition purpose
development capabilities
Date of acquisition 2022.04.20
Company name Biogen Therapeutics Inc.
Transferring CEO Michel Vounatsos

party Main business Biopharmaceutical development and manufacturing
Main address 225 Binney Street, Cambridge, MA 02142, United States
1) Payment method: Cash

(If there is a transfer amount that is not paid until two years from the date of
closing of the transaction, it may be paid as new shares issued by the Company.)
2) Payment date:
- The transferred amount of $2.3 billion is the amount converted from KRW
Transaction 2,765,520,000,000
amount - USD 1,000,000,000 will be paid on the transaction closing date, USD 812,500,000
will be paid within one year from the transaction closing date, and USD
437,500,000 will be paid within two years from the transaction closing date.
- Earn-out, which can be paid up to USD 50,000,000 of the transferred amount, will
be paid in 2027 depending on whether the conditions are met or not.
3) financing method: New financing through self-funding and capital increase
External Evaluation Yes

Evaluation of adequacy in accordance with Article 165-4 (1) 2 and 2 of the Capital
Evidence Markets and Financial Investment Business Act, and Article 176-6 (3) of the
Enforcement Decree of the same Act
External Name of agency Hanul LLC
evaluation
Duration 2021.12.21 ~ 2022.01.28
Opinion Unqualified
Board resolution 2022.01.28
Contract date: 2022.01.28
Important
Major report submission date: 2022.01.28
dates
Acquisition date: 2022.04.20
※ This transaction is the acquisition of 10,341,852 shares of Samsung Bioepis Co., Ltd. owned by Biogen
Therapeutics Inc., and the contract was signed on January 28, 2022. For details of the acquisition, please refer
to the Report on Major Matters initially published on January 28, 2022 (decision to acquire shares and
investment securities of other corporations).
(2) Comparison of forecasts and performance related to the major financial matters before and after the
stock acquisition
(KRW Bil)
Estimate Result
1st Year 2nd Year Remarks
1st Year 2nd Year
Result Diff Result Diff
Revenue 657.0 1,406.8 663.8 -1% - - -
Samsung Operating
95.2 292.9 168.4 -77% - - -
Bioepis profit
Net income 78.7 241.9 168.2 -114% - - -
※ 1 year forecast and performance data are for the period after stock transfer. (May ~ Dec 2022)
st
※ Profit in the first year increased compared to the forecast due to changes in the market environment.
C. Green management
The Company is making efforts to meet the government’s green growth policy through greenhouse-
gas/energy reduction activities, water reuse, waste resource circulation, environmental performance
evaluation, and management to establish a green management system and take full responsibility as
an eco-friendly company. The Company is also doing its best to preserve the environment through
continued management of environmental management indicators and disclose relevant information to
its stakeholders in a transparent manner.
The Company’s management indicators by each environmental area for the last 3 years are listed below.
※ The current management indicators may change depending on the results of the performance report
by the Ministry of Environment.
[Greenhouse Gas & Energy]
Unit 2020 2021 2022

Greenhouse Gas Emission tCO2e 124,807 130,867 163,933
Energy Consumption TJ 2,529 2,678 3,357
[Water Resources Management]
Unit 2020 2021 2022

Water Usage Ton 1,578,639 1,900,995 2,507,331
Wastewater Discharge Ton 1,025,916 1,178,678 1,278,543
Water Reuse Ton 100,828 73,367 98,117
Water Reuse Rate % 9.8 6 7.7
Note 1) Water reuse facility was newly installed on December 2017.
[Waste Management]
Unit 2020 2021 2022

General Waste Discharge Ton 5,558 7,704 9,095
Designated Waste Discharge Ton 431 595 1,054
Water Recycling Ton 4,330 6,123 7,602
Recycling Rate % 72.3 73.8 74.9
[Contaminant Management]
Unit 2020 2021 2022

Air Pollutant(NOx) Ton 19.804 21.015 24.070
Water Pollutant(Note 1) Ton 13 27 41
Note1) Water Pollutant: COD, SS, T-N, T-P
D. Government Certification and Cancellation
[Samsung Biologics]
□ AEO (Export Division of Excellent Import and Export Safety Management Company)
- Related laws: Article 255-2 of the「Customs Act」, Article 259-2 and Article 259-3 of the Enforcement
Decree of the Customs Act
- Certification Department: Korea Customs Service
- Date of Certification: Apr. 1, 2019
- Validity period: Apr. 1, 2019 ~ Mar. 31, 2024
□ Best Family Friendly Management
- Related laws: Act on Development of Family Friendly Environment
- Certification Department: Ministry of Gender Equality and Family
- Date of Certification: Dec. 1, 2020
- Validity period: Dec. 1, 2020 ~ Nov. 30, 2023

□ Best Company for Environment Management by the City of Incheon
- Related laws: Article 56 of the Framework Act on Environmental Policy (Environmental management
support for businesses)
- Certification Department: Incheon Metropolitan City
- Date of Certification: Dec. 17, 2021
- Validity period: Jan. 1, 2022 ~ Dec. 31, 2024
[Samsung Bioepis]
□ AEO (Export/Import Division of Excellent Import and Export Safety Management Company)
- Related laws: Article 255-2 of the「Customs Act」, Article 259-2 and Article 259-3 of the Enforcement
Decree of the Customs Act
- Certification Department: Korea Customs Service
- Date of Certification: Jan. 15, 2020
- Validity period: Jan. 15, 2020 ~ Jan. 14, 2025

XII. Table of Information
1. Consolidated Subsidiaries(Details)
(Unit : KRW mil)
Basis of a
Total asset of
Established Main dominant- Major
Name of Company Address the last
Date business subordinate Subsidiary
business years
relationship
Majority
ownership of
Samsung Biologics California, Biologics
2020.01 16,678 voting rights X
America, Inc. U.S. R&D
(K-IFRS
1110)
Majority
ownership of
Incheon, Biologics
Samsung ioepis 2012.02 2,832,857 voting rights O
Korea R&D
(K-IFRS
1110)
Majority
SAMSUNG ownership of
Brentford, Other
BIOEPIS UK 2014.01 871 voting rights X
UK Service
LIMITED(*1) (K-IFRS
1110)
Majority
Luzern, Other
BIOEPIS CH 2015.06 180 voting rights X
Swiss Service
GMBH(*1) (K-IFRS
1110)
Majority
Sydney, Other
BIOEPIS AU PTY 2016.06 25 voting rights X
Australia Service
LTD(*1) (K-IFRS
1110)
Majority
SAMSUNG
ownership of
BIOEPIS BR Sao Paulo, Other
2016.05 403 voting rights X
PHARMACEUTICAL Brazil Service
(K-IFRS
LTDA(*1)
1110)
Majority
Auckland, Other
BIOEPIS NZ 2018.01 25 voting rights X
Newzealand Service
LIMITED(*1) (K-IFRS
1110)
Majority
ownership of
SAMSUNG Ramat-Gan, Other
2018.03 60 voting rights X
BIOEPIS IL LTD(*1) Islael Service
(K-IFRS
1110)
Majority
Delft, Other
BIOEPIS NL 2018.06 17,606 voting rights X
Netherland Service
B.V.(*1) (K-IFRS
1110)
Majority
Taipei, Other
BIOEPIS TW 2020.03 54 voting rights X
Taiwan Service
Limited(*1) (K-IFRS
1110)
Majority
Warsaw, Other
BIOEPIS PL Sp z 2020.06 201 voting rights X
Poland Service
o.o(*1) (K-IFRS
1110)
Majority
Tsim Sha Other
BIOEPIS HK 2020.06 10 voting rights X
Tsui, HK Service
Limited(*1) (K-IFRS
1110)
Majority
Delaware Other
BIOEPIS United 2021.08 2,297 voting rights X
U.S.A Service
States Inc.(*1) (K-IFRS
1110)
※ On April 20, 2022, Samsung Bioepis and its subsidiaries were included as consolidated subsidiaries.
2. Affiliates(details)
No. of
Category Name of company Business registration No.
companies
Samsung C&T Corporation 1101110015762
Samsung Biologics Co., Ltd. 1201110566317
Samsung Life Insurance Co., Ltd. 1101110005953
Samsung SDI Co., Ltd. 1101110394174
Samsung SDS Co., Ltd. 1101110398556
Samsung Engineering Co., Ltd. 1101110240509
Samsung Electro-Mechanics Co., Ltd. 1301110001626
Samsung Electronics Co., Ltd. 1301110006246
Listed 16
Samsung Heavy Industries Co., Ltd. 1101110168595
Samsung Securities Co., Ltd. 1101110335649
Samsung Card Co., Ltd. 1101110346901
Samsung Fire & Marine Insurance Co., Ltd. 1101110005078
Multicampus Corporation 1101111960792
S-1 Corporation 1101110221939
Cheil Worldwide Inc. 1101110139017
Hotel Shilla Co., Ltd. 1101110145519
Samsung Display Co., Ltd. 1345110187812
Samsung Medison Co., Ltd. 1346110001036
Samsung Bioepis Co., Ltd. 1201110601501
Samsung Venture Investment Corporation 1101111785538
Samsung Life Service Claim Adjustment Co., Ltd. 1101111855414
Samsung Futures Inc. 1101110894520
Unlisted 43
Samsung Active Asset Management Co., Ltd. 1101116277382
Samsung SRA Asset Management Co., Ltd. 1101115004322
Samsung Welstory Co., Ltd. 1101115282077
Samsung Asset Management Co., Ltd. 1701110139833
Samsung Electronics Logitech Corporation 1301110046797
Samsung Electronics Service Co., Ltd. 1301110049139
No. of
Category Name of company Business registration No.
companies
Samsung Electronics Service CS Co., Ltd 1358110352541
Samsung Electronics Sales Co., Ltd. 1801110210300
Samsung Card Customer Service Co., Ltd. 1101115291656
Samsung Corning Advanced Glass LLC. 1648110138904
Samsung Hedge Asset Management Co., Ltd. 1101116277390
Samsung Fire Service Co., Ltd. 1101111237703
Samsung Claim Adjustment Service Co., Ltd. 1101111595680
SEMES Co., Ltd. 1615110011795
Suwon Samsung Football Club Co., Ltd. 1358110160126
Steel Structure Technologies Co., Ltd. (STECO) 1647110003490
Shilla Stay Co., Ltd. 1101115433927
SD Flex Co., Ltd. 1760110039005
SBTM Co., Ltd. 1101116536556
S1CRM Corporation 1358110190199
SUMaterials Co., Ltd. 1648110061337
S-Core Co., Ltd. 1101113681031
STM Co., Ltd. 2301110176840
HDC Shilla Duty Free Ltd. 1101115722916
Open Hands Co., Ltd. 1311110266146
Cheil Fashion Retail Co., Ltd. 1101114736934
Miracom Inc Co., Ltd. 1101111617533
Samsung Economic Research Institute (SERI) 1101110766670
Samsung Lions Co., Ltd. 1701110015786
Samsung Life Financial Service Co., Ltd. 1101115714533
Samsung Fire & Marine Financial Service Co., Ltd. 1101116002424
Samwoo Architects & Engineers Co., Ltd. 1101115494151
Seoul Lake Side Co., Ltd. 1101110504070
SECUI Co., Ltd. 1101111912503
CVnet Corporation 1101111931686
Harman International Korea 1101113145673
Human TSS Co., Ltd. 1101114272706
3. Investments in Other Companies
(As of December 31, 2022) (Unit: KRW Mil, Thousand shares, %)
Financial status in
Beginning balance Increase(decrease) Ending balance
recent business year
Name of Listing Acquisition Purpose of Acquisition (disposal)
Acquisition cost Gain
company status date Investment Share Book Share Book Total Net profit
Volume (loss) on Volume
ratio value Volume Amount ratio value assets (loss)
valuation
Samsung
Management
Bioepis Co., Unlisted 2012.02.28 139,995 10,342 50.0 517,100 10,342 2,748,080 - 20,684 100.0 3,265,180 2,834,624 218,422
Participation
Ltd.(*1)
Samsung
Biologics Management
Unlisted 2020.03.09 11,914 10 100.0 11,914 - - - 10 100.0 11,914 16,678 376
America, Participation
Inc.
Archigen
Management
Biotech Ltd. Unlisted 2014.06.23 71,372 131,000 50.0 - - - 3,813 131,000 50.0 3,813 4,223 -113
Participation
(*2)
SVIC 54
New
Technology Management
Unlisted 2021.08.23 12,375 - 33.0 12,375 - 15,510 - - 33.0 27,885 81,818 -2,317
Investment Participation
Association(
*3)
Total - - 541,389 - 2,763,590 3,813 - - 3,308,792 - -
(*1) In order to acquire 10,341,852 shares of Samsung Bioepis Co., Ltd. held by Biogen Therapeutics Inc., Samsung biologics
entered into a stock purchase agreement after the resolution of the board of directors on January 28, 2022, and the total purchase
price was USD 2,300,000,000 (with conditional cost including USD 50,000,000). On April 20, 2022, the Company acquired all
10,341,852 shares of the target stock by paying USD 1,000,000,000 in the first round.
(*2) In March 2022, the company and AstraZeneca were approved by the board of directors for the liquidation of Archigen Biotech
Limited, a joint venture, and liquidation is currently underway.
(*3) The company made a new investment in SVIC 54 New Technology Investment Fund for equity investment in bio-field startups
during the previous year, and additionally invested KRW 3,135 million in June 2022 and KRW 12,375 million in August 2022 in
SVIC 54 New Technology Investment Fund during the current year.
3. Research and Development(details)
[Samsung Bioepis]
(1) Product : SB2
① Product type Biosimilar

Ankylosing Myelitis
② Application
Rheumatoid and psoriatic arthritis
psoriasis
Inhibition of the action of TNF (tumor necrosis factor) that causes
③ Mechanism of action
inflammation
④ Product
Second infliximab (Remicade) biosimilar approved to be sold in EU and US
specifications
Since the initial launched in Korea in 2015, it is sold in Europe, US, Canada,
and Australia.
⑤ Progress
Sales distribution agreement signed with Biogen (Europe), Organon
(Canada, USA, Australia) and Yuhan Corporation (Korea)
⑥ Future plan Plans on expanding sales in pre-approved countries
- J&J : Remicade (Originator drug)
- Celltrion : Remsima (EU, US Approved)
- Sandoz : Zessly (EU Approved)
- Amgen : Avsola (US Approved)
⑦ Competitive product
※ The development progress of competing products of competitors was
investigated based on information disclosed to the outside, and there may
be actual differences in the actual research and development situation. In
addition, the above products may be externally shrunk or there may be
products in the early stages of development.
⑧ Related -
⑨ Market size USD 4.6 billion in 2022 (Evaluate Pharma)
⑩ Others -
(2) Product : SB3

② Application Breast cancer
Inhibit proliferation of HER2-expressing tumor cells by binding to HER2
(Human Epidermal growth factor Receptor 2)
④ Product
First trastuzumab (Herceptin) biosimilar approved to be sold in EU
specifications
⑤ Progress Since the global approval, it is currently in sale
⑥ Future plan Plans on expanding sales in pre-approved countries
- Roche : Herceptin (Originator drug)
- Amgen : Kanjinti (EU, US Approved)
- Pfizer : Trazimera (EU, US Approved)
- Celltrion : Herzuma(EU, US Approved)
- Mylan : Ogivri (EU, US Approved)
- Accord : Zercepac (EU Approved)
※ The development progress of competitive products has been investigated
and described based on externally disclosed information and may differ from
the actual R&D situation. In addition, there may be competing products that
are not known externally or are in the early stages of development other
than the products described above.
⑧ Related -
⑩ Others -
(3) Product : SB4

② Application Rheumatoid arthritis and others
③ Mechanism of Inhibition of the action of TNF (tumor necrosis factor) that causes
action inflammation
④ Product
First etanercept (Enbrel) biosimilar approved to be sold in EU
specifications
Since the initial launched in Korea in 2015, it is sold in Europe, US, Canada,
and Australia.
⑤ Progress
Sales distribution agreement signed with Biogen (Europe), Organon
(Canada, USA, Australia) and Yuhan Corporation (Korea)
⑥ Future plan Expects to launch in the U.S. after the expiration of originator patent
- Amgen & Pfizer : Enbrel (Originator drug)
- Sandoz : Erelzi (Approved in EU and US)
- Mylan : Nepexto (Approved in EU)
- Eucept : LG Chemical(approved in Korea and Japan, pending in EU and
US)
A randomized phase l pharmacokinetic study comparing SB4 and etanercept
⑧ Related Thesis reference product (Enbrel®) in healthy subjects
(British Journal of Clinical Pharmacology, 2016)
⑩ Others -
(4) Product : SB5

② Application Rheumatoid arthritis, psoriatic arthritis, etc.
③ Mechanism of In vivo neutralization of tumor necrosis factor (TNF)-alpha, a common cause
action of autoimmune disease
④ Product
First adalimumab (Humira) biosimilar approved to be sold in EU
specifications
Sales approval in Europe(EMA) in August 2017
Product release in October 2018
Sales approval in US(FDA) in July 2019
④ Progress
Sales approval of high concentration formulation in Europe(EMA) in April 2022
Sales approval of high concentration formulation in U.S.(FDA) in August 2022
Launched high-concentration formulation in Europe in November 2022
Expansion of sales in approved countries and commercialization after
⑥ Future plan
approval of new formulations
- Humira (Abbvie) : Originator's reference product
- Amjevita (Amgen) : approval in US and EU
- Hyrimoz (Sandoz) : approval in US and EU
- Hulio (FujifilmKyowa Kirin Biologics; Viatris) : approval in US and EU
- Cyltezo (Boehringer Ingelheim) : approval in US
- Abrilada (Pfizer) : approval in US and EU
- Idacio (Fresenius Kabi (Merck KGaA), Germany) : approval in EU
- Yuflyma (Celltrion) : approval in EU
⑦ Competitive product - Hukyndra (Alvotech Swiss AG) : approval in EU
- Yusimry (Coherus) : approval in US

are not known externally or are in the early stages of development other than
the products described above.
- A randomized phase I comparative pharmacokinetic study comparing SB5
with reference adalimumab in healthy
volunteers, Journal of Clinical Pharmacy and Therapeutics, Jul 2017
⑧ Related Thesis - Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus
Reference Adalimumab in Patients With
Moderate-to-Severe Rheumatoid Arthritis, Arthritis & Rheumatology, Sep
2017
⑩ Others -
(5) Product : SB8

② Application Lung cancer, colon cancer, ovarian cancer, etc
③ Mechanism of Prevent the growth of blood vessels that nourish tumors by blocking a
action protein called Vascular Endothelial Growth Factor(VEGF)
④ Product
Bevacizumab (Avastin) biosimilar
specifications
Sales approval in Europe(EMA) in 2020
⑤ Progress
Sales approval in Korea(MFDS) in 2021
⑥ Future plan
- Mvasi (Amgen/Allergen): approval in US and EU
- Zirabev (Pfizer): approval in US and EU
- Alymsys (Mabxience Amneal): approval in US and EU
- Abevmy/Lextemy (Biocon/Mylan): approval in EU, approval in progress in
US
- Oyavas (STADA Arzneimittel AG): approval in EU
- FKB238 (Centus Biotherapeutics Limited): approval in EU
⑦ Competitive product - BAT1706 (Bio-Thera/Sandoz): approval in progress in US and EU
- CT-P15 (Celltrion): approval in progress in US, EU, and KR

1. A phase III, randomized, double-blind, multicenter study to compare the
efficacy, safety, pharmacokinetics, and immunogenicity between SB8
(proposed bevacizumab biosimilar) and reference bevacizumab in patients
with metastatic or recurrent nonsquamous non-small cell lung cancer
(Lung Cancer, Published Aug 2020)
⑧ Related Thesis 2. Study comparing sb8 (bevacizumab biosimilar) with reference
bevacizumab in healthy volunteers (Cancer Chemother Pharmacol.,
Published Oct 2020)
3. Evaluation of the Physico-Chemical and Biological Stability of SB8
(Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-
Use Conditions (Adv. Ther., Published Oct 2020)
Global sales in Bevacizumab of USD 4 billion in 2022
⑨ Market size
(Evaluate Pharma)
⑩ Others -
(6) Product : SB11

② Application macular degeneration
Combining with vascular endothelial growth factor (VEGF) inhibits abnormal
production of new blood vessels
④ Product
Ranibizumab (Lucentis) biosimilar
specifications
Global clinical completion in 2020
Sales approval in US/Europe(FDA/EMA) in 2021
⑤ Progress
Sales approval in Korea(MFDS) in 2022
Available for sale in US in 2022
⑥ Future plan
- FYB-201 (Formycon/Bioeq) : approval in UK, US and EU
- Xlucane (Xbrane/STADA) : approval in in EU
- LUBT010 (Lupin) : phase 3 in progress
- CKD-701 (Chong Kun Dang) : approval in progress in Korea
※ The development progress of competitive products has been
investigated and described based on externally disclosed information and
may differ from the actual R&D situation. In addition, there may be
competing products that are not known externally or are in the early stages
of development other than the products described above.
- Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a
Reference Ranibizumab Product for Patients
With Neovascular Age-Related Macular Degeneration: A Randomized
Clinical Trial (JAMA Ophthamol. Nov 2020)
- Biosimilar SB11 versus reference ranibizumab in neovascular age-related
macular degeneration: 1-year phase III
randomised clinical trial outcomes (Br J Ophthamol. Oct 2021)
- Evaluation of the Structural, Physicochemical, and Biological
⑧ Related Thesis
Characteristics of SB11, as Lucentis® (Ranibizumab)
Biosimilar (Ophthamol Ther. Jan 2022)
- 2022 ASRS(American Society of Retina Specialist) the presentation of an
academic conference
- 2022 KRS(The Korean Retina Society) Summer Symposium
Presentation
- 2022 AAO(American Academy of Ophthalmology) an academic
presentation
Global sales of Lucentis (ranibizumab) of USD 2.9 billion in 2022
⑨ Market size
(Roche/Norvatis Annual Report)
⑩ Others -
(7) Product : SB12

② Application Paroxysmal nocturnal hemoglobinura and 3 others
A drug that directly inhibits the complement (C5) acting on the hemolytic
② Mechanism of action mechanism
④ Product
Eculizumab (Soliris) biosimilar
specifications
Completed clinical trial phase 3 in 2021
⑤ Progress
Applied for drug approval in Europe in 2022
⑥ Future plan Plan to apply for global application approval
- Amgen : ABP959 (Approval process in EU)

⑦ Competitive product and described based on externally disclosed information and may differ from
A Phase III Randomized Clinical Trial Comparing SB12 (Proposed
Eculizumab Biosimilar)
⑧ Related Thesis
With Reference Eculizumab in Patients with Paroxysmal Nocturnal
Hemoglobinuria (2022 EHA Annual congress, 2022)
⑩ Others -
(8) Product : SB15

Treatment of neovascular(wet) age-related macular degeneration
Treatment of visual impairment due to retinal vein occlusive macular edema
(central retinal vein occlusion or branch retinal vein occlusion)
② Application
Treatment of visual impairment due to diabetic macular edema
Treatment of visual impairment due to choroidal neovascularization due to
pathologic myopia
Inhibits neovascularization in the choroid by binding to vascular endothelial
growth factors (VEGFs)
④ Product
Aflibercept (Eylea) biosimilar
specifications
⑤ Progress Completed clinical trial phase 3 in 2022
⑥ Future plan Plan to apply for global application approval
- MYL-1701P (Biocon) : approval in progress in US
- SCD411 (Sam Chun Dang Pharm) : phase 3 finished
- ABP-938 (Amgen) : phase 3 in progress globally
- CT-P42 (Celltion) : phase 3 in progress globally
- Lucentice (Novartis, Genentech)
⑧ Related Thesis -
Global revenue of Eylea (Aflibercept) in 2021: USD 9.4 billion
⑨ Market size
(Regeneron Annual Report)
⑩ Others -
(9) Product : SB16

② Application Osteonecrosis
By combining with RANKL(Receptor Activator of Nuclear factor Kappa-B
Ligand), inhibits RANKL from binding to RANK
④ Product specifications Denosumab (Prolia/Xgeva) biosimilar
⑤ Progress Clinical trial phase 1 and 3 in progress in 2022
⑥ Future plan Plan to apply for global approval after clinical completion
- GP-2411 (Sandoz) : phase 3 finished
- CT-P41 (Celltrion) : Phase 3 in progress
- TVB-009 (TEVA) : Phase 3 in progress
- FKS-518 (Fresenius Kabi) : Phase 3 in progress
- EB-1001/JHL-1266 (Eden Biologics / JHL Biotech) : Phase 3 in progress
- RGB-14-P (Hikma / Gedeon Richter): Phase 3 in progress
- MB-09 (mAbxience) : Phase 3 in progress
⑦ Competitive product - HLX12 (Henlius) : Phase 3 in progress
- Bmab 100 (Biocon) : Phase 3 in progress
Global revenue of Prolia (Denosumab) in 2022 : USD 5.6 billion (Amgen
⑨ Market size
Annual Report)
⑩ Others -
(10) Product : SB17

Plaque psoriasis
Psoriatic arthritis
② Application Crohn's disease
Ulcerative colitis
Pediatric plaque psoriasis
③ Mechanism of action Inhibition of inflammation through interleukin (IL-12/23) binding
④ Product specifications Ustekinumab (Stelara) biosimilar
⑤ Progress Clinical trial phase 1 finished, and Phase 3 in progress
⑥ Future plan Plan to apply for global approval after clinical completion
- ABP654 (Amgen) : Approval 3 in progress (Global)
- CT-P43 (Celltrion) : Phase 3 finished
- AVT04 (Alvotech) : Approval 3 in progress (Global)
- DMB-3115 (DM Bio) : Phase 3 finished
- FYB-202 (Formycon AG) : Phase 3 finished
- BAT-2206 (Bio-Thera) : Phase 3 in progress
- Bmab1200 (Biocon) : Phase 3 in progress
⑦ Competitive product - Neulara (Neuclone) : Phase 1 finished
- BFI-751 (Biofactura) : Phase 1 finished

Global revenue of Stelara (Ustekinumab) in 2022 : USD 9.7 billion (Johnson
⑨ Market size
& Johnson Annual Report)
⑩ Others -
(11) Product : SB26
① Product type New biological drug

② Application Acute pancreatitis
③ Mechanism of action Inhibition of inflammation through inhibition of human trypsin and other
serine proteases
④ Product specifications Fc-fusion recombinant protein infused with human ulinstatin and antibody Fc
(Ulinastatin-Fc)
⑤ Progress Completed clinical trial phase 1 (2018-2020)
⑥ Future plan Future development strategy to be determined by checking the market and
competitive situation
⑦ Competitive product No products approved for acute pancreatitis in the US/EU
⑨ Market size Acute pancreatitis global market estimated to be KRW 5 trillion (2018,
Biospectator)
⑩ Others -
[Confirmation by Expert]
1. Confirmation by Expert
- Not applicable
2. Expert’s Relations
- Not applicable

Samsung 2022 Annual Report

Uploaded by

Copyright:

Available Formats

You might also like

Samsung 2022 Annual Report

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Samsung 2022 Annual Report

Uploaded by

Copyright:

Available Formats

The 12th Accounting Period

From January 1, 2022

To. Financial Services Commission

Type of Corporation Subject to Submit Stock-listed Corporation

Reason for Exemption Not applicable

Name of Company Samsung Biologics Co., Ltd.

CEO Rim John Chongbo

Place of Principal Office 300, Songdo Bio-daero, Yeonsu-gu, Incheon, Korea

Principal Officer (Title) Director of Business Support Center

A. Consolidated subsidiaries overview(summary)

Number of consolidated subsidiaries Number of

※ For details, refer to XII. Table of Information – 1. Consolidated subsidiaries overview

B. Change of consolidated subsidiaries

C. Legal and commercial name

E. Address, telephone number, and homepage

Venture company Not Applicable

Medium Enterprises Not Applicable

Credit Rating Agency

[Credit rating system]

D A ‘D’ rating indicates default.

- Korea Ratings : Rating of Bonds

AAA Capacity for timely payment is extremely strong.

B Capacity for timely payment is poor and speculative.

CCC Contain the possibility of default.

CC Contain more possibility of default.

C Highly likely default.

D In default at the present time.

Stock market (KOSPI) 2016.11.10 Not applicable Not applicable

A. Company location changes

3003, Songdo Technopark IT Center M, 172-1, Songdo-dong, Yeonsu-gu,

2012.06.26 201-2, Songdo-dong, Yeonsu-gu, Incheon, South Korea -

B. Important changes in management executives

(1) Change of Chief Executive Officer

(2) Change in key management

※ On January 18, 2023, independent director Bahk Jaewan resigned.

C. Changes in the largest shareholder

Date Before After Remarks

Samsung Everland (Old) Cheil Industries The change of the largest

Following the merger between

D. Company name changes

F. Mergers and Acquisitions

(1) Transfer of Samsung Bioepis Shares

Contract Between Shareholders 2011.12.06

Evaluation of external evaluation agencies 2018.06.22 ~ 2018.06.29

Key item report submission date 2018.06.29

Transfer of shares and payment date 2018.11.07

(2) Transfer of Samsung Bioepis Shares

Contract Between Shareholders 2022.01.28

Evaluation of external evaluation agencies 2021.12.21 ~ 2022.01.28

Key item report submission date 2022.01.28

Transfer of shares and payment date 2022.04.20

G. Important changes in the Company’s business

H. Other important matters related to the management activities

2016.04.01 Signed a contract with Samsung Bioepis regarding biosimilar manufacturing

Status of capital increase (decrease)

A. Total number of shares

Ⅰ. Authorized shares 500,000,000 - 500,000,000 -

Ⅱ. Issued shares (cumulative) 71,174,000 - 71,174,000 -